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ABSTRACT 
Natural products have been a source of many pharmaceutical drugs and a number of drugs that are 
currently used in the treatment of cancer are derivatives of compounds originally isolated from 
natural products. There is evidence that extracts of Tulbaghia violacea can be used to treat cancer. 
The activation of apoptosis in cancer cells is a target for the development of novel anti-cancer drugs 
since one of the characteristics of cancer cells is resistance to apoptosis due to the deregulation of 
biochemical pathways leading to apoptosis. In fact, many current anti-cancer drugs exert their 
effects through the activation of apoptosis. Previous studies showed that extracts of T.violacea 
induce apoptosis in cancer cells and one study reported on the isolation of a compound (methyl--
D-glucopyranoside), which is responsible for the pro-apoptotic activity of the T.violacea extract. 
Therefore the aim of this study was to investigate the anti-cancer activity of methyl--D-
glucopyranoside and extracts prepared from T.violacea. In this study the pro-apoptotic activity of 
methyl--D-glucopyranoside and extracts prepared from T.violacea were investigated on a panel of 
human cancer cell lines, which included HepG2, MCF7, H157, HT29 and the non-cancerous cell 
line, KMST6. The induction of apoptosis was evaluated by flow cytometry using several bioassays 
which measures biochemical events (caspase activation, phosphatidylserine externalisation and 
reactive oxygen species (ROS) production that is associated with the induction of apoptosis. The 
results demonstrated that the effects of methyl--D-glucopyranoside on cultured cells are transient 
and that the cells recover from the effects of methyl--D-glucopyranoside. This suggested that 
methyl--D-glucopyranoside is not the compound responsible for the pro-apoptotic bioactivity in 
the T.violacea extract. This study also showed that cytotoxic and pro-apoptotic bioactivity of the 
leaf-extract was significantly higher in comparison to the tuber-extract. The bioactivity of the 
organic solvent extracts (dichloromethane, hexane, methanol and 50% methanol/water) of 
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T.violacea leaves was also significantly higher than water extracts of T.violacea leaves. A 
comparison of the different organic extracts prepared from the T.violacea leaves showed that the 
highest activity was observed for the dichloromethane and hexane extracts. In an effort to identify 
the bioactive compound(s) the dichloromethane extract was subjected to Versaflash
®
 column 
chromatography. However, due to problems experienced with the solubility of the dichloromethane 
sub-fractions, these compounds could not be tested for their bioactivity. Palmitone (16-
hentriacontanone) was identified as one of the major compounds present in the dichloromethane 
sub-fractions. This compound was previously shown to have anticonvulsant bioactivity but there is 
no evidence in the literature that it has anti-cancer or pro-apoptotic activities. Fingerprinting of the 
methanol extract showed the presence of long chain fatty acid derivatives, flavonoids and allicin 
derivatives in the methanol extract. Although, this study failed to isolate the pro-apoptotic bioactive 
compound(s) present in the extracts of T.violacea, it confirmed that extracts of this plant induce 
apoptosis in cultured human cancer cell lines.  
 
Key words: Tulbaghia violacea, Apoptosis, Cancer, Cytotoxicity, Bio-assay guided fractionation, 
Flow cytometry, Natural products, Palmitone, Methyl--D-glucopyranoside 
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          1.0 Cancer Overview  
Cancer is a hyper proliferative disorder which is characterised by deregulation of apoptosis, 
increased cell proliferation, cell invasion, angiogenesis as well as metastasis (Bharat, et al., 
2006). Cancers are also characterised by uncontrolled growth of cells (Weinberg, 2007). 
Cancer is the second leading cause of death in both developed and developing countries 
(Michael, et al., 2010; Ahmedin, et al., 2011). Through metastasis, cancer cells can leave 
the place of origin and invade surrounding tissue and organs. It is often the failure of vital 
organs due to cancer cell invasion that result in the death of the cancer patient. According to 
the World Health Organisation (WHO), over 11 million people were diagnosed with cancer 
in 2005, and this figure may increase to 16 million by the year 2020 (World Health 
Organisation, 2009). 
 
South Africa has one of the highest incidence rates of cancer in Africa (Mqoqi, et al., 
2004), where one out of six males and one out of eight females are at a risk of developing 
cancer (Carl, 2006). Common human cancers affecting female South Africans include 
cancers of the breast, cervix, uterus, colorectal and oesophagus. However, in males, cancers 
of the prostate, lung, oesophagus colon/rectum and bladders are the most common (National 
Cancer Registry, 2004).  
 
It is estimated that a mature adult human consist of about 10
15
 cells (John, 2001). 
These cells undergo constant division and differentiation. Cells possessing capacity for 
division and replenishment are known as stem cells (Kuo-Chen, 2002). Nearly 10
12
 cell 
divisions occur daily in the stem cell compartments. However, the human body maintains a 
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constant weight over a significant length of time in spite of this massive generation of new 
cells. A complex network of molecular mechanisms that regulate cell proliferation on one 
hand and cell death on the other is responsible for the control of cell multiplicity. Any factor 
that results in the alteration of the balance between these two opposing mechanisms in 
favour of increased cellular multiplication has the potential to alter the total number of cells 
in a particular organ or tissue if not promptly and adequately halted. This increased cellular 
multiplicity is clinically detectable as neoplasia (John, 2001). 
 
Neoplasia is described as being benign when the cell mass or the tumour remains 
localized, encapsulated, and does not spread to other sites (Aguiar, et al., 2011). This kind of 
tumour is generally indolent and often amenable by local surgical removal. However, a 
neoplasia is described as malignant when the mass invades and destroys surrounding 
structures and is also capable of metastasis (i.e. able to spread to distant sites) (Stedman’s, 
2003; World Health Organisation, 2009).  
 
Cancer cells can be classified according to the type of tissue from which they 
originate, as well as their resemblance to the particular normal cell type. Generally, they 
may be classified as: carcinomas (cancers of epithelial tissues), sarcomas (cancers of smooth 
muscles), lymphomas (cancer of lymphoid tissues), leukaemia (cancer of blood tissues), 
germ cells tumours and blast tumours (cancers of embryonic tissues or stem cells) (Pascal & 
Jurg, 2000).  
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  1.1 Carcinogenesis 
Development of cancer involves multistage processes, which includes initiation, promotion 
and progression. During the initiation stage, there is an initiator agent that causes physical or 
chemical changes to the cell leading to DNA damage (Kang, et al., 2005). Cells may 
respond to the damage and repair such damage by shutting down cell division and activating 
cell repair mechanisms. Tumour suppressor genes such as p53 play a role in sensing DNA 
damage, blocking the expression of genes involved in the regulation of cell growth and 
activating cell repair mechanisms. If the damage to the cell is too severe the cell will commit 
suicide through the activation of apoptosis. However, if these two processes (sensing 
damage and activating cell death) do not happen, the damaged cell will survive and 
replicate. The result is that the daughter cells, which are referred to as initiated cells, will 
carry the same damaged DNA (John, 2001). The result is the uncontrolled growth of these 
cells. Several mutations in tumour suppressor genes such as p53 have been identified. These 
mutations result in the loss of p53 function. The etiopathogenesis of up to half of all cancers 
has been linked to the loss of p53  function (Bridonneau, et al., 1998). 
 
The promotion stage of cancer involves accumulation of pro-neoplastic cells and the 
process is reversible at various points. At this stage, the initiated cells go through selective 
clonal expansions due to the acquisition of a proliferative advantage, and/or the ability to 
evade growth inhibitory or apoptotic signals (DiGiovanni, 1992). This clonal expansion of 
initiated cells may enhance the probability of additional genetic mutations that could result 
in the development of malignant lesions (Xi, 2003). 
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The progression stage involves the growth of mutated cells to a malignant cell 
population with increased metastatic and invasive potential (Kang, et al., 2005; Lee & Surh, 
2005). This phase occurs as a result of cellular adaptations to harsh micro environmental 
conditions including acidosis and hypoxia (Robert & Robert, 2004). This condition has a 
potent proliferative advantage due to the acidic environment it creates via an unregulated 
glycolysis (Vincent & Gatenby, 2008). The rate of proliferation of tumour cells varies 
widely and depends on the cell type. For example, normal intestine mucosa and lymphoma 
tumour cells proliferate faster than solid tumours while acute leukaemia proliferates slower 
than the corresponding precursors in normal bone marrows (Kang, et al., 2005; Lee & Surh, 
2005). In summary, tumour cells are characterised by uncontrolled proliferation of cells, 
resistance to anti-growth signals, self-sufficiency in the absence of growth signals, sustained 
angiogenesis, tissue invasion, metastasis and resistance to apoptosis (Jorgen, et al., 2011). 
 
1.2 Apoptosis Overview 
Apoptosis is a process of cell death that is induced by a tightly regulated suicide programme 
in which cells destined to die activate enzymes capable of degrading the cells nuclear DNA, 
and cytoplasmic proteins (Bahr & Groner, 2004). Portions of the apoptotic cells then break 
off, resulting in the appearance of apoptotic bodies. The dead cells or cell fragments are 
engulfed and eliminated by phagocytes. This death signalling mechanism does not evoke 
inflammation reaction which is often associated with another form of cell death called 
necrosis (Gopinath, et al., 2006). Necrosis is a type of cell death with no features of 
apoptosis and the death is usually considered to be uncontrolled. It is also referred to as the 
premature death of cells in living tissue (Pierre & Guido, 2006). The morphological 
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characteristics of apoptosis include cell shrinkage and membrane blebbing, disappearance of 
microvilli on plasma membrane, the fragmentation of chromosomal DNA into nucleosome 
size units of about 200bp and the formation of apoptotic bodies (figure 1.1). All of these 
changes occur before the loss of plasma membrane integrity. These morphological 
characteristics are distinct from that of necrosis (Lawrence & Jonathan, 2001). Necrosis is 
characterized with unwarranted cell loss in human pathologies and it always results in 
inflammation (Pierre & Guido, 2006). Cell death through the induction of apoptosis is 
characterized by controlled autodigestion of the cell, but this characteristic is different from 
necrosis through distinct morphological and biochemical features. This includes chromatin 
condensation, membrane surface blebbing, oligonucleosomal DNA fragmentation as well as 
the breakdown of the cell into a series of smaller units also known as apoptotic bodies, they 
are phagocytosed through by adjacent cells in most tissues (Thompson, 1995). However, 
apoptosis processes are associated with activation caspases and loss of membrane 
phospholipid asymmetry leading to externalization of phosphatidylserine (Fabisiak, et al., 
1998). 
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Figure 1.1 Hallmarks of the apoptotic and necrotic cell death processes.  
PM=Plasma membrane, NM= Nuclear membrane. Adapted from (Rajesh & Rajeshwar, 2009). 
 
Apoptosis forms a part of biological processes of multi-cellular organisms; and is 
present in diverse organisms from worms to human (Gregory, et al., 1999). It is a 
mechanism that enables multi-cellular organisms to tightly regulate or control cell growth in 
order to prevent pathological processes such as immune deficiency, auto immunity, and 
cancer (George, 1999). The major role of apoptosis is to remove cells that have incurred 
irreparable DNA damage or replication defects that might enhance proneness to or 
development of pathological conditions such as autoimmune diseases and cancer (Aguiar, et 
al., 2011). In other words, apoptosis is involved in the maintenance of cell homeostasis and 
prevention of tumour development. It counter-balances cell division and cell differentiation 
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and ensures proper functioning of different tissues such as the immune system as well as 
reproductive organs. The balance between cell proliferation and programmed cell death is 
maintained by controlling the number of differentiated cells (Bridonneau, et al., 1998). 
Apoptosis is thought to be confined to multi-cellular organisms, however, some bacteria are 
also able to control bacterial colony numbers through similar mechanisms (Lewis, 2000). 
 
Apoptosis is triggered by death signal which could either be a physiological 
messenger molecule such as hormone or cytokine, a stress stimulus  such as deprivation of 
growth factors or a harmful condition such as radiation, pharmacological and chemical 
substances (Hengartner, 1996). Therefore, apoptosis is a protective response in cells 
exposed to stress stimuli and damaging conditions, thus preventing the appearance and 
proliferation of potentially dangerous cells (Kensler, 1997). The induction of apoptosis 
forms the basis of therapeutic effects of most of the antitumour drugs, including the drugs 
that cause DNA damage or inhibit DNA replication such as anthracyclines. 
 
 Defects in apoptosis may also lead to drug resistance (Scott & Athena, 2000). 
Moreover, excessive apoptosis could lead to diseases such as Alzheimer’s, Parkinson’s, 
amyotrophic lateral sclerosis and Huntington’s disease, Acquired Immune Deficiency 
Syndrome (AIDS) and ischemia (Thompson, 1995). 
 
Flemming in 1885 proposed that cell deaths are involved in rabbit graafian follicles. 
He later developed the theory of apoptosis involvement within the cell in the same year. He 
observed a similar mechanism in the degeneration of testicular germ cell populations, and 
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coined the term “chromatolysis” to describe the phenomena. Flemming documented the 
morphological features of apoptosis, but the concept was not fully understood by many 
scientists including him (Susan, 2007). Councilman, a pathologist studying liver diseases in 
1890 also observed this form of cell death, which he referred as “hyaline” or acidophilic 
bodies’. Councilman described hyaline bodies in the liver of dying patients of yellow fever 
and subsequently, after studying the cells under electron microscope concluded and named 
the single dying hepatocytes “Councilman bodies”. Sixty years after, an Australian 
pathologist, John Kerr during his PhD study proposed the term “apoptosis” to describe a 
relatively conserved set of morphological features observed in various cell types during 
physiological episodes of cell death (Kerr, et al., 1972). Apoptosis was known to have 
resulted from coagulative necrosis of single cells and it was also observed that the remains 
of these cells called apoptotic bodies were phagocytosed by macrophages. The word 
“apoptosis” is a Greek word meaning “falling off” or “dropping off” and is used in reference 
to the formation of apoptotic bodies. Thus, apoptosis can be referred to as a manifestation of 
a process or programme of events leading to cell death which is recognized by distinct 
morphological and biochemical features (George, 1999). 
 
1.2.1 Molecular mechanisms of apoptosis  
Most of the discoveries on apoptotic death machinery in mammalian cells were obtained 
from work done on the nematode worm, Caenorhabditis elegans as a model to study 
apoptosis (figure 1.2). At mitochondrial level, there are two different survival mechanisms 
in mammalian system (i) One resembles the CED-9/CED-4/CED-3 pathway this was 
described in Caenorhabiditis elegans, and it proposed that Bcl-xL binds APAF-1 leading to 
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prevention of activation of caspase and subsequent apoptosis (figure 1.2) (Green & Reed, 
1998), (ii) The second one implicates anti-apoptotic members which includes Bcl-2 and Bcl-
xL and these are used for maintenance of the integrity of the mitochondrial, regulation of 
membrane permeability to small pro-apoptotic molecules such as cytochrome c, (Kluck, et 
al., 1997; Yang, et al., 1997) and finally apoptosis inducing factor (AIF) (Susin, et al., 1996) 
(figure (1.2). However, it has not been known how mitochondrial integrity were being 
controlled by Bcl-2 family but because of the structure of Bcl- xL which are similar to pore-
forming bacterial toxins and since Bcl-2, Bcl-xL and Bax do form ion channels in lipid 
bilayers, therefore it is assumed that by regulation of the small conductance ion channels 
through these molecules could assist in preservation of mitochondrial physiology (Adams & 
Cory, 1998; Green & Reed, 1998)  
The major impact on the study of apoptosis has been on the aspect of identification 
of different genes that encode the proteins that are responsible for the various stages of 
apoptosis, such as initiation, processing and execution of cell death. C. elegans is a free 
living non-parasitic, non-hazardous, non-infectious and non-pathogenic multi-cellular 
organism that is widely used as a model to address fundamental questions in developmental 
biology, neurobiology and behavioural biology (Donald, 1997). In the C. elegans, 131 out of 
the 1090 somatic cells that are usually produced during development undergo apoptosis. The 
analogues of Ced genes which control apoptosis in C. elegans was found in humans and 
these genes have been observed in directly activating the actions of anti-apoptotic factors 
which were found to be capable of suppressing the actions of these proteins (such as Bad 
and Egl-1) (Imawati, et al., 1999). This programmed cell death depends on the actions of 
three key genes which includes ced -3, ced -4 and ced -9 (CED, cell-death abnormal), 
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(Hengartner, 1996). The cloning of these three genes has revealed the existence of 
homologues (Bcl2, Apaf-1 and caspase) in other species including humans (figure 1.2). The 
cell-death genes ced-3 (a caspase), ced-4 (an Apaf-1 homolog), and ced-9 (a Bcl-2 homolog) 
are all capable of controlling cells  autonomous in order to control apoptosis (Chinnaiyan, et 
al., 1997). Worms that are deficient in these genes are either ced -3 or ced-4 or both contain 
at birth 131 superfluous cells, which shows that these gene are involved in killing processes 
(Ellis & Horvitz, 1986; Shaham & Horvitz, 1996). 
However, in contrast, ced -9 is a negative regulator of PCD. ced-4 binds to ced -3 
and thus leads to ced -3 activation, that is ced-3 and ced -4 function to kill cells and ced-9 
gene helps in preventing the death-promoting action of these genes and it is however 
homologous to the Bcl-2 family (Chinnaiyan, et al., 1997). 
 
Figure 1.2: Highly conserved programmed cell death pathways. Adapted from (Lewis, 2000). 
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ced -4 plays a vital role in the cell death pathway through linking of ced-9 and the 
Bcl-2 family biochemically to ced -3 as well as the ICE family of pro-apoptotic cysteine 
proteases. The protective nature of ced-9 and also the killer nature of ced-3 and ced-4 are 
usually present in normal cells (Seshagiri & Miller, 1997). Death by overexpression of ced-3 
does not require endogenous ced-4 function, while killing by overexpression of ced-4 is 
dependent on endogenous ced-3 function. Therefore, ced-4 acts upstream of ced-3 and ced-4 
function can be bypassed by high levels of ced-3 activity or it may be that ced-3 and ced-4 
act in parallel, with ced-3 leading to a greater chance to kill (Spector, et al., 1997; Wu, et al., 
1997; Imawati, et al., 1999). Inhibition of Ced-9 or Bcl-2 leads to activation of the next 
stage in the suicide programme while the subsequent activation of Ced-4 or Apaf-1 factors 
initiate the final executors of apoptosis figure 1.2) (Amarante-Mendes & Green, 1999). The 
analogous gene that regulates apoptosis in C. elegans has been observed in directly 
activating the actions of anti-apoptotic factors which were found to be capable of 
suppressing the actions of these proteins (such as Bad and Egl-1) (Imawati, et al., 1999).  
Apoptosis in mammalian cells is mediated through two major pathways, namely, the 
intrinsic pathway and extrinsic pathway. The intrinsic pathway is associated mitochondrial 
dysfunction while the extrinsic pathway is associated with activation of the death receptors 
(DRs) on the cell membrane. These two distinct pathways ultimately result in activation of a 
family of cysteine aspartyl specific- proteases, (caspases) (Thompson, 1995). 
 
The intrinsic pathway involves utilization of mitochondria to initiate cell death 
through the opening of mitochondrial permeability transition pore (MPTP) or rupture of the 
outer mitochondrial membrane. The intrinsic apoptotic mechanism can also be initiated by 
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cellular stress, specifically mitochondrial stress caused by several factors such as DNA 
damage, free radicals, and deprivation of growth factors or trophic hormones (Weinberg, 
2007). This leads to the  activation of the pro-apoptotic members of the Bcl-2 family known 
as Bad and Bax, which dimerise and insert into the mitochondrial outer membrane, and form 
channels through which cytochrome c and other mitochondrial proteins escape into the 
cytosol (Gopinath, et al., 2006; Johnstone, et al., 2008; Papenfuss, et al., 2008). In the 
cytoplasm, cytochrome c combines with Apaf-1 to form a large oligomeric complex known 
as the apoptosome, that activates procaspase-9 (Wilson, et al., 2009). The active caspase-9 
known as the initiator caspase, activates the executioner caspases, caspases- 3, 6 and 7 
which execute the full implementation of the apoptotic programme (Scaffidi, et al., 1999).  
 
The extrinsic pathway is initiated by the interaction of certain members of the 
tumour necrosis factor (TNF) receptor family, often referred to as ‘death receptors’ with 
their cognate death ligands such as TNF-α, CD95L, or TRAIL (Fischer & Schulze-Osthoff, 
2005). Once activated by ligand binding, the death domains (DD) of these receptors bind to 
and activate a protein called Fas-associated death domain protein (FADD) in the cytoplasm, 
to form the death inducing signalling complex (DISC) which activates the initiator caspase-
8 and less commonly, caspase-10. The activated initiator caspases activate the executioner 
caspases (caspases-3, -6 and -7) (Weinberg, 2007). Activated caspase-3 trigger events that 
will result in the death of the cell. Activated caspase-8 can also activate the intrinsic 
pathway. Active caspase-8 can cleave and activate a protein in the cytosol known as Bid 
(figure 1.3). Bid is a pro-apoptotic member of the Bcl-2 protein family. The truncated Bid 
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(tBid) translocates to the mitochondrial outer membrane and opens the mitochondrial 
channels resulting in release of mitochondrial apoptotic factors into the cytosol.  
 
Figure 1.3: Schematic diagram showing intrinsic and extrinsic mechanisms of apoptosis. 
Bid is cleaved by the initiator caspase-8 to form truncated Bid (tBid) which translocates into the 
mitochondrial outer membrane and opens the mitochondrial channels to release pro-apoptotic factors 
including cytochrome c. Taken from (Kumar, et al., 2007). 
 
Other pro-apoptotic proteins of the Bcl-2 protein family, such as Bax and Bak can 
also translocate to the mitochondrial outer membrane resulting in the formation of pores or 
mitochondrial apoptosis-induced channels (MAC). This leads to release of pro-apoptotic 
factors like cytochrome c which are released into the cytosol through these pores. 
Cytochrome c combines with ATP, Apaf-1 and pro-caspase 9 to form the apoptosome 
(figure 1.3). Anti-apoptotic proteins of the Bcl-2 family such as Bcl-2, Bcl-XL and MCL-1 
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can inhibit the formation of MAC (Gopinath, et al., 2006; Kumar, et al., 2007). The 
apoptosome activates pro-caspase-9 (Wilson, et al., 2009) and the active caspase-9 activates 
the executioner caspases such as caspase-3 which execute the full implementation of the 
apoptotic programme (Scaffidi, et al., 1999). 
 
1.2.2 Regulation of apoptosis 
Cells require extracellular growth factors and mitogens to continue to grow and divide and 
also survival factors to escape cell death. Insufficient levels of survival factors could result 
in the activation of apoptosis (Boets & Goethals, 2011). Inappropriate activation or 
inhibition of apoptosis may lead to diseases such as cancer and other types of disorders 
(Barr & Tomei, 1994). The universality and incidence of apoptosis in the multi-cellular 
organisms stress the importance of its regulation. Several stimuli are capable of inducing 
apoptosis. Some could be universal and can generate or produce apoptosis in nearly all cells, 
but most apoptosis-inducing factors have shown selectivity of their targets (Avci-Adali, et 
al., 2010). If the pro-apoptotic signals predominate, a dedicated death program will then be 
activated and the cell will undergo apoptosis. These signals could either positively or 
negatively (i.e. trigger or repress) affect apoptosis. The induction involves binding and 
subsequent initiation of apoptosis by a signal molecule while the active repression or 
inhibition of apoptosis by a transducer molecule is referred to as the negative induction.  
In addition to physiological control mechanisms of apoptosis, different variety of 
pathological insults can trigger apoptosis by various stimuli either from outside or within the 
cell such as the ligation of cell surface receptors, DNA damage due to defects in DNA repair 
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mechanisms, treatment with cytotoxic drugs or irradiation, lack of survival signals, 
contradictory cell cycle signalling or developmental death signals (Christopher, 1996).  
 
Most cells initiate intracellular apoptotic signalling in response to a stress such as 
hypoxia, nutrient deprivation, radiation, infections, free radicals, heat and so on (Cotran, et 
al., 1998). Death signals of such diverse origins ultimately activate common cell death 
mechanism which could later lead to the characteristics features of apoptosis (Morita & 
Tilly, 1999). Depending on the damage and the cell type, p53 could either cause cell cycle 
arrest or activate the apoptotic self-destruction sequence (Balint & Vousden, 2001). Figure 
1.4 shows the four stages leading to apoptosis as proposed by Morita and Tilly in 1999. The 
first stage involves various harmful stimuli that interact with a cell. The second stage, 
involves early activation of a signalling molecule. This signal is produced by a regulatory 
mechanism that assesses the strength of the apoptosis inducing signal over anti-apoptotic 
signals in the third stage. If the death inducers prevail, the cell commits to apoptosis and 
enters the fourth and final stage that involve specific executionerr proteins which 
responsible for the organized destruction of the cell (Morita & Tilly, 1999). 
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Figure 1.4 : Four stages leading to apoptosis.  
Adapted from (Morita & Tilly, 1999) 
 
 
Increased activities of caspases-8 and 9 have been noticed in peripheral blood 
mononuclear cells of patients with neurodegenerative disorders such as Alzheimer’s disease 
(Tacconi, et al., 2004) and Parkinson’s disease (Viswanath, et al., 2001). Apoptosis-
regulating genes are found in every metazoan organism and are conserved throughout 
evolution (Liu & Hengartner, 1999).  
 
Mitochondria are important in eukaryotic organisms without which the cells will 
cease to respirate aerobically and eventually die. This has been exploited by some apoptotic 
pathways and some of the associated proteins target mitochondria affecting them in several 
ways. This may lead to swelling of the mitochondria forming membrane pores, or increasing 
the permeability of the mitochondrial membrane which could later lead to the leakage of 
apoptosis signalling molecules (Cotran, et al., 1998). For example, nitric oxide induces 
apoptosis by aiding the dissipation of mitochondria membrane potential thus making it more 
permeable (Brüne, 2003). Second mitochondria-derived activator of caspases, (SMACs) 
proteins when released into the cytosol cause an increase in the mitochondrial permeability 
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(Fesik & Shi, 2001). SMAC binds to IAPs to prevent its inhibition of apoptosis. In most 
cases, IAP represses the activity of caspases that degrade the cells (Fesik & Shi, 2001). This 
suggests that the activities of caspases are indirectly regulated by mitochondrial 
permeability.  
 
The dissipation of the mitochondrial inner transmembrane potential (∆ψ) and the 
permeability transition (PT) also lead to a loss of the biochemical homeostasis of the cell. 
ATP synthesis is stopped, redox molecules such as NADH, NADPH, and glutathione are 
oxidized, and reactive oxygen species (ROS) are increasingly generated (Kroemer, et al., 
1997). An increase in the level of ROS directly leads to the oxidation of lipids, proteins, and 
nucleic acids, therefore enhancing the disruption of ∆ψ (Marchetti, et al., 1997). However, 
there appears to exist a consensus that a permeability transition pore (PTP) is formed and it 
consist of the adenine nucleotide translocator (ANT) as well as the voltage-dependent anion 
channel (VDAC) as its core components (Bruno & Kiel, 2002). ANT has been the most 
abundant protein of the inner mitochondrial membrane as well as a transmembrane channel 
which is responsible for the export of ATP in exchange with ADP (antiport). 
Overexpression of ANT-1 in human cancer cell lines exclusively induces apoptosis by 
means of its characteristic features through mediation of RIP which affects the interaction 
between both cyclophilin D and ANT. This allows the binding of zVAD.fmk (zVAD) to 
ANT, thus preventing ANT from adopting the conformational c-state and later results in 
inhibition of ADP/ATP exchange, the reduction of cellular ATP as well as and necrotic cell 
death (Flierl, et al., 2005). They are closely conserved homologue ANT-2, but they do not 
induce apoptosis, which suggests a specific mechanistic role of ANT-1 in mitochondrial 
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apoptosis events (Bauer, et al., 1999). VDAC, is the most abundant protein of the outer 
mitochondrial membrane, it forms a non-selective pore via the outer membrane 
(Christopher, et al., 2004). Through direct protein-protein interactions, VDAC-ANT 
complexes likely connect both the inner and the outer mitochondrial membranes together to 
a site called “contact sites”, which is similar to an association of the two membranes and 
thereby constituting the PT pore (Beutner, et al., 1998). Since PT, the loss of ∆ψ, as well as 
the release of mitochondrial proteins is of central importance in mediating and enhancing 
apoptosis pathways, these mitochondrial events must therefore be kept under strict control 
which in most cases are dependent on members of the Bcl-2 family.  
 
1.3 Anti-cancer therapies targeting the extrinsic and intrinsic apoptosis pathways  
Apoptosis is one of the build-in mechanisms used by organisms to prevent the development 
of cancer. One of the characteristics of cancer cells is resistance to apoptosis. The goal of an 
effective anti-cancer therapy is to selectively kill cancer cells without harming the normal 
cells. In some cases, resistance to apoptosis may explain why cancer therapies fail. Many 
anti-cancer strategies involve the reactivation of apoptosis in cancer cells or sensitising 
cancer cells to apoptosis. Physiological differences between normal and cancerous tissue is 
often exploited to develop such anti-cancer treatment strategies (Nguyen & Wells, 2003; 
Mashima & Tsuruo, 2005). For example, the microenvironment of a solid tumour is 
characterized by low pH, hypoxia, and growth factor deprivation (Mashima & Tsuruo, 
2005).  
 
 
 
 
 
 21 
 
Most of the key regulators of apoptosis signalling pathways have been identified, 
and many have emerged as main targets for design of anti-cancer therapeutic strategies. 
These include the death receptors, Bcl-2 proteins (also referred to as the gatekeepers of the 
intrinsic apoptosis pathway), caspases, caspase inhibitors, and various transcriptional 
regulators of proteins paying a role in apoptosis (Fischer & Schulze-Osthoff, 2005). Several 
novel therapeutic approaches are being developed. For instance, death receptor ligands are 
being mimicked by recombinant ligands or agonistic antibodies; caspases are being 
activated by small molecule drugs; pro-survival factors such as inhibitors of apoptosis 
(IAPs) in cancer cells are being specifically down-regulated by antisense therapy or other 
strategies (Fulda, et al., 2002; Chen, et al., 2007; Higuchi, et al., 2008; Barcic & Ivancic, 
2010). 
 
An in-depth understanding of apoptosis signalling pathways led to the understanding 
of how several human cancers develop and progress. For example, the relatively slow 
growing nature of basal cell cancers, in spite of their high mitotic rate, can be explained by 
their associated high rate of apoptosis (Kerr, et al., 1972). Studies on knockout and 
transgenic mice demonstrated strong association between over-expression of Bcl-2 protein 
and B cell lymphomas, leukaemia, melanoma and some myelomas (Strasser, et al., 1993; 
Leiter, et al., 2000). Expression of a bcl-2 transgene alone in mice did not result into a fast 
tumour development, but, when it was combined with a c-myc transgene, leukaemia 
developed extremely rapidly (Strasser, et al., 1990). This synergy between an oncogene and 
an apoptosis inhibitor suggested that apoptosis is necessary for preventing a survival of cells 
that have acquired activating mutations in growth-promoting genes. Studies have 
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demonstrated positive correlation between the expression of nearly all of the anti-apoptotic 
proteins and various types of cancer. For instance, elevated levels of X-linked Inhibitor of 
Apoptosis protein (XIAP) have been observed in small cell carcinoma of  lung (Hofmann, et 
al., 2002) and Melanoma inhibitor of apoptosis (ML-IAP) expression was noted in 
melanoma cells (Kasof & Gomes, 2001).  
 
1.3.1 Death receptor ligands 
The discovery of death ligands known as tumour necrosis factor-related apoptosis-inducing 
ligands (TRAILs) raised optimism for anti-cancer therapy because they target the tumour 
cells and spare the normal cells. That is, they selectively induce apoptosis of various cancer 
cells leaving the normal cells unharmed (LeBlanc & Ashkenazi, 2003). Trail receptors, 
TRAIL-R1/R2 are selectively expressed on tumour cells. TRAIL binds and then activates its 
receptors and then in turn triggers death receptor-mediated apoptotic tumour death. Five 
members of the human TNF receptor (TNFR) super-family have been identified that bind 
TRAIL, these include, the death receptors DR4 (death receptor 4, also known as TRAIL-R1 
or TNRFIOA) and DR5 (death receptor 5, also known as TRAIL-R2 or TNFR10B) 
(Walczak, et al., 1997). Both DR4 and DR5 contain a conserved cytoplasmic death domain, 
which is capable of binding TRAIL as well as initiating death signals. Two decoy receptors, 
DcR1 (also known as TRAIL-R3 or TNFR10C) (Degli-Esposti, et al., 1997b) and DcR2 
(also known as TRAIL-R4 or TNFR10D) (Degli-Esposti, et al., 1997a), have close 
homology to the extracellular domains of DR4 and DR5. However, DcR1 does not have a 
transmembrane domain or a death domain, while DcR2 has a truncated, non-functional 
death domain. 
 
 
 
 
 23 
 
1.3.2 Nuclear Factor κB (NF- κB) 
The death receptor mediated apoptotic signalling pathway is also involved in regulation of 
NF-κB activation (Wen-Hui, et al., 1999). Several cancers are characterized by chronic 
activation of NF-κB as an adaptation mechanism to their high micro-environmental 
oxidative stress (Avendano & Menendez, 2008). This result in prolonged cancer cell 
survival due to increased expression of c-Jun N-terminal kinase (JNK)-phosphatase, which 
inhibits the activation of pro-apoptotic kinase, JNK (Kamata, et al., 2005). The enhancement 
of apoptotic signalling mechanism by inhibiting NF-κB activity might offer a prospect for 
apoptosis targeted anti-cancer therapy. Inhibitors of NF-κB activation are therefore potential 
anti-cancer drugs. An example of such drug is CHS-282, a potent inhibitor of I kappa B 
kinase (IKK), which blocks NF-κB activation. (Avendano & Menendez, 2008).  
 
1.3.3 Bcl-2 Proteins 
Proteins of the Bcl-2 family are essential checkpoints of the intrinsic apoptotic signalling 
pathway (Cory, et al., 2003) and focus has been a target for the development of the 
strategies targeting the intrinsic apoptosis pathway (Letai, et al., 2004). A mechanism was 
proposed through which Bcl-2 controls antioxidant pathways at sites of free radical 
generation (Hockenbery, et al., 1993). Studies in non human primates have shown no 
toxicity at low and high dosages of TRAIL despite in vitro study suggesting sensitivity of 
normal human astrocytes to the drug (Ashkenazi, 2002).  
 
Most conventional anticancer drugs and radiotherapy induce apoptosis primarily by 
activating the mitochondrial apoptosis machinery, and tumour refractoriness (that is cancers 
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that resist treatment over time) to these therapies often develop. This can be explained by 
overexpression of anti-apoptotic Bcl-2 proteins in the tumour which accounts for their drug 
resistance. Since TRAIL-mediated death signalling does not utilize these proteins, 
combination treatment of TRAIL with conventional chemotherapeutics or radiotherapy 
often results in enhanced cytotoxic effects (Degli-Esposti, et al., 1997a). These synergistic 
effects are due to the activation of the intrinsic and the extrinsic apoptotic pathways, reduced 
expression of anti-apoptotic proteins such as Bcl-2 or Bcl-XL, and an up-regulation of pro-
apoptotic molecules such as caspase-8 and FADD. Members of this family of protein are 
categorized as either pro-apoptotic or anti-apoptotic based on their ability to induce or 
prevent the release of mitochondrial apoptotic factors such as cytochrome c into the cytosol 
to trigger mitochondria-mediated apoptotic death. The stochiometric balance of pro-and 
anti-apoptotic proteins appears to be a critical event in regulating cell death (Fischer & 
Schulze-Osthoff, 2005).  
 
The pro-apoptotic members of Bcl-2 include Bax, Bak, Bok, Bad, Bik, Bid, Bim, 
Noxa and Puma, while the anti-apoptotic proteins include Bcl-2, Bcl-XL and Mcl-1. Over-
expression of Bcl-2 proteins has been demonstrated in majority of hormone-resistant 
prostatic carcinoma, malignant melanoma, and estrogen-positive breast cancer (Avendano & 
Menendez, 2008). This implies that over-expression of these proteins enhances resistance to 
anti-cancer therapy that mainly targets the mitochondrial pathway. Oblimersen sodium is an 
antisense oligonucleotide compound which acts by reducing the expression of Bcl-2 genes. 
They are specifically designed to bind to human Bcl-2 mRNA, leading to catalytic 
degradation of Bcl-2 mRNA and further decrease in Bcl-2 protein translation. However, 
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there has been baseline and inducible expression of Bcl-2 in small cell and non-small cell 
lung cancer and this may contribute to cancer resistance therapy (Roy & Stanley, 2004). 
 
1.3.4 Mitochondria permeabilization in intrinsic (MMP) pathway 
Mitochondrial membrane permeabilization (MMP) is an essential event in intrinsic 
apoptotic pathway. Several agents have been shown to induce MMP by a direct action on 
mitochondria, and might therefore trigger apoptosis in cells in which upstream apoptotic 
signals have been hampered (Debatin, et al., 2002). These agents are either proteins of the 
permeability transition pore complex, including the peripheral benzodiazepine receptor 
(PBR) and the adenine nucleotide translocase (ANT), or small molecules such as CD437, a 
synthetic retinoid that exert a lethal effect due to their physicochemical properties (Fischer 
& Schulze-Osthoff, 2005). Agents that directly target the mitochondria would be potential 
anti-cancer therapy since they seem to act independent of the Bcl-2 protein machinery. 
 
1.3.5 P
53 
 proteins 
P
53
 does not participate directly in the apoptosis signalling mechanism. However, as a 
transcription factor, it regulates the expression of a variety of pro-apoptotic members of Bcl-
2 family (Vousden & Lu, 2002). Damage to the DNA by chemotherapy, radiotherapy or any 
other agent results in phosphorylation of P
53
, resulting in the expression of pro-apoptotic 
proteins such as Bax, Bak, Puma and Noxa (Yu & Zhang, 2008). These proteins alter the 
permeability of mitochondrial membrane resulting in release of cytochrome c into the 
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cytosol, and ultimately trigger mitochondria-mediated apoptotic cell death (Ashkenazi, 
2002). Results from ongoing clinical trials of INGN201 (Ad-p53), a P
53
 gene therapy drug, 
that utilizes adenovirus as the delivery vector to cancer cells, showed broad-spectrum anti-
tumour activity in many models of human cancers (Avendano & Menendez, 2008). The 
results also showed that, combining INGN201 with chemotherapy or radiotherapy in these 
models resulted in enhanced activity with no apparent increase in toxicity.  
 
1.3.6 Caspases 
Caspase activation would be a potential strategy for cancer therapy since the activation of 
intrinsic and extrinsic apoptotic signalling pathways culminate in activation of the effector 
caspases. Several strategies to develop tumour specific inducible caspase activators have 
been studied. For instance, tumour-selective apoptosis might be triggered by chimeric 
proteins, such as immunocasp-3 and -6, comprised of anti-erbB2/HER2 antibody (e23sFv) 
and the translocation domain of Pseudomonas exotoxin-A fused to an active caspase (Xu, et 
al., 2004; Chow, et al., 2011). Tumour specificity of this strategy is due to the over 
expression of erbB2/HER2 in several cancers such as breast, ovarian, endometrial, gastric, 
bladder, prostate, and lung cancers (MacCorkle, et al., 1998; Shariat, et al., 2001).  
 
In vivo studies also showed that iCasp9 (inducible caspase-9) triggers apoptosis in 
xenografted prostate tumours following chemical induction (Xie, et al., 2001). Increased 
regression of the prostatic tumour and increased host survival were also observed in these 
mice models. Gene therapeutic approaches have been employed to transfer caspase-6 
(regulated by human telomerase reverse transcriptase promoter) into glioma cells (Komata, 
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et al., 2001). This strategy was expected to trigger tumour-specific apoptosis, since 
telomerase expression is reactivated in tumour cells but not in normal cell. In addition, 
apoptotic potential of several small molecule caspase activators such as MX2060 and 
MX2167 has been evaluated on a variety of tumour cell lines. The MX2060 series is one of 
more than 40 compound families identified by Maxim Pharmaceuticals through its 
proprietary caspase-based high-throughput screening system that targets the identification of 
compounds that modulate apoptosis (Zhang, et al., 2004a). X2167 is the lead member of 
Maxim Pharmaceuticals MX2060 series of compounds derived from a natural compound, 
gambogic acid.  
 
The MX2060 series are apoptosis-inducing anti-tumour compounds which triggers 
apoptosis by a novel molecular mechanism which is different from the actions of traditional 
anti-cancer drugs (Fischer & Schulze-Osthoff, 2005). MX2167 was found to induce 
apoptosis in multiple cancer cell lines including prostate, breast, colorectal, lung cancer, and 
leukaemia cells (Korkolopoulou, et al., 2004; Zhang, et al., 2004b). These studies suggest 
that caspase activation might be exploited as potential anti-cancer therapeutic strategy. 
 
1.3.7 Inhibitors of apoptosis proteins (IAPs) 
Inhibitors of apoptosis (IAPs) are caspase-inhibiting proteins and constitute an important 
regulatory system in apoptosis pathways (Salvesen & Duckett, 2002). Over-expression of 
some IAPs has been noted in a number of tumours. For instance, XIAP is over-expressed in 
acute myeloid leukaemia and this is associated with poor prognosis (Tamm, et al., 2004). 
There are strong correlations between IAPs expression and oesophageal cancer (Imoto, et 
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al., 2001) and mucosa-associated lymphoid cancer (caused by Helicobacter pylori) (Baens 
et al., 2000). Survivin, one of the most studied IAPs, is over-expressed in cancer cells, 
which makes it a potential target for cancer therapy (Ambrosini, et al., 1997). XIAP inhibits 
caspase-3, -7, and -9. Antisense targeting of this protein combined with vinorelbine proved 
effective in a mouse xenograft model of lung cancer (Barcic & Ivancic, 2010). SMAC and 
Omi/HtrA2 are proteins within the mitochondria that inhibit IAPs and restore caspase 
activity. SMAC peptides or SMAC-mimetic drugs such as TWX024 and embelin are 
currently being developed as potential cancer therapeutic strategy (Wu, et al., 2003; 
Nikolovska-Coleska, et al., 2004). However, SMAC-like peptides often fail to induce 
apoptosis as single agents, they help sensitize tumour cell lines to other chemotherapeutic 
agent (Fulda, et al., 2002).  
 
1.4 Reactive Oxygen Species 
ROS can induce several cellular effects, depending on the cell type involved and the 
concentration of ROS (Haendeler, et al., 2004; Okuyama, et al., 2005; Fujino, et al., 2006). 
Low levels of ROS could act as signal transduction messengers by modulating gene 
expression (Haendeler, et al., 2004). High levels of ROS have been shown to drive the cell 
into a state of oxidative stress (Cheng, et al., 2004), oxidative, lipid and protein damages 
(Fujino, et al., 2006). However this can be overcome through the use of cells that have 
oxidative enzymes (such as oxidases and peroxidises) which will protect them from 
oxidative damage so that intracellular ROS would be maintained at appropriate levels 
(Fujino, et al., 2006). Failure to regulate the levels of ROS can lead to impairment of 
cellular functions which can result in the induction of apoptosis (Fujino, et al., 2006).  
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Thioredoxin-2 (Txn2) plays a vital role in protecting the mitochondria against 
oxidative stress (Pérez, et al., 2008). Thioredoxin (Trx) and glutathione redox systems are 
intracellular redox systems that helps in controlling cell proliferation and cancer 
development (Marks, 2006). The thioredoxin (Trx) system consist of thioredoxin (Trx), 
thioredoxin reductase (TrxR1) as well as nicotinamide adenine dinucleotide phosphate 
(NADPH) (Arnér & Holmgren, 2006).  
 
Cell viability depends on the nature as well as type of stress exerted on them. Cells 
still maintain progressive lipid peroxidation after an apoptotic signal, thus oxidative damage 
and ROS have been linked to apoptosis induction (Amstad, et al., 1994; Czene, et al., 1997). 
A mechanism was proposed through which Bcl-2 controls antioxidant pathways at sites of 
free radical generation (Hockenbery, et al., 1993). BcL-2 acts by protecting against 
apoptosis through blocking of cytochrome c release, but this process only helps to prevent 
superoxide production when it is over expressed, they can also be used as antioxidant (Cai 
& Jones, 1998).  
 
Oxidative stress is also a mediator of apoptosis, it acts by decreasing intracellular 
glutathione, the main buffer of the cellular redox status or through the increase of cellular 
reactive oxygen species (Bojes, et al., 1997; Suzuki, et al., 1998). Hydrogen peroxide 
induces apoptosis through the production of hydroxyl radicals as well as changes in 
oxidant/antioxidant pathway at low concentration (Toledano, et al., 1997). However, at the 
same low concentrations, hydrogen peroxide increases cell proliferation even in the absence 
 
 
 
 
 30 
 
of serum, but these stimulatory changes do not involve free radicals as they are enhanced by 
the presence of mannitol or DMSO in the medium (Burdon, et al., 1989). Hence, 
superoxides as well as hydrogen peroxide are the regulatory signals. 
 
1.5 Treatment of Cancer 
Current regimens of cancer therapy include immunotherapy, chemotherapy, radiation 
therapy, monoclonal antibody therapy and surgery (Hamdy, 2012). The preference of any of 
these cancer treatments depends on the location and the stage of the disease, as well as the 
general state of the patient. Total removal of the cancer tissue without injuring the normal 
tissue is the goal of the treatment. Sometimes this can be achieved by chemotherapy and 
radiation, however, the effectiveness of this treatment is often limited by toxicity to normal 
tissues (Patyah, et al., 2010). In severe cases surgery becomes the only alternative to treat 
these patients (Erhabor & Adias, 2011).  
 
In Western medicine, many chemotherapeutic, cytotoxic and immunomodulating 
agents are available for cancer treatments. Chemotherapy is the treatment of cancer with 
cytotoxic drugs. Most of these drugs target rapidly growing cells (Robert 2006). A higher 
than normal growth rate is often a characteristic of cancer cells and therefore these drugs can 
target cancer cells. Cancer chemotherapy has been dominated by potent drugs, which either 
interrupt the synthesis of DNA or destroy its structure once it has formed (Sivalokanathan, 
et al., 2005). Unfortunately, their toxicity is not limited to cancer cells, since fast growing 
normal cells (e.g. hair follicles) are also harmed. Apart from the fact that the drugs are 
expensive, they are also associated with serious side effects and morbidity. Major obstacle 
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for successful cancer treatment is the development of drug resistance in cancer cells during 
chemotherapy. The development of multidrug resistance (MDR) to chemotherapy plays a 
major role in the failure of cancer therapy. MDR is caused by: (i) the up-regulation of 
membrane proteins which lower intracellular drug concentration by pumping the drugs out 
of the cell, (ii) changes in phase I and phase II metabolic pathways from 
activation/detoxification of drugs, (iii) changes in DNA repair response and (iv) changes in 
apoptosis response (Kumar & Clark, 1990). Generally most of the known cancer therapies 
cause side effects such as vomiting, nausea, nephrotoxicity (kidney failure), platelet 
reduction, granulocytopenia, erythemia, exfoliate dermatitis, facial edema, myelo 
suppression (reduction of bone marrow function), rash, alopecia (hair loss), hypomelanosis, 
anaphylaxis, gingival discoloration, injection-site cellulites, oral mucosal lesions, diarrhoea, 
anorexia, loss of appetite and taste, neurotoxicity and emetogenesis (American Cancer 
Society, 2006). These side effects may be due to poor drug pharmacokinetics profile, low 
accumulation in cells, increased production of intracellular thiols and increased DNA repair 
capacity. Many neoplasms exhibit a resistance phenotype either before treatment (de novo) 
and /or during treatment (acquired) (Kumar & Clark, 1990; Oommen, et al., 2004; Brabek & 
Kasparkova, 2005; Elwell, et al., 2006). 
 
The designs of new drugs are often challenged by physico-chemical properties such 
as insufficient solubility or hydrolytic instability, making it difficult to control their delivery, 
stability and ultimately their specific effects in vivo. The unresolved problems and side 
effects of current cancer therapy demand an urgent attention, this can be achieved through 
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the development of novel drugs with improved efficacy against tumour cells but with less 
toxicity to normal cells.  
 
1.6 Drug discovery from natural products 
Naturally occurring compounds are the end products of secondary metabolism within living 
organisms. They are biological molecules that are not necessarily essential or directly 
implicated in the normal growth, reproduction or survival of the organism (Verpoorte, 
2000). They are produced by living organisms and may have pharmacological and 
biological properties that can be used in drug development. The metabolites in plants (also 
called phytoconstituents) include alkaloids, glycosides, tannins and flavonoids (Ameenah, 
2006). Some of these phytoconstituents are used by plants in defence mechanisms against 
pathogens, herbivores and environmental stress. They are also produced to promote the 
survival of the plant in its ecosystem. Examples of this include increasing the plant’s 
reproductive appeal through pigmentation (Wink, 1999).  
 
For ages, human beings have relied on nature for shelter, food, clothing, transport 
and medicine. Plants of medicinal importance have been known since the time of 
Hippocrates (5th century BC), and have been used by tribes as infusions, decoctions, 
concoctions and enemas to feed, retard growth, heal, kill, sedate, hypnotise, empower, 
relieve pain and evoke psychiatric disorders, (Dewick, 2001). They contribute significantly 
to rural livelihoods. Apart from the traditional healers practicing herbal medicine, many 
people are involved in collecting and trading medicinal plants to treat a variety of diseases 
and abnormalities such as diarrhoea, malaria, high blood pressure, cancer and psychiatric 
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disorders. World health Organization estimates that 80% of the world’s population depends 
on medicinal plants for their primary health care (Gurib-Fakim & Schmelzer, 2007; 
Mothana, et al., 2008).  
 
Most of the developing countries depend on traditional medicine for their primary 
health care needs because they cannot afford the cost of Western drugs. This made the 
developing countries to encourage the use of herbal medicines in the public traditional 
health clinics (Pieters & Vlietinck, 2005). There has been longstanding scientific and 
commercial interest in screening medicinal plants with the aim of discovering new drugs 
that are more effective (Kinghorn, et al., 2003). Examples of drugs that are of plant origin 
include artemisinins from Artemisia annua (used in the treatment of malaria), atropine from 
Atropa belladonna (used in the treatment of cardiac arrest), digoxin from Digitalis lanata 
(used in the treatment of congestive heart failure) and vincristine from Catharanthus roseus 
or rose periwinkle (used in the treatment of leukaemia).  
 
1.6.1 Ethnobotanical bioprospecting for anti-cancer drugs  
Medicinal plants such as Sutherlandia frutescens, Cotyledon orbiculata, Tulbaghia violacea, 
Taxus baccata and Camptotheca acuminate have a long history of use in the treatment of 
cancer. Sixty five percent of the widely used anti-cancer agents are derived from natural 
sources such as plants and marine organism (Balunas & Kinghorn, 2005). Anti-cancer 
agents from plants currently in use can be categorized into following classes of compounds 
viz,; vinca alkaloids, epipodophyllotoxins, taxanes, camptothecins, homoharringtonine and 
elliptinium (Okouneva, et al., 2003). 
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1.6.1.1 Vinca alkaloids 
Vinblastine and vincristine are alkaloids (Figure 1.5) isolated from Catharanthus roseus, 
formally known as Vinca rosea. These drugs are used in combination with other cancer 
chemotherapeutic drugs for the treatment of different types of cancers such as leukaemia, 
lymphomas, acute leukaemia, advanced testicular cancer, Kaposi’s sarcoma, Hodgkin’s 
disease, neuroblastoma, breast cancer and lung cancer (Cragg & Newman, 2005). The drugs 
act by interfering with glutamic acid metabolism, and by inhibiting cell division (mitosis) in 
metaphase. The drugs bind to tubulin which later prevents the cells from making the 
spindles it requires to separate its chromosomes during cell division (Ngan, et al., 2001). 
Vinblastine and vincristine have a series of side effects such as, headache, stomach pain, 
constipation, nausea, numbness, mouth sores, hair loss, lowered blood cell counts, and 
sensory impairment (Engert, et al., 2007). 
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Figure 1.5 Chemical structures of vinblastine and vincristine.  
 
Vinblastine = 1 R (Me), Vincristine = 2 R (CHO). 
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1.6.1.2 Epipodophyllotoxins  
Epipodophyllotoxin is an isomer of podophyllotoxin, it was isolated from the roots of 
Podophyllum peltatum and Podophyllum emodi. Podophyllotoxin and its derivatives are 
anti-mitotic glycosides. They act by blocking the cell cycle at both G1 and S phases by 
causing damage to DNA through its interaction with DNA topoisomerase II (Clarke, et al., 
1993). The two semi-synthetic derivatives of epipodophyllotoxin are etoposide and 
teniposide (figure 1.6). They are used for treatment of lymphomas and bronchial and 
testicular cancers, chronic carcinomas, Kaposi sarcoma, malignant melanomas and 
lymphoma (Harvey, 1999; Cragg & Newman, 2005). Podophyllotoxin is used in creams to 
treat genital warts which are caused by human papillomavirus (HPV) and this is associated 
with squamous cell carcinomas (Edwards, et al., 1988). Some of the side effects of these 
drugs include low leucocytes and platelet count, hair loss, nausea, vomiting and diarrhoea.  
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Figure 1.6 Chemical structures of podophyllotoxin (A) and etoposide (B) 
 
1.6.1.3 Taxanes  
Taxanes was isolated from Taxus brevifolia nutt (Okouneva, et al., 2003; Gordaliza, et al., 
2004; Horwitz, 2004). Paclitaxel, an example of taxanes was isolated from the bark of the 
Pacific Yew, also known as Taxus brevifolia. The structure of paclitaxel (figure 1.7) was 
elucidated in 1971. Different parts of Taxus brevifolia, Taxus canadensis and Taxus baccata 
 
 
 
 
 37 
 
have been used by some native American tribes for treatments other than cancer, while 
Taxus baccata was used in the Indian Ayurvedic medicine for the treatment of cancer 
(Cragg & Newman, 2005). 
Paclitaxel was clinically introduced to the US market in the early 1990s (Rowinsky, 
et al., 1992; Mohammad, 2006). It has been widely used in the treatment of ovarian cancer, 
advanced breast cancer, small and non-small cell lung cancer (Rowinsky, et al., 1992). 
Paclitaxel acts by binding to the microtubules thereby affecting their depolymerisation into 
tubulin (Schiff & Horwitz, 1980). Paclitaxel exerts its action by preventing the assembly of 
mitotic spindle which leads to failure of chromosome segregation during cell division (Yoo, 
et al., 1998). Side effects of taxol include, edema, low platelet count, anaemia and breathing 
problems. 
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Figure 1. 7 Chemical structure of Paclitaxel (Taxol®) 
 
1.6.1.4 Camptothecin 
Camptothecin is a quinoline-based anti-cancer drug (figure1.8A) that was isolated from the 
Chinese ornamental tree Camptotheca acuminate Decne (Nyssaceae) (Okouneva, et al., 
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2003; Gordaliza, et al., 2004; Horwitz, 2004). Camptothecin induces apoptosis by targeting 
the nuclear enzyme topoisomerase I. Information on the structure-activity relationships of 
the parent compound camptothecin has led to the development of a more effective soluble 
analogues with manageable toxicities (Dancey & Eisenhauer, 1996). The National Cancer 
Institute (NCI) took the drug into clinical trials in the 1970’s but its use was stopped due to 
severe bladder toxicity (Potmeisel, 1995). Semi-synthetic derivatives of camptothecin, 
which include topotecan (figure1.8 A and B) and irinotecan, are used to treat ovarian, small 
cell lung cancers and colorectal cancers, respectively (Creemers, et al., 1996; Bertino, 
1997). Anti-tumour activity of irinotecan and topotecan has been confirmed in phase I/II 
preclinical studies. The side effects of these drugs include nausea, vomiting, lowered blood 
cell counts and severe diarrhoea. 
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Figure 1.8 Chemical structures of camptothecin (A) and topotecan (B) 
 
1.6.1.5 Homoharringtonine  
Homoharringtonine (figure 1.9) was isolated from the Chinese tree, Cephalotaxus 
harringtonia (Powell, et al., 1970; Itokawa, et al., 2005). Homoharringtonine (HHT) is a 
cephalotaxus alkaloid plant that was originally isolated in the People's Republic of China. 
HHT was obtained by alcoholic extraction from the evergreen tree Cephalotaxus 
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harringtonia k. koch var harringtonia. The use of racemic mixture of harringtonine and 
homoharringtonine was reported for the treatment of acute and chronic myelogenous 
leukaemia after failure with interferon (Kantarjian, et al., 1996; Cragg & Newman, 2005). 
They inhibit the synthesis of proteins which later leads to apoptosis. Previous studies have 
suggested antitumor activity of HHT in many neoplastic diseases such as acute non 
lymphoblastic leukaemia and there are no record of cross-resistance with conventional 
antileukemic agents (Warrell Jr, et al., 1985). The activity of HHT against myeloid 
leukaemias has been through inhibition of protein synthesis, promotion of cell 
differentiation as well apoptosis induction through a caspase-3-dependent mechanism 
(Fresno, et al., 1977; Kuliczkowski, 1989; Yinjun, et al., 2004). 
 
 
  
 
 
 
 
 
 
Figure 1.9 Chemical structure of homoharringtonine 
 
1.6.1.6 Elliptinium 
Elliptinium is an intercalating agent belonging to the ellipticine family. In France, 
elliptinium (figure1.10), was isolated from species of the plant family Apocynaceae, 
including Bleekeria vitensis, and it is presently marketed for the treatment of metastatic 
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breast cancer (Cragg & Newman, 2005). They are topoisomerase II inhibitor and help in 
stabilizing the cleavable complex of topoisomerase II and induces DNA breakages, leading 
to inhibition of DNA replication, RNA and protein synthesis (Rouëssé, et al., 1993). 
Elliptinium can be oxidized to yield a reactive electrophilic form which then covalently 
binds to a nucleophilic biological molecule. Elliptinium has shown clinical activity in 
treatment of breast cancer using a weekly regimen. However, some toxicities effects such as 
xerostomia and immune-mediated haemolytic reactions occurred as a result of development 
of anti-elliptinium IgM antibodies (Rouëssé, et al., 1993).  
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Figure 1. 10 Chemical structure of elliptinium  
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1.7 Tulbaghia violacea  
1.7.1 Taxonomy and geographical distribution of Tulbaghia violacea plant 
     
Figure 1.11 Photo of Tulbaghia violacea showing the green hairless leaves and purple flowers.  
Adapted from (Van Wyk, et al., 1997)  
 
T.violacea (figure 1.11) is commonly known as wild garlic, wilde knoffel (Afrikaans), 
isihaqa (Zulu) or itswele iomlambo (Xhosa). T.violacea is indigenous to the Eastern part 
of South Africa (figure 1.12). It belongs to the subclass monocotyledonae, superorder 
Liliiflorae, and order – Asparagales, with about 30 genera and 600 species (Dahlgren, et 
al., 1985) belonging to the alliacea family (Fay & Chase, 1996). The subfamily name is 
derived from the generic name of the genus known as Allium. Allium sativum belongs to a 
member of the lily family.  Southern African species include Tulbaghia violacea, Tulbaghia 
acutiloba, Tulbaghia capensis, Tulbaghia leucantha, Tulbaghia ludwigiana and Tulbaghia 
natalensis (Burbidge, 1978). A few species were reported in the UK, such as T.violacea, 
T.cominsii, T. acutiloba, T.natalensis, and T. montana, although most are rather tender 
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and are best grown as warm greenhouse plants (Burbidge, 1978). In the USA, it is 
cultivated as a decorative plant (Watson & Dallwitz, 1992). 
 
 
   T.violacea                                                                     
                     T.violacea                                                           
Figure 1. 12 Geographical distribution of Tulbaghia violacea in Eastern Cape and KwaZulu-Natal  
                     
 Tulbaghia species are plants with small flowers and grassy foliage. It is a perennial 
plant with corm-like rhizomes and narrowly linear, evergreen aromatic leaves with tubular 
mauve or pale purple flowers, occurring in groups of about ten at the tip of the slender stalk 
(Burbidge, 1978) (figure1.11). They are characterized by rhizomatous rootstalks with a 
pungent, skunky or alliaceous scent. The height of T.violacea at maturity ranges from 30 
cm to 120 cm depending on the environmental conditions. The plant can be grown 
successfully in a tub and transferred to a greenhouse or a frost free place for the winter 
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(Watson & Dallwitz, 1992). T. violacea produce a strong odour of onion or garlic when 
bruised (Watt & Breyer-Brandwijk, 1962), hence its common name wild garlic (van Wyk et 
al., 2000) and/or society garlic (Watson & Dallwitz, 1992). 
 
1.7.2 Medicinal uses, reported chemistry and biological activities of Tulbaghia violacea 
T.violacea is an edible plant which has been cultivated for hundreds of years. (Van Wyk, et 
al., 1997). The leaves and tubers are widely used as herbal remedies for various ailments 
such as fever, colds, asthma, tuberculosis, rheumatism, paralysis, hypertension, stomach 
problems and cancer. It can also be used as a snake repellent or consumed as vegetable 
delicacies (Van Wyk & Gericke, 2000). They are used as decoctions that are either taken 
orally or as enema (Hutchings, et al., 1996).   
                          
 Despite its garlic-like flavour, T.violacea consumption is not accompanied by the 
development of bad breath when compared with the consumption of A. sativum (Kubec, et 
al., 2002). Hence it is commonly called “sweet garlic”. This suggests that T.violacea and 
A.sativum do not contain the same volatile chemical compositions. It was reported that 
T.violacea contain a carbon-sulphur lyase enzyme whose mode of action is related to that of 
lyases in the other Allium species (Jacobsen, et al., 1968). Studies have shown that 
T.violacea have secondary metabolites similar with garlic, thus both show similar biological 
activities and moreover they both belong to the same family (Order Asparagales, Family 
Alliaceae) and have the characteristic sulphur smell of garlic (Van Wyk, et al., 1997; Van 
Wyk & Gericke, 2000; Bungu, et al., 2006; Thamburan, et al., 2006). The medicinal 
properties of garlic have been attributed to the sulphur compounds, which incidentally have 
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been isolated in both plants (Burton & Kaye, 1992; Kubec, et al., 2002). These sulphur 
containing compounds are produced when alliinase, an enzyme present in all plants 
belonging to the Allium species, reacts with alliin when the plant is bruised/ crushed (Burton 
& Kaye, 1992; Kubec, et al., 2002). 
 
Jacobsen et al. (1968) reported the presence of C-S lyase as well as three 
unidentified S-substituted cysteine sulfoxide derivatives. This was corroborated by Burton 
and Kaye (1992) who isolated 2, 4, 5, 7-tetrathiaoctane 2, 2-dioxide and 2, 4, 5, 7-
tetrathiaoctane from the leaves of T.violacea. Similarly, Kubec et al. (2002) isolated 2,4,5,7-
tine derivatives detected by Jacobsen et al. (1968) as (RSRC)-S- (methylthiomethyl)cysteine-
4-oxide (marasmin); (SSRC)-S-methyl and (SSRC)- S-ethylcysteine sulfoxides (methiin, 
MCSO and ethiin, ECSO, respectively). Other classes of compounds reported in 
T.violacea include falonols e.g kaempferol and saponins/sapogenins, which are generally 
present in Allium and Tulbaghia (Watson & Dallwitz, 1992).  
 
The crude leaf extracts of T.violacea inhibited angiotensin I converting enzyme 
(ACE) and also blocked the rise in mean arterial pressure (MAP) associated with infusion of 
exogenous angiotensin I in normotensive male Wistar rats;(Raji, et al., 2012). Mackraj, et. 
al, (2008) observed a reduction in systemic arterial BP associated with decreased renal 
angiotensin II type 1 (AT1) receptor gene expression in Dahl Salt–sensitive (DSS) rats. 
Studies have also shown that T.violcea has anti-fungal activity against Candida albicans 
(Motsei, et al., 2003) potential benefits in treating coccidial infections (Naidoo, et al., 2008) 
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and also anti-bacterial activity against Staphylococcus aureus and Bacillus subtilis 
(Gaidamashvili & van Staden, 2002; Motsei, et al., 2003).  
 
  Lyantagaye,( 2005) used the whole plant of T.violacea, and did water extraction, he 
tested the extract on extract on CHO, MCF7, HeLa, H157 and MG63 cell lines using 
APOPercentage
TM
 assay and found out that T. violacea crude water extract induced 
the apoptotic cell death in CHO, MCF7 and HeLa cells but not in H157 and MG63 cells, 
he went further to do apoptosis–guided fractionation to further purify the compound 
responsible for the apoptotic activity of T.violacea plant. He used elemental analysis, IR, 
NMR and single crystal X-ray diffraction to characterize and identify the structures of 
active compounds and he was able to identify the structures of the active compounds, as 
methyl-α-D- glucopyranoside (MDG) (figure 1.14), as one of the major compounds 
responsible for the activity. He tested those three compounds on CHO cell lines using 
APOPercentage
TM
 assay and found MDG to induce apoptosis within 1hour of induction 
and that MDG was the most active compound and it is also commercially available. Burton 
(1990)  also identified free sugars including glucose, fructose, sucrose, maltose, arabinose, 
rhamnose, xylose and galactose, and glycosides from water extract of T.violacea. Therefore 
MDG was used in this study, because it is commercially and readily available.  
 
 T. violacea leaves and bulbs have been reported to have anti-proliferative and pro-
apoptotic activities on human cancer cell lines (Bungu, et al., 2006; Bungu, et al., 2008). It 
was observed that T. violacea exhibited biological activities which were similar to garlic, 
suggesting T. violacea extract can be substituted for garlic. T. violacea also has 
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anticoagulant (Bungu, et al., 2008), antithrombotic (Bungu, et al., 2008) and antioxidant 
properties (Naidoo, et al., 2008). These properties play very significant roles towards the 
prevention and treatment of hypertension as well as some other cardiovascular diseases. 
1.8 Research questions 
A study by Lyantagaye (2005) reported that MDG was one of the compounds present in 
the water extract of T.violacea that was responsible for the pro-apoptotic activity of the 
plant extract. This study also proposed that this compound could be further investigated as 
an anti-cancer agent. The study by (2005) did not investigate the mechanism by which 
MDG induces apoptosis. Hence the main focus of this study was to further investigate 
MDG as a novel anticancer agent with pro-apoptotic activity that can be used to treat 
cancer. The question that this study wanted to address is how MDG induces apoptosis in 
cultured human cancer cells. Furthermore, to isolate and identify additional compounds 
with pro-apoptotic activity from T.violacea using alternative extraction methods based on 
organic solvent extraction. 
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Figure 1. 13 Structure of Methyl- α-D-glucopyranoside 
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1.9 Objectives:  
The objectives of this research are : 
1. To confirm the pro-apoptotic activity of MDG both in human cancer and non-
cancerous cells. 
2. To investigate the mechanism of MDG induced apoptosis. 
3. To isolate and characterise pro-apoptotic compounds from different parts of the 
T.violacea plant using bioactivity guided fractionation. 
 
1.10 Hypothesis:  
Based on traditional knowledge, the T.violacea plant can be used to treat cancer and anti-
cancer agents can suppress cancer by inducing cell death through the activation of apoptosis 
(Harpreet, et al., 2011). Therefore if extracts of the T.violacea plant have anti-cancer 
activity, it is likely that the extracts can induce apoptosis in human cancer cells. This pro-
apoptotic activity can be ascribed to the presence of a bioactive compound or compounds in 
the extract. The hypothesis is that it should be possible to extract these compound(s) using 
bioactivity bio-guided fractionation. This may lead to the identification of novel anticancer 
agents. 
1.11 Problem Statement: 
Cancer is the second leading cause of death globally (World Health Organisation, 2009). 
Many currently used anti-cancer drugs are associated with serious side effects and resistance 
(Michael, 2002; Xing-Jie, et al., 2010). Most anti-cancer drugs are derived from medicinal 
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plants (Harpreet, et al., 2011). There is therefore need for more research to discover new 
anti-cancer treatments from herbal medicines used in the traditional medicine modality and 
identify novel compounds and mechanisms of action.  
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2.1. GENERAL CHEMICALS 
 Chemical                                                              Suppliers 
Acetone...................................................................... Sigma  
n-Butyl alcohol.......................................................... Sigma 
Chloroform................................................................ Sigma 
D2O (Deuterated water)........................................... Sigma  
DCM (Dichloromethane).......................................... Sigma 
DMSO (Dimethyl sulfoxide)..................................... Sigma  
Ethanol...................................................................... Sigma 
Ethyl acetate............................................................   Sigma 
Hexane....................................................................... Sigma 
Hydrochloric acid...................................................... Sigma 
Methanol.................................................................... Sigma 
Silica gel 60 F254........................................................ Merck 
Sulfuric acid (H2SO4). .............................................. Merck  
TLC plates (Silica gel 60 F254)................................ Merck  
Toluene......................................................................  Merck  
Vanillin......................................................................  Merck  
             Liquid Nitrogen...................................................Merck 
The solutions and chemicals used were of HPLC, UnivAR and AnalaR or equivalent 
grade 
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2.1.1 Commercial Kits/ Molecular Probes: 
APOPercentage™ apoptosis assay (A1000)……………………………Biocolor Ltd 
CM-H2DCFDA) molecular probe (C6827)…………………………..…Invitrogen 
Active caspase-3-PE apoptosis kit........................................................BD Biosciences 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-   
Diphenyltetrazolium bromide (MTT dye)..............................................Sigma 
 
2.1.2 Tissue Culture Media 
Nutrient mixture F-12 (Ham) with L-Glutamine..... Invitrogen  
Phosphate Buffered Saline (PBS)  
 without CaCl
++
 MgCl,
++
....................................... Gibco      
FoetalBovineserum(FBS)...................................... Invitrogen  
Penicillin-streptomycin                                          Invitrogen  
             Dulbecco’s Modified Eagle’s Medium (DMEM)....... Invitrogen  
Trypsin..................................................................Invitrogen  
 
2.1.3 General Solutions and Buffers 
Doxorubicin: 10µM of Doxorubicin in DMSO. 
Vanillin-H2SO4 spray reagent: 15ml of 10% vanillin in ethanol mixed with 0.5ml H2SO4  
70% Ethanol: 700ml of ethanol in 300ml of distilled water. 
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2.1.4 Plant Collections 
T.violacea plants were collected from Van Den berg garden village in Stellenbosch, South 
Africa in May 2009 during winter season. It was authenticated at Biodiversity and 
Conservation Biology department, University of the Western Cape by Mr Frans Weitz and 
the voucher specimen numbered 6975 was deposited at the university herbarium. 
 
 2.2 METHODS 
 2.2.1 Tissue Culture                
All the cells (table 2.1) used in this study were maintained in a 37°C incubator with 5% CO2 
saturation. All the cells used for this study were kindly provided by Prof Denver Henricks, 
Department of Clinical and Laboratory Medicine, University of Cape Town, South Africa. 
HepG2, HT29, MCF7, H157 and KMST6 cells were maintained in DMEM media 
containing 10% FBS, 10% penicillin-streptomycin, while CHO cells were maintained in 
Ham F-12 media containing 10% FBS, 10% penicillin-streptomycin. 
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Table 2.1: Cell lines used for the study  
 
 
 
CELL LINE 
SPECIES MEDIA 
HT-29 (Colon 
adenocarcinoma 
grade II) 
Human DMEM 
H157 (Non 
Small Cell Lung 
Carcinoma) 
Human DMEM 
HepG2 (Human 
hepatocellular 
liver carcinoma) 
Human DMEM 
MCF-7 (Breast 
adenocarcinoma) 
Human DMEM 
KMST-6 (Non 
Cancer Human 
Fibroblast) 
Human DMEM 
 
CHO (Chinese 
Hamster Ovary) 
Chinese 
Hamster 
Hams 
F-12 
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2.2.1.1 Thawing of cells. 
An amount of 5ml of DMEM media was placed at 4°C to cool. A vial of frozen cultured 
cells indicated in table 2.1 was taken from the -150
o
C freezer cells were removed from the -
150°C freezer and thawed in a 37°C water bath. The cells were transferred to a 15ml tube 
which contained the pre-cooled 5ml of DMEM media and centrifuges at 3000g for 
3minutes. The supernatant was decanted and the pellet detached. The cells were then 
resuspended in 5ml media. The latter was put into a 25 cm
2
 tissue culture flask. The flask 
was incubated at 37°C at 5% CO2 until confluence was reached. 
 
2.2.1.3 Cell count 
Cell counts were performed using the countess
TM
 automated cell counter (Invitrogen). The 
countess
TM
 automated cell counter is a bench top automated cell counter that performs cell 
counts and cell viability measurements using trypan blue stain. The countess
TM
 automated 
cell counter uses disposable cell counting chamber slides that contain two enclosed 
chambers to chambers to hold the samples to allow for measurement of two different 
samples or perform replicates of the same sample. The cell counting occurs in the central 
location of the counting chamber and the volume counted is 0.4μL, the same as counting 
four (1mM x1mM) squares in a standard hemocytometer. 
 
2.2.1.4. Trypsinization of cells 
The cells were trypsinized once confluency was reached. The DMEM media in the flask was 
discarded and cells were washed with phosphate buffered saline (PBS). The PBS was 
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discarded and cells were trypsinized with the addition of 1 x trypsin and allowed to 
trypsinize at 37°C for 2–3minutes. DMEM media was added to the flask to stop 
trysinization. The cells were collected by centrifugation at 3,000g. 
 
2.2.1.5 Seeding of cells 
Once cells were thawed and incubated in a 25cm
2
 tissue culture flask, cells were incubated 
at 37°C until confluency was reached. Cells were then trypsinized and centrifuged to 
remove the supernatant and resuspended in 5ml of DMEM media. Cells were counted with 
the use of the countess
TM
 automated cell counter (Invitrogen) and seeded at the following 
densities: 5ml of 2.4 x 10
4
 cells/ml in 25 cm2 flasks, 1 ml of 1.0 x10
5 
in 24 well plates, 2ml 
of 2.5 x 10
4
 cells/ml/well in 6-well plates or 100μl of 0.25 x 105 cells/ml/well in 96-well 
plates. When 6, 24 or 96 well plates were used, 2ml, 1ml, 500µl or 100µl of cells were 
seeded respectively. Cells were incubated at 37
o
C until ready for testing.  
 
2.2.1.6 Freezing of cells 
For long term storage the cells were trypsinized and centrifuged. The cell pellet was 
resuspended in DMEM media containing 10% DMSO. The latter was aliquot into 2ml cryo-
vials and stored at -150°C. 
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2.3 BIOGUIDED FRACTIONATION OF ACTIVE COMPOUNDS 
2.3.1 Plant Extraction Flowchart 
 
KEY: 
A-E – 90% HEX/ DCM 
F-I - 25% DCM/HEX 
J - 75% DCM/HEX 
K -75% DCM/HEX 
L -75% DCM/HEX 
M -90% DCM/HEX 
N=100%EA 
P=90%EA/MEOH 
Q=50%EA/MEOH 
R =50%EA/MEOH TO 100% MEOH  
TVL- Tulbaghia violacea leaves 
 
Figure 2.1: Flow chart of activity-guided fractionation of Tulbaghia violacea leaves and 
tubers. 
KEY: 
MF1 - 100% Hex 
MF2 – 50% Hex /DCM 
MF3 – 100% DCM 
MF4–70% DCM/MeOH 
MF5-50% DCM/MeOH 
MF6-20%DCM/MeOH 
MF7-100% MeOH 
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2.3.2 Preparations of the plant material for water extraction  
The leaves and the tubers were separated, rinsed with distilled water and dried at room 
temperature for 7days. The plants parts were cut into pieces and later pulverized and 
blended using a domestic blender (PHILIPS HR 1737, Cucina, Brazil). About 100g of the 
leaves and tubers were soaked separately and shaken overnight. This process was repeated 
thrice. The extract was later filtered with Buchner vacuum filter. After filtration, both 
leaves and tuber extracts were concentrated using VIRTIS SENTRY
TM 
freeze dryer (The 
Virtis company, Garner, New York), powdered extracts were later obtained and kept in 
desiccators until further use. 
 
2.3.3 Organic extraction preparation 
About 75.5g of Tulbaghia violacea leaves (75 g) were extracted with hexane (3 x 7.5liters) 
for 24hours by continuous stirring and shaking at 37
0
C and then filtered. Combined Hexane 
extracts were evaporated to dryness under reduced pressure. This residue was sequentially 
extracted with DCM, Methanol and 50% methanol. After solvent extraction, the concentrate 
was dried under reduced pressure on a rotary evaporator (Rotary Vacuum Evaporator NE-1 
Eyela Tokyo Rikakikai co, Ltd). The extracts were kept in desiccators at room temperature 
till needed and later tested for bioactivity. 
 
2.3.4 DCM fraction preparation 
DCM fraction was obtained from the sequential extraction made on the leaves. The fraction 
was further purified using Versaflash (figure 2.2). The solvents were chosen based on 
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solvent polarity as follows in this order:– 90% HEX/ DCM(A-E), 25% DCM/HEX (F-I), - 
75% DCM/HEX (J), 75% DCM/HEX (K), 75% DCM/HEX (L), 90% DCM/HEX (M), 
100%EA (N), 90%EA/MEOH (P), 50%EA/MEOH (Q) and, 50%EA/MEOH TO 100% 
MEOH (R). All the fractions were spotted on TLC to monitor the purification processes. 
 
2.3.5 Methanol fraction preparation 
Methanol fraction was obtained from the sequential extraction made on the leaves. The 
fraction was further purified using Versaflash (figure 2.2). The solvent were chosen based 
on solvent polarity as follows in this order: 100% Hexane (MF1), 50% Hex/DCM (MF2), 
100% DCM(MF3), 70%DCM/Methanol (MF4), 50% DCM/Methanol (MF5), 20% 
DCM/Methanol (MF6) and finally with 100% Methanol (MF7). The fractions were spotted 
on TLC to monitor the purification processes. 
 
2.3.6 Determination of extraction yield (% yield) 
The percentage yield of dried plant material were calculated as follows  
%Yield = (weight of dried extract / weight of dried sample) *100 
The yield (%, w/w) from all the dried extracts was calculated as: 
Yield (%) = (W1 * 100)/W2 
Where W1= weight of the extract after lyophilization of solvent, and 
 W2 = weight of the plant powder. 
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2.3.7 Bio-Guided fractionation of T. violacea leaves  
Bio-guided fractionation of the DCM extract of T.violacea leaves was performed on 
VersaFlash high throughput flash purification (HTFP) (figure 2.3) system eluting first with 
100% Hexane and gradually increase polarity by adding DCM, then ethylacetate and finally 
100% methanol. (see Figure 2.1 for flowchart). Fractions were dried by rotary evaporator 
then sealed and kept at room temperature until needed. VersaFlash High Throughput Flash 
Purification (HTFP) system (Figure 2.2) is the first system to offer all of the capabilities 
required for flash separations and the versatility to perform unique purification tasks that 
conventional ash systems do not allow. These capabilities allow scientists to expand beyond 
the limitations of contemporary flash chromatography, saving time and money while 
improving their separations.  
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Figure 2.2 Versaflash High Thoroughput Flash Purification System (HTFP) (image 
from (www.sigmaaldrich.com)). 
 
2.3.8 Thin layer chromatography (TLC) 
TLC was used to monitor the purification process from the crude extract to the final 
stage. It was done by using silica gel 60 F254 analytical TLC aluminium plates, and 
three different combinations of mobile phase; Hexane: Ethyl acetate (8:2v/v) (HE), 
Ethyl acetate: Hexane (2:8v/v) (EH) and Butanol: acetic acid: water (5:1:4v/v) (BAW). 
The developed TLC plates were visualized under UV at 254 nm and then sprayed with 
anisaldehye or vanillin spraying reagents then heating at 105 
o
C for 1-3 min. The relative 
retention factor (RRf) values were used to compare the compounds present in different 
apoptotic fraction from the crude extract. 
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2.3.9 Characterization and identification of the apoptotic compounds 
2.3.9.1 Nuclear Magnetic Resonance (NMR) 
A white crystalline compound isolated from DCM extract (Fraction A-E) (Figure 2.2) was 
characterised on NMR. NMR spectra were recorded, on a 600 MHz Varian Unity Inova 
spectrometer (Gemini 2000)  equipped with an Oxford magnet (14.09 T) and a 5 mm 
indirect detection PFG probe housed at the Department of Chemistry, Stellenbosch 
University. Software used to run the instrument and generate the spectra is VNMR 6.1C. 
1D and 2D. 10mg of the purified fraction (fraction A-E) (Figure 2.2) was dissolved in D -
chloroform (1ml). 
1
H chemical shifts were referenced to the residual signals of the 
protons of solvent and were quoted in ppm downfield from tetramethylsilane (TMS).  
2.3.9.2 Gas chromatography mass spectroscopy (GC-MS) 
 GC-MS was used to identify the compound (s) present in DCM extract (Fraction 
A-E) of Tulbaghia violacea. The instrument used was Agilent 6890N GC; Agilent 
5975MS housed at Stellenbosch University, Central Analytical Facility (CAF). 
The injector temperature was 260
0
C, the column used was HPS (30m, 0.25, mm 
ID, 0.25 µM film thickness), with injection volume of 1 µl and split ration of ratio 
1:10. The constant flow was 1 ml/min, the carrier gas used was Helium while the 
MS transfer temperature was at 280
0
C. The electron energy used was 70eV with 
scanning mass ranging from 35 to 550m/z with 3.9 minutes solvent delay.  
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The oven temperature programme was set as follows: 
Oven 
Ramp 
°C/minutes Temp 
(°C) 
Hold 
(minutes) 
Initial  40 5 
Ramp 
1 
10 300 10 
Ramp 
2 
15 310 0 
 
2.3.9.3 Liquid chromatography mass spectroscopy (LC-MS) 
The fractions were obtained according to the method described in Figure 2.2. Mass 
spectrometry was done at Stellenbosch University, Central Analytical facility 
(CAF). The fractions were introduced into a Waters (Milford, Massachusetts, 
USA) Time of Flight (TOF) Synapt G2 mass spectrometer by injecting into a 
Waters UPLC front-end. The chromatographic separation was achieved on a 
Waters BEH C18 column (2.1 x50mm) at a flow rate of 0.4 ml/minute using mobile 
phase A ( water + 0.1% formic acid) and mobile phase B (acetonitrile + 0.1 formic 
acid). Gradient elution was done as follows: 0-0.5mon 100% A, 0.5-17 minutes 
linear gradient to 100% B, then return to original conditions in the last 2 minutes. 
The TOF MS/MS system was operated in electrospray positive ion mode with 
capillary voltage of 3 kV and cone voltage of 15V. Mass spectra were acquired in 
the range of 100-2000 m/z. All experiments were conducted under automatic gain 
conditions.  
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2.4 BIOASSAYS  
2.4.1 Morphological Evaluation treated and untreated cells 
Different cell lines shown in table 2.1 were cultured in 6 well culture plates to 90 % 
confluence. The cells were induced to undergo apoptosis with the plants extracts while the 
negative control cells were left without treatment and the positive control treated with 
10µM of doxorubicin. The cells were incubated for 24hours at 37C in 5% humidified 
incubator. Following incubation, the cells were inspected under an inverted (Nikon) light 
microscope using 20X objective and pictures were taken using a Leica EC3 digital camera. 
The morphology of the cells was evaluated and recorded (Fink & Cookson, 2005; Kroemer, 
et al., 2005; Kroemer, et al., 2007). 
 
2.4.2. xCELLigence System 
xCELLigence system (see Figure 2.1) was used to evaluate the effect of MDG on cell 
proliferation using CHO (Chinese Hamster Ovary ) cell lines. This system is the predecessor 
of the new xCELLigence system jointly developed by Roche Applied Science and ACEA 
Biosciences. These systems utilize an electronic readout called impedance to non- 
invasively quantify adherent cell proliferation and viability in real-time 
(com/sis/apoptosis/docs/manual_apoptosis.pdf). The cells were seeded in standard microtiter 
plates that contain microelectronic sensor arrays. The interaction of cells with the electronic 
biosensors generates a cell-electrode impedance response that not only indicates cell 
viability but also correlates with the number of the cells seeded in the well. This impedance 
technology offers an innovative solution to a number of limitations in current assay systems. 
First, impedance measurements are non-invasive, so the cells remain in a more normal 
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physiological state during assays of cell proliferation and cytotoxicity. Secondly, the system 
is more economical, since it does not require labelling the cells with expensive reagents. It 
allows real-time, rather than end point, measurement of cell proliferation, viability and 
cytotoxicity. Real-time and continuous monitoring offers several distinct advantages. For 
example, it provides constant quality control for the cells allowing the user to make 
informed decisions about the timing of certain manipulations such as compound addition.  
 
In addition, an actual kinetic record of the cells prior or subsequent to a certain 
manipulation provides important information about the biological state of the cell, revealing, 
for example, enhanced cell growth, cell quiescence, morphological changes or cell death. 
Furthermore, when cytotoxic drugs are tested, real-time monitoring allows calculation of 
time-dependent IC50 values; these are more informative than single time point IC50 values, 
which can vary dramatically depending on the time the experiment was terminated. 
Traditional methods would require multiple assays and experiments to gather that much 
information about the mechanism of action of various drugs. In order to show that this new 
method is superior to traditional methods and suitable for cell proliferation, viability and 
cytotoxicity studies, and a number of experiments were conducted to assess cell 
proliferation and drug interaction with different cell lines (https://www.roche- applied-
science.com/publications/print_mat/ lab_faqs.pdf).  
 
To assess dynamic apoptosis induction of MDG and ascertain whether cell Index 
units correlate with the number of cells in the well, increasing numbers of CHO (Chinese 
hamster ovary) cell lines were seeded at 2500 and 10000 cells per well in triplicate in a 
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standard microtiter plates that contain microelectronic sensor arrays. CHO cells were grown 
and cell counts were done according to sections 2.2.1.1 and 2.2.1.2 respectively. Plates were 
monitored until when the cell reaches 70 to 80% confluence, at which time the cell Index 
was obtained they were also monitored every 30minutes for the indicated period of time. 
Each cell type has its own characteristic kinetic trace, based on the number of cells seeded, 
the overall size, morphology of the cells and the degree to which the cells interact with the 
sensor surface. Also, each of the cell lines can be characterized by its unique adhesion and 
spreading kinetics, as well as the time at which it enters the log growth phase.  
 
 
 
Figure 2.3: The xCELLigence system 
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2.4.3 Measurement of cell surface modifications (externalization of PS) using 
APOPercentage apoptosis assay measured by Flow cytometer. 
After cells were grown to 90% confluence in 24 well culture plates, they were treated with 
various concentrations of the plant crude extracts for 24hours. l0µM doxorubicin was used 
as a positive control for cells induced with the plant crude extracts for 24hours. The cells 
were induced for 24hours because APOPercentage showed good positive results at 
24hours of induction. This was also consistent with other studies (Jirsova, et al., 2006). 
Negative control cells were however, left untreated for 24hours so that they could be used to 
properly distinguish normal cells from apoptotic cells. Following incubation, floating 
(apoptotic) cells were transferred to 15ml centrifuge tube and the adherent cells were 
trypsinized and mixed with the tube containing the floating cells. The cells were washed 
twice with PBS, and resuspended in the residual PBS. APOPercentage dye in complete 
culture media diluted 1:160 was prepared. 200 l of the dye was added to the tube and the 
cells were incubated for 30minutes at 37
o
C in a humidified CO2 incubator. After the 
incubation period, 500μl of PBS was added to the tube and spun down for 5minutes at 
300xg. The pellet was washed one more time with PBS. After which the pellet was 
resuspended in 400l of PBS and the cells were acquired and analyzed on a FASCanTM 
(Becton Dickson) instrument equipped with a 488 nm Argon Laser as a light source within 
one hour.  
 
Acquisition was done by setting forward scatter (FSC) and side scatter (SSC) on a 
log scale dot plot to differentiate population of cells and cellular debris. On a linear 
histogram dot plot, APOPercentage. (FL-3 channel) was measured against relative cell 
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numbers. Negative control cells were used to set the cells in the negative quadrant before all 
samples were acquired. The instrument settings were as follow: voltage set at 470 and 
AmpGain set at 1. Acquisition was done in Log mode. A minimum of 10,000 cells per 
sample were acquired and analysed using CELLQuest PRO software (BD Biosciences) by 
setting the non stained (untreated) cell population in the first quadrant (10
1
) of the forward 
side scatter histogram dot plot and cells which appeared in the second (10
2
) or third quadrant 
were regarded APOPercentage
TM
 positive (apoptotic/necrotic).  
2.4.4 Measurement of Caspase-3 activity.  
In this assay, cells were seeded at a density of 2.5x10
4
 cells per ml in 24 well culture plates 
and were incubated at 37
o
C in a humidified CO2 incubator for 24hours. The culture media 
was then removed and replaced with media containing 2mg/ml of water and organic extracts 
of T.violacea leaves extracts. The cells were incubated for 24hours at 37
o
C in a humidified 
CO2 incubator. Positive control cells for the plant extract were induced with 10 μM of 
doxorubicin for 24hours. Negative control cells received no treatment. The adherent cells 
were gently washed once with 1000μl PBS trypsinized with 500μl of 0.125% trypsin and 
incubated for 5-10 minutes at 37
o
C in a humidified CO2 incubator. When the cells were 
detached, 500μl of complete culture media was added to the cells to stop the action of trypsin, 
and then the cells were transferred into the 15ml tube containing apoptotic cells and 
centrifuged to a pellet at 300xg for 5minutes. The pellet was washed twice with 1ml cold PBS 
and resuspended in 0.5ml Cytofix/Cytoperm at a concentration of ~1.0x106 cells/ml then 
incubated on ice for 20 minutes. After incubation on ice, the cells were spun down in a bench 
top centrifuge for two minutes at 2000g. The Cytofix/Cytoperm was aspirated and 
discarded and pellet washed twice with 0.5ml Perm/Wash buffer at room temperature. Total 
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number of samples was determined and the amount of Perm/Wash buffer and antibody 
calculated so that each sample received 100 μl Perm/Wash buffer and 20μl Antibody. The 
cells were incubated for 30minutes at room temperature in the dark. At the end of the 
incubation period, the cells were washed twice in 1.0ml of Perm/Wash buffer. The 
supernatant was discarded and the pellet resuspended in 0.5ml Perm/Wash buffer by 
flicking the tube (Fujita & Tsuruo, 1998).  
 
The cells were acquired and analyzed on a FASCan (Becton Dickson) instrument 
equipped with a 488 nm Argon Laser as a light source.  Using dot plot cell fluorescence was 
measured by setting the Forward (FSC) and Side Scatter (SSC) to differentiate cell 
populations and cell debris. On a log histogram dot plot, FL1 channel (Active Caspase-3 
FITC) was measured against relative cell numbers. Negative control cells were used to set the 
cells in the negative quadrant before all samples were acquired. A minimum of 10,000 cells 
per sample was acquired and analyzed using CELLQUEST PRO Software (BD Biosciences). 
 
2.4.5 Evaluation of cytotoxicity using MTT Assay 
Cell proliferation was determined using the MTT assay following the methods described by 
Mosmann, 1983; Eguchi, et al., (1997) and Freimoser, et al., (1999) with minor modifications 
(Mosmann, 1983; Eguchi, et al., 1997; Freimoser, et al., 1999). The MTT assay is a method 
that is technically convenient, it doesn’t involve washing steps and it is easy to apply in most 
experimental designs. Cells were trypsinized and cell counts of 2.4104 were prepared in 
50ml cell culture tubes. From this 100 µl was withdrawn and seeded in each well of 96 well 
plates and were let to grow to the required confluence. Then culture medium was removed 
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and replaced with 100 µl of fresh medium without or with various concentrations of the test 
compounds. Triplicate wells were established for each concentration and the cells were 
incubated for 24hours for 4 hours at 37
0
C in a humidified CO2 incubator. Tetrazolium salt 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was dissolved in PBS 
(pH 7.2) to obtain a concentration of 0.5 mg/ml and 10 µl of MTT solution was added to each 
well. The plates were incubated for 4 hours at 37
0
C in a humidified CO2 incubator. At the end 
of the incubation period media was removed from each well and replaced with 100 µl DMSO. 
The plates were shaken on a rotating shaker for 10 minutes before taking readings at 560 nm 
using a microplate reader. Results of cellular viability were tabulated as mean absorbance of 
each compound expressed as a percentage of the untreated control and plotted against 
compound concentration. IC50 values were tabulated from the graphs as compound 
concentrations that reduced the absorbance at 560 nm by 50% of the untreated control wells. 
To exclude background readings, three wells were seeded with untreated cells in which MTT 
was not added. Assays were done in triplicate to ensure reproducibility.  
The percentage inhibitions of cell proliferation were calculated using the following formula: 
% cytotoxicity =    Abs of negative control – Abs of treated cells       * 100 
                         Abs of negative control 
 
Dose– response curves were plotted from % IC (Inhibition of cell proliferation values versus 
concentration of crude extracts (mg/ml) x-axis, log scale. Concentrations that inhibit cells 
proliferation by 50 % (IC50) were calculated by locating the x-axis values corresponding to 
50 % inhibition of cell proliferation Y – axis. 
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2.4.6 Determination of Reactive Oxygen Species 
To evaluate intracellular ROS, we used the molecular probe 5-(and-6)-chloromethyl-2', 7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) method as described by 
Wei et al. (2000) with minor modifications. It is a most common probe widely used in in- 
vitro biological research. CM-H2DCFDA is a non-fluorescent probe that freely permeates into 
cells, however, it hydrolyzes to DCFH when inside the cell. Recently studies have shown that 
DCFH2-DA fluorescence is much more likely due to cytosolic redox change because the 
probe cannot penetrate into mitochondria (Abramov, et al., 2007). The background 
fluorescence exhibited by DCFH2-DA could also be due to some metal impurities present in 
the culture media. Oxidation of DCFH2-DA can occur in the presence of intracellular reactive 
oxygen species which includes  H2O2, peroxy radicals and peroxynitrite (Royall, et al., 
1993a). In the presence of DCFH, correct oxidant oxidizes to highly fluorescent 2', 7'-
dichlorodihydrofluorescein (DCF), and can be detected by flow cytometry. Its detection is 
specific for intracellular ROS.  
 
Briefly, H157, HepG2, HT29, MCF7 and KMST6 cells were cultured in 24 well 
culture plates and were either left untreated or treated with 2mg of the plant extracts. In 
addition positive control cells were treated with 1% hydrogen peroxide for 24hours. After 
the treatments, cells were trypsinised and transferred to 15ml cell culture tubes and washed 
twice with PBS and stained with 7.5µM of (CM-H2DCFDA) prepared in PBS. The cells 
were incubated for 30minutes at 37
o
C in a humidified CO2 incubator following which the 
cells were acquired and analyzed on a FACScan
TM
 (Becton Dickson) instrument equipped 
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with a 488 nm argon laser. Cell fluorescence (DCF) was measured using (FL-1 channel) 
against relative cell numbers.  
 
2.5 STATISTICAL ANALYSIS 
Results were statistically compared by conducting a one way ANOVA using graph pad 
program. Differences between the mean ± SEM (standard error of the mean) of samples 
were considered significant at P < 0.05., the IC50 values were generated using GraphPad 
Prism software (GraphPad software, San Diego, CA, USA). 
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CHAPTER THREE: INVESTIGATING THE PRO-APOPTOTIC ACTIVITY OF 
MDG 
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system  
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3. 1 Background: 
A number of previous studies demonstrated that extracts of T.violacea induce apoptosis in 
cultured cells and more specifically in cell lines generated from human cancer tissue. These 
studies therefore also propose that the potential anticancer activity of T.violacea can be 
ascribed to this bioactivity. A study by Lyantagaye (2005) isolated three compounds with 
pro-apoptotic activity from the water extract of T.violacea. Two of these compounds were 
novel and were not commercially available. The third compound was identified as MDG 
(figure 3.1) and is commercially available. In the Lyantagaye (2005) study a commercial 
equivalent of MDG was used to demonstrate that MDG induce apoptosis in CHO and MCF7 
cells. This study did not investigate the possible mechanism of MDG induced apoptosis. 
Hence, the objective of this chapter was to carry out an independent evaluation of the pro-
apoptotic activity of MDG on MCF7 and CHO cells in an effort to better understand the 
mechanism of MDG induced apoptosis. The effects of MDG on CHO and MCF7 cells were 
investigated using theAPOPercentage assay, morphological evaluation and the 
xCELLigence system.  
OCH3
H
O
H
OH
H
HO
OH
H
OH
H
 
 
Figure 3.1 Structure of Methyl α-D-glucopyranoside 
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3.2 A study of the morphological changes induced by MDG in cultured cells.
 
The induction of apoptosis is associated with changes in cell morphology (reviewed in 
chapter1). CHO and MCF7 cells were treated for 24hours with MDG and the effects on cell 
morphology were evaluated. The morphology of MCF7 and CHO cells treated for 24hours 
with 2mM MDG were compared to the negative control (untreated cells) and positive control 
(cells treated with 10µM . doxorubicin) cells, respectively (figure 3.2). Doxorubicin is a well 
known chemical inducer of apoptosis and it also used in the treatment of cancer (Weiss, 
1992; Max, et al., 2009). It was observed that there were no discernible morphological 
changes in the cells treated with MDG (even of the highest dose of 2mM), while there were 
morphological changes in both cell types (CHO and MCF7) treated with 10µM doxorubicin. 
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Untreated
Untreated 2mM MDG 10µM Doxorubicin 
2mM MDG 10µM Doxorubicin 
 
Figure 3.2: Morphologicaevaluation of CHO and MCF7 cells treated with MDG 
CHO (panel A) and MCF7 (panel B) cells were treated for 24hours with 2mM MDG or 10µM doxorubicin. The cells were studied by light microscopy using a 
Nikon microscope. Pictures were taken at x20 magnification using a Leica digital camera. The experiments were done in triplicate.  
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3.3. Quantification of apoptosis in CHO and MCF7 cells treated with MDG 
 
CHO and MCF7 cells were treated for 24hours with various concentrations (0.06 to 2mM) 
of MDG. Doxorubicin (l0µM) was used as a positive control. The cells were stained with 
the APOPercentage
TM
 dye and analyzed by flow cytometry (described in section 2.4.3). 
Figures 3.3a and 3.3b show that there was little or no significant difference (P< 0.05) in the 
percentage of apoptotic cells between the control cells (untreated) and cells treated with 
MDG. However, the positive control (cells treated with 10µM doxorubicin) induced 
significant levels of apoptosis in both CHO and MCF7 cells. 
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Figure 3.3: Quantification of apoptosis induced by MDG. 
CHO (A) and MCF7 (B) cells were treated with various concentrations (0.06 to 2mM) MDG. Apoptosis was 
quantified by flow cytometry using the APOPercentage
TM
 assay. The graphs indicate the percentage of 
apoptotic cells observed with the different treatments. The experiments were done in triplicate. 
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3.4 Evaluating the cell proliferation of cells treated with MDG using the xCELLigence 
system  
The xCELLigence system was used to evaluate the effects of MDG on the proliferation of 
CHO and MCF7 cells as described in section 2.4.2. The xCELLigence system measures 
electrical impedance across a microelectrode on an e-plate, thus providing a quantitative 
measurement on the biological status of the cells in real time. The electrical impedance was 
measured every minute over 24hours and is expressed as the cell index (figures 3.4a and 
3.4b). The cell index reduced immediately after MDG was added to the cell culture. This 
reduction was observed for a period of 30minutes, after which the cell index increased 
again. The cell index of the untreated cells continued to increase over time while the cell 
index of the positive control (cells treated with 10µM doxorubicin) decreased continuously 
(graph not shown). 
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Figure3.4a: Cell proliferation assay showing the effects of 1 and 2mM of MDG on 
MCF7 cells. The cells were cultured for 24hours and were then either left untreated or treated with 1mM or 
2mM MDG. The cells were continuously monitored using the xCELLigence system. The arrow indicates the 
time point at which MDG was added to the MCF7cells. 
 
 
 
 
 
 
 
 
 
MDG added 
 
Keys: 
Untreated = Green 
 
1mM MDG = Red 
2mM MDG = Blue 
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Figure 3.4b: Cell proliferation assay showing the effects of 0.5, 1 and 2mM of MDG on 
CHO cells. The cells were cultured for 24hours and were then either left untreated or treated with 0.5Mm, 
1mM or 2mM MDG. The cells were continuously monitored using the xCELLigence system. The arrow 
indicates the time point at which MDG was added to the CHO cells. 
 
 
 
 
 
 
 
 
 
 
 
 
MDG added 
Keys: 
 Untreated = Pink 
0.5 mM MDG = Red  
1.0 mM MDG = Green  
2.0 mM MDG = Blue 
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3.5 Discussion  
A previous study aimed at isolating and identifying the pro-apoptotic compounds present in 
T.violacea extracts identified MDG as one of the bioactive compounds present in the plant 
extract. The objective of the current study was to investigate the pro-apoptotic activity of 
MDG further and to unravel the mechanism by which MDG induce apoptosis in cancer 
cells.  
 
CHO and MCF7 cells were treated with 2mM MDG and Figure 3.2 shows the 
morphological features of the cells after 24hours. The cells treated with 2mM MDG shows 
no discernible morphological changes when compared to the untreated control cells, while 
the morphology of cells treated with 10µM doxorubicin was clearly affected. The cells 
appear to be more rounded and lost contact with one another. It can also be observed that a 
large number of the cells detached from the plate. Although the absence of morphological 
changes suggested that MDG had no effect on the cells, morphological studies on its own 
cannot be used to conclude or confirm that the tested compound did not affect the cells at all. 
This is in agreement with Hacker’s report in 2000 that morphological features of apoptosis 
should be used in combination with other apoptosis assays to evaluate the mechanisms 
underlying apoptosis (Häcker, 2000). The use of biomarker staining and light microscopy 
has been one of the methods used to detect apoptosis (reviewed in section 1.3). Apoptosis is 
associated with a conserved set of morphological features observed in various cell types 
during physiological episodes of cell death (Kerr, et al., 1972). Kerr used changes in 
morphological features to develop the concept of cell death as a tool for the disposal of 
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unwanted cells during embryonic development, normal cell turnover in proliferating tissues 
as well as during pathological conditions such as cancer (Kerr, et al., 1972).  
 
There was need to confirm the apoptotic activity of MDG using an assay that is 
specific for apoptosis. The APOPercentage
TM
 assay is a specific assay for apoptosis. To 
confirm and quantify apoptosis, the assay that takes advantage of the ‘flip-flop’ mechanism 
that is activated in apoptotic cells only. This process causes externalization of a 
phospholipid phosphatidylserine during the apoptotic process (Fadok, et al., 2001). Figure 
3.3a and figure 3.2b shows the result for APOPercentage
TM
 assay following the treatment of 
MCF7 and CHO cells with various concentrations (0.6, 0.125, 0.25, 0.5, 1 and 2mM) of 
MDG. It was observed that less than 10% of the cells treated with MDG (even of the highest 
concentration of 2mM) were positive for apoptosis, 80% of the cells treated with 10µM . 
doxorubicin were positive for apoptosis. The result also indicates that there was little or no 
significant difference (P< 0.05) between the negative control cells (untreated) and cells 
treated with MDG. This was true for both cell lines. 
  
These findings appear to contradict the work done by Lyantagaye (2005). However, 
differences in the execution of the experiments may account for the apparent discrepancies. 
In the study by Lyantagaye (2005) the cells were treated with 0.08 mM MDG for 1hour and 
apoptosis was then quantified using the APOPercentage
TM
 assay. In contrast, in the current 
study, the cells were treated for 24hours before apoptosis is quantified. It is therefore possible 
that the effects observed by Lyantagaye 1hour after the treatment started was in fact a 
transient affect and that the cells recovered from these effects after time. This demonstrates 
 
 
 
 
 84 
 
the limitations of the APOPercentage
TM
 assay, which is based on end-point analysis. To 
overcome this, an assay which measures the effects of MDG in real time was required. The 
xCELLigence system allows for the analysis of cell proliferation in real time. 
 
The xCELLigence system was able to monitor and evaluate the activity of MDG on 
proliferation of treated cells (CHO and MCF7) every minute (figures 3.4a and 3.4b) in real 
time compared to APOPercentage
TM
 assay, which provides an end-point analysis. However, 
in this experiment, CHO cells could not reach 70% confluence until after 72 hours of 
seeding. The cells were monitored from the time of seeding the cells till the end of 
experiment and this gave an edge over APOPercentage experiment. Figure 3.4a shows the 
effects of 1 and 2mM MDG on the proliferation of MCF7 cells and figure 3.4b shows the 
effects of 0.5, 1 and 2mM MDG on the proliferation of CHO cells. The cell index of both 
cell lines reduce immediately after MDG was added to the cell cultures. However, this 
reduction in cell index was a transient event since the cells recovered from the effects of 
MDG after about 1hour. This is indicated by the increase in the cell index. This transient 
reduction in cell index may suggest that the cells change shape and possibly shrink within 
the first hour, but recover after 1hour. It was observed that the cell index of the untreated 
cells continued to increase over time while the cell index of the cells treated with 10µM 
doxorubicin continually decreased over time (data not shown). 
 
It can be concluded from this study that MDG does not induce apoptosis in CHO and 
MCF7 cells at the doses tested in this study. This was confirmed by the apoptosis assay 
(APOPercentage
TM
 assay) and the cell proliferation assay (xCELLigence assay). This is in 
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sharp contrast to the findings by Lyantagaye (2005). However, the contradiction is 
explained by cell proliferation assay which shows that the effects of MDG are only transient 
and that the cells recover from these effects after 1hour. Considering the fact that the studies 
carried out by Lyantagaye (2005) was performed within 1hour of treatment with MDG, it 
can be concluded that MDG is most probably not the bioactive compound responsible for the 
pro-apoptotic activity that was observed in the water extract of T.violacea. Since the other 
two carbohydrate compounds isolated by Lyantagaye (2005) are not commercially available, 
these compounds could not be tested. Consequently, the compound(s) that is responsible for 
this bioactivity (induction of apoptosis) is still unknown. This prompted a renewed study 
into the chemistry of T.violacea to identify these compounds. 
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CHAPTER FOUR: PRO-APOPTOTIC AND ANTI-PROLIFERATIVE ACTIVITIES 
OF T.VIOLACEA EXTRACTS 
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4.1 Background: 
Although the T.violacea plant has been used in traditional medicine to treat various ailments 
including cancer, very little scientific research has been done on this plant to validate the 
uses of this plant. Although a study by Lyantagaye (2005) suggested that MDG could be one 
of the bioactive compounds responsible for the anticancer activity of the plant extract, the 
scientific findings reported in Chapter 3 of this study disputed the findings of the 
Lyantagaye (2005) study.  
 
In the study by Lyantagaye (2005) water extraction of the whole plant was used to 
isolate the bioactive compounds. The water extract was subjected to organic solvent 
extraction to fractionate and isolate the bioactive compounds using bioassay-guided 
fractionation. Hexane, ethyl acetate/water, chloroform/water and n-butylacetate/water were 
used as solvents. In the study by Bungu et al. (2006), cell growth inhibition of methanol 
extracts of T. violacea leaves and bulbs were tested on MCF7, WHCO3, HT29 and Hela 
cancer cell lines. Apoptosis activities were investigated using the Hoechst 33342 dye to 
stain the treated cells for detection of chromatin condensation, nuclear fragmentation and 
Annexin V-FITC/propiodium iodide staining, they however found out that in WHCO3 
treated cell, the leaf extract were more active than the bulb. 
 
This study aimed to use a different approach to isolate bioactive compounds from the 
plant material. Instead of using the whole plant, the tubers and leaves were separated and 
tested independently. In addition, solvent extraction was performed directly on the plant 
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material which thus differs from the previous work done by Bungu et al.(2006) and 
Lyantagaye (2005). 
 
4.2.1 Determining the IC50 values of tuber and leave extracts using the MTT assay 
The cytotoxic activity of water extracts of T. violacea were investigated using 3-(4, 5-
dimethylthiazole-2yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay on different cell 
lines. Various concentrations of the water extracts of T. violacea leaves and tubers were 
prepared and screened against four human cancer cell lines (HepG2, HT29, MCF7 and 
H157) and a non-cancerous human cell line (KMST6). The cells were treated for 24hours 
with increasing doses of the extracts and the cytotoxicity was measured using the MTT 
assay (described in section 2.4.5). The IC50 values (concentration that inhibits cell 
proliferation by 50%) were determined for the extracts using GraphPad prism software 
(GraphPad software, San Diego, CA, USA) (table 4.1). The water extract of the T. violacea 
leaves exhibited higher cytotoxcity compared to the tuber extracts. The IC50 values for the 
tuber extracts were more than 5 mg/ml on all the cell lines tested in this study, while the IC50 
values for the leaf extracts were less than 3 mg/ml. MCF7 was the most sensitive cell line 
with an IC50 value of 1.2mg/ml, while the non-cancerous cell line, KMST6 was more 
resistant to the effects of the leaf extract with an IC50 value of 3mg/ml.  
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Table 4.1: IC50 values and selectivity index for T. violacea tuber and leave extracts 
determined by MTT assays. 
Cell 
lines 
leaf extract 
(mg/ml) 
Tuber extract 
(mg/ml) 
Selectivity 
index 
MCF7 1.2 ± 0.5 Inactive 2.5 
H157 1.5 ± 0.76 Inactive 2 
HT29 2.6 ± 1.5 Inactive 1.15 
HepG2  2.8 ± 0.45 Inactive 1.07 
KMST6 3.0 ± 0.85 Inactive 1 
 
Four human cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) 
were treated for 24hours with various concentrations of water extracts of T. violacea leaves and tubers. 
Cytotoxcity was determined using the MTT assay. The experiments were done in triplicate and IC50 values 
were determined using GraphPad prism software. Data were expressed as the means of the triplicate. 
IC50 >2.5 mg/ml is considered to be inactive 
Selectivity index >1 indicates high selectivity  
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4.2.2 Morphological studies on MCF7 cells treated with leave and tuber extracts of 
T.violacea. 
The effects of T.violacea leaves and tubers on morphological evaluation of different 
concentrations of T.violacea leaves and tubers were evaluated on MCF7 according to the 
method described in sections 2.3.1. Based on the IC50 values generated using the MTT 
assay, MCF7 cells were more sensitive to the effects of T.violacea. Consequently this cell 
line was used to evaluate the effects of T.violacea leaves and tubers on the morphology of 
the cells.  
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        Tuber extract (2.5 mg/ml)                              Untreated 
 
                                               
                                                                                                     
                        
 
 
 
 
Leaf extract (2.5 mg/ml)                                        .   Doxorubicin (10µM .)  
 
Figure 4.1: Morphological changes induced in MCF7 cells by water extracts of 
T.violacea leaves and tubers. MCF7 cells were treated for 24hours with 2.5 mg/ml of a water extract of 
T.violacea or10µM doxorubicin. The cells were studied by light microscope using a Nikon microscope. 
Images were taken at x20 magnification using a Leica digital camera. The experiments were done in triplicate. 
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The morphology of MCF7 cells treated for 24hours with 2.5 mg/ml of the tuber and leaf 
extracts were compared to negative control (untreated cells) and positive control cells (cells 
treated with 10µM . doxorubicin) (figure 4.1). The water tuber extracts failed to induce any 
morphological changes in MCF7 cells, while the leaf extract induced morphological 
changes indicative of apoptotic cell death. The morphological changes include; membrane 
blebbing, cell shrinkage, vacuolisation and cell detachment. These morphological changes 
can also be observed in cells treated doxorubicin, a known inducer of apoptosis.  
 
4.2.3 Assessing the induction of apoptosis using the APOPercentage
TM
 assay  
Sections 4.2.1 and 4.2.2 demonstrated that the leaf extracts have cytotoxic effects on human 
cancer cells. These cytotoxic effects are accompanied with morphological changes that are 
indicative of the induction of apoptosis. However, none of these bioassays are specific for 
the evaluation of apoptosis. Therefore the APOPercentage
TM
 apoptosis assay was used to 
evaluate the activation of apoptosis in the cells. A panel of 5 human cell lines (the cancerous 
cell lines; HepG2, HT29, MCF7, H157 and the non-cancerous cell line; KMST6) were 
treated for 24hours with increasing concentrations (0-2.5mg/ml) of the leaf and tuber 
extracts. The induction of apoptosis was determined using the APOPercentage
TM
 apoptosis 
assay (figure 4.2a). The staining of the cells with the APOPercentage
TM
 dye was quantified 
using flow cytometry.  
 
 A dose dependent increase in the number of apoptotic cells can be observed for the 
leaf extract, while the tuber extract failed to induce significant levels of apoptosis. An 
overlay of the relative fluorescence obtained for MCF7 cells treated with 2.5mg/ml tuber 
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and leaf extract is shown in Figure 4.2b. Also shown in the overlay is the fluorescence for 
the untreated control and positive control cells. An increase in relative fluorescence, which 
is indicated by a shift to the right, can be observed for cells that stain positive with the 
APOPercentage
TM 
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Figure 4.2a: Quantification of apoptosis induced by different concentrations of water leaf and tuber extracts. Four human 
cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) were treated with increasing concentrations (0.06 to 
2.5 mg/ml) of water extracts of T. violacea leaves and tubers. Apoptosis was quantified by flow cytometry using the APOPercentage
TM 
assay. Each 
graph indicates the percentage of apoptotic cells observed with different treatments. The experiments were done in triplicate. Graphs A represents 
HepG2,B represents HT29, C represents MCF7, D represents H157 and E represents KMST6 cell lines. A significance difference between the leave 
extract and tuber extract (P < 0.05) is indicated by ***  
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 The Selectivity Index (SI) which implies the cytotoxicity (safety) selectivity of the 
water extracts of T.violacea was calculated against non-cancerous cell (KMST6) was 
calculated from the IC50 obtained from the induced significant levels of apoptosis in all five 
cell lines, while the water extract of the tuber induced little leaf The IC50 for the extracts 
against the cell lines are presented in Table 4.2. The result showed that the extracts induced 
apoptosis at concentrations of 1.21, 0.19, 0.28 and 2.09mg/ml for HT29, MCF7, H157 and 
HepG2 respectively, while the non cancerous KMST6 cells were less susceptible to the extract 
with the IC50 value of 4.40 mg/ml indicating that the water extracts of T. violacea is not toxic 
this was also confirmed from the result obtained from selectivity index. Moreover, the water 
extract of the leaves induced apoptosis in a dose and time dependant manner (Figure 4.2a). 
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Figures 4.2b: Histogram overlay of flow cytometry data obtained for MCF7 cells treated 
with extracts of T.violacea leaves and tubers. The histogram overlays show an overlay of untreated 
control, positive control, 2.5 mg/ml of leaf and tuber extract on MCF7 cells. A positive control (cells treated ‘;l9   
10µM . doxorubicin) was also included. Cellular fluorescence was measured in the FL3 channel on the flow 
cytometry. The experiments were done in triplicate and it shows the overlay of untreated control, positive control 
and 2.5 mg/ml of both tubers and leaf extracts on MCF7 cells. 
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Table 4.2: IC50 values for T. violacea tuber and leave extracts 
Four human cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) 
were treated for 24hours with various concentrations of water extracts of T. violacea leaves and tubers. Apoptosis 
was determined using the APOPercentage
TM
 assay. The experiments were done in triplicate and IC50 values were 
determined using GraphPad prism software. 
IC50 >2.5 mg/ml was considered to be inactive. 
Selectivity index >1 is indicating high selectivity. 
 
 
 
Cell 
lines 
Tulbaghia violacea 
(IC50 in mg/ml) 
Leaves Selectivity 
index 
 
Tubers 
MCF7 0.19 ± 
0.43 
23.16 >2.5 
H157 0.28 ± 
0.10 
15.71 >2.5 
HT29 1.21± 
0.60 
3.64 >2.5 
HepG2 2.09 ± 
1.40 
2.11 >2.5 
KMST6 4.4 ± 
1.36 
1 >2.5 
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     4.2.4 Assessing the activation of caspase-3 in human cell lines treated with T.violacea leaf 
     extract. 
 It was demonstrated in Section 4.2.3 that the water extract of the T.violacea tubers have very 
low bioactivity (in particular pro-apoptotic activity) against the human cancer lines used in this 
study. In contrast the water extract of the T.violacea leaves induced significant levels of 
apoptosis in these human cancer cell lines. Therefore the rest of this study focused on the leaf 
extract. This was demonstrated using the APOPercentage
TM 
assay. This assay detects apoptosis 
at the stage of phosphatidylserine exposure. In order to further investigate the activation of 
apoptosis, two additional markers of apoptosis (the activation of caspase-3 and the production 
of ROS) was also used to confirm the induction of apoptosis. 
 
              Four human cancer lines (HepG2, HT29, MCF7 and H157) and a non-cancerous 
human cell line (KMST6) cell lines were treated for 24hours with 2mg/ml of water extract of 
T.violacea leaves. The activation of caspase-3 was assessed using a PE-conjugated anti-active 
caspase-3 monoclonal antibody and flow cytometry as described in section 2.3.4. Figure 4.4 
shows that the water extract of T. violacea leaves induced significant levels of caspase-3 in the 
cancerous cell lines HepG2, MCF7, H157 and HT29, with the highest bioactivity in HepG2 
cells. Close to 70% of HepG2 cells were positive for the presence of activated caspase-3 
compared to ~30% of MCF7, H157 and HT29 cells. The water extract of T.violacea leaves 
failed to induce capase-3 activation in KMST6 cells.  
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Figure 4.4: Evaluating the activation of caspase-3 on a panel of human cell lines. Four 
human cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) were 
treated for 24hours with 2mg/ml of water extract of T. violacea leaves. The cells were fixed, permeabilized and 
stained with an anti-active caspase-3-PE antibody. As a positive control, the cells were also treated with 10µM 
doxorubicin. Cell fluorescence was measured by flow cytometry. The bar graph indicates the percentage of cells 
staining positive for active caspase-3. The experiments were done in triplicate. A significance difference between 
untreated and extract (P < 0.05) is represented by (*); (a) represent significant difference between the most 
sensitive cell line and other cell line (P< 0.05), (b) represent significant difference between the most resistance cell 
line and other cell lines (P< 0.05). 
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4.2.5 Assessing the production of ROS in human cell lines treated with T.violacea. 
A non-fluorescent probe known as 2', 7’-dichlorfluorescein-diacetate (DCFH-DA) can be used 
to evaluate the production of intracellular Reactive Oxygen Species (ROS) in cultured cells. 
This probe freely permeates into cells and was used to evaluate the production of ROS in 
response to treatment with the T.violacea leaf extract. The production of ROS was observed in 
all the cancer cell lines, while no ROS production was observed in the non-cancerous KMST6 
cell line (Figure 4.5). A varied response was observed for the cancer cell lines with ~80% of 
H157 cells and ~50% of HepG2 cells, respectively staining positive for ROS production. Less 
than 30% of MCF7 and HT29 cells were positive for ROS production.  
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Figure 4.5: Evaluating the production of ROS on a panel of human cell lines. Four human 
cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) were treated 
for 24hours with 2mg/ml of water extract of T. violacea leaves. ROS production was measured by flow cytometry 
using the DCFH-DA probe. As a positive control, the cells were also treated with 1% H202. Cell fluorescence was 
measured by flow cytometry. The experiments were done in triplicate. * represent significance difference between 
untreated and extract (P < 0.05); a represent significant difference between the most sensitive cell line and other 
cell lines(p < 0.05), b represent significant difference between the most resistance cell line and other cell lines (P< 
0.05) 
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4.3 Discussion  
Based on the IC50 values calculated from the MTT results, all the cell lines were remarkably 
sensitive to the leaf extract of T.violacea compared to the tuber extract. MCF7 cells were the 
most sensitive cells with an IC50 of 1.20 mg/ml followed by H157, HT29, HepG2, and KMST6 
with IC50 of 1.5, 2.6, 2.8 and 3.0 mg/ml, respectively. However, IC50 values of the cell lines 
treated with the tuber extract were greater than 5mg/ml. 
 
 Morphologic characteristics of apoptosis include cell shrinkage, nuclear disintegration 
and cell detachment. This was reported by Kerr et al., in 1972. These morphological changes 
were also observed in cells treated with doxorubicin, a known inducer of apoptosis. MCF7 
cells treated with water extract of T.violacea leaves for a period of 24hours also displayed these 
morphological changes. All the other cell lines (KMST6, HT29, H157 and HepG2) displayed 
the same morphological changes (data not shown). In contrast the water extract of T.violacea 
tubers failed to induce these morphological changes in all the cells used in this study. This result 
suggests that the leaf extract of T. violacea induced apoptosis while the water tuber extract of 
T. violacea had no effect on the cells. The apoptotic activities could not be quantitated based on 
the morphological changes. Therefore there is need to do a quantitative assay to evaluate the 
percentage of apoptosis in the treated cells.  
 
Figure 4.2a showed that a dose of 2mg/ml and 2.5mg/ml of the leaf extract induced 
significant levels of apoptosis. The leaf extracts induced apoptosis in a dose dependent manner 
in the cell lines used in this study. The tuber extract failed to induce significant levels of 
apoptosis in the cell lines used in this study. These results are in agreement with what was 
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observed in the study on the morphology of cells treated with tubers and leaf extracts of 
T.violacea.  
 
The potency of a drug or a chemical is as the measure of its strength as a poison when 
compared with other drugs where threshold is the important aspect of dose-response 
relationship (Kenakin, 2009). Since apoptosis requires involvement of active cell participation 
and is therefore primarily caused by physiological stimuli, varied doses could result in cell 
death by apoptosis (Lennon, et al., 1991). Fig 4.2b shows histogram overlays of MCF7 cells 
treated with different concentrations of water extracts of T.violacea leaves and tubers and 
assayed using APOPercentage
TM
 assay. MCF7 cells were treated with 2.5 mg/ml of water 
extract of T. violacea leaves and tubers, respectively. Doxorubicin (10µM) treatment was used 
as a positive control and untreated cells served as the negative control. After 24hours, the cells 
were stained with the APOPercentage dye and analyzed by flow cytometry. An increase in the 
relative fluorescence of the cells suggests that the cells stained positive for the dye and that the 
cells are undergoing apoptosis. This increase in fluorescence can only be observed for the 
positive control and cell treated with 2.5mg of leaf extract.  
 
The results obtained for the APOPercentage
TM
 assay was used to determine the IC50 
values for the tuber and leaf extracts on all five human cell lines. The IC50 values were 
calculated using GraphPad Prism software (table 4.2). MCF7 was the most sensitive cell line 
with an IC50 value of 0.19 mg/ml followed by H157, HT29, and HepG2 with IC50 values of 
0.28, 1.21, and 2.09 mg/ml, respectively. KMST6 was the most resistant cell line with an IC50 
value of more than 2.5 mg/ml. These findings confirm that, water extracts of T.violacea leaves 
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induced significant apoptotic activities in all the treated cell lines while the water tuber  
extract of the plant lack pro-apoptotic activity at the doses used in this study. 
 
            The caspase-3 assay was one of the additional assays used to further characterise the 
induction of apoptosis in the cell lines. HepG2, HT29, MCF7, H157 and KMST6 cell lines 
were treated with 2mg/ml of water extract of T. violacea leaves for 24hours. The cleavage and 
activation of caspase -3 are known markers of apoptosis (Frankline, et al., 2008). Caspases are 
crucial mediators of apoptosis. These proteases catalyze the specific cleavage of several 
cellular proteins and they are indispensable for apoptosis to occur (Jacobson, et al., 1997; 
Adams & Cory, 1998; Nicholson, 1999). Figure 4.4 shows that the water extract of T.violacea 
leaf induced a significant level of caspase-3 cleavage in all the cell lines used in this study 
except for KMST6 cells where little or no casapase-3 cleavage was observed. A higher number 
of HepG2 cells were positive for caspase-3 cleavage compared to MCF7, H157 and HT29 
cells. This is an interesting finding since the leaf extract has been shown to induce apoptosis 
more readily in MCF7, H157, and HT29 compared to HepG2 cells (see table 4.2). This may 
suggest that the activated caspase-3 is inhibited in HepG2 cells. 
 
                ROS serve as signalling molecules in mitochondrial death receptor and P53 
modulating apoptosis (Nordberg & Arnér, 2001). ROS production in H157 cells was the 
highest, while ROS production in KMST6 and HT29 were the lowest compared to H157 and 
HepG2 cells, ROS production in MCF7 cells were much lower. However, MCF7 were more 
susceptible to the leaf extract, since higher levels of apoptosis were observed for MCF7. This 
suggests that an increased level of ROS does not necessarily result in increased risk of 
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apoptosis. This may be explained by the varying ability of different cancer cell types to 
suppress the effects of ROS through the production of anti-oxidants. 
 
The findings from this study showed that extracts of T.violacea leaves demonstrated 
higher pro-apoptotic activity compared to tubers in the cancer cell lines used in this study, and 
therefore validates some of the claims towards the application of this plant for the treatment of 
cancer. The ability of a compound or a plant extract to induce apoptosis in cancer cells 
can be used as a test to evaluate its potential to treat cancer. The study has shown that the 
water extract of T. violacea leaves selectively induced apoptosis in human cell lines thus 
exhibiting a potential as an anti-cancer remedy. It should also be noted that ability of the 
extract to induce apoptosis in the non-cancerous cell line, KMST6 was much was much lower 
compared to the cancer cell lines. This suggests that the compounds selectively induce 
apoptosis in the cancer cells, which is a desired characteristic for anti-cancer treatment.  
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CHAPTER FIVE: THE BIOACTIVITY-GUIDED FRACTIONATION OF ORGANIC 
EXTRACTS OF T.VIOLACEA 
Table of Contents/Outline 
 
5.1  Background 
 
5.2 Sequential extraction of T.violacea leaves using different organic solvents 
5.3 Evaluating the apoptotic activity of organic solvent extracts  
5.4 Assessing the activation of caspase-3 in response to treatment with a DCM extract of 
T.violacea 
 
5.5 Evaluating the production of ROS in cells treated with the DCM extract 
5.6 Discussion  
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5.1 Background: 
Medicinal plants are widely used for the treatment and prevention of various diseases including 
cancer. These plants can be a source of novel bioactive compounds. However, the complex 
mixtures of compounds present in these plants can act individually, additively or in synergy. 
(Gurib-Fakim, 2006). As a result separation of these compounds may lead to loss of 
bioactivity. The previous chapters demonstrated that the water extract of T. violacea leaves 
contains bioactive compounds with pro-apoptotic activity towards some human cancer cell 
lines. Therefore, the objective of this chapter was to attempt to isolate the active compounds 
from the leaves through bioassay guided fractionation.  
5.2 Sequential extraction of T.violacea leaves using different organic solvents  
In order to identify the compounds responsible for the pro-apoptotic activity in the leaf extract 
of T.violacea, sequential extraction of the leaves was done using hexane, followed by 
dichloromethane (DCM) methanol and finally 50% methanol/water. Extraction with each of 
these solvents was repeated thrice (section 2.3.3). The extracts of each solvent were combined 
and evaporated to dryness using a rotary evaporator. The final extracts were then weighed and 
the percentage yield for each solvent was calculated. The percentage yield for hexane, DCM, 
methanol and 50% methanol as shown in table 5.1 represents~70% of dry leaf mass. This 
implies that some compounds were not extracted with these solvents and these were probably 
due to the presence of fibres or complex polysaccharides or plant tissue. 
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Table 5.1 Percentage yield of the organic solvent extraction of T.violacea leaves. 
Extract 
 
 
 
 
 
% Yield of extraction  
Hexane 7 
Dichloromethane 15 
50% Methanol / Water 20 
Methanol 25 
 
Powdered leaves of T. violacea were sequentially extracted using solvents of increasing polarity (hexane, 
dichloromethane (DCM), methanol and 50% water/ methanol. The percentage yield of organic solvent of T. 
violacea leaves are calculated as %Yield = (weight of dried extract / weight of dried sample) x 100. 
.  
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5.3 Evaluating the apoptotic activity of organic solvent extracts  
Three bioassays, the APOPercentage
TM
 assay (section 2.4.3), the caspase-3 assay (section 
2.4.4), and the ROS production assay (section 2.4.6) were used on a panel of 5 human cell 
lines (KMST6, HepG2, HT29, MCF7 and H157) to investigate the bioactivity of the four 
organic solvent extracts.The apoptotic activity was used as a guide to purify the active 
compound(s) present in T.violacea leaf extract. Stock solutions (20mg/ml) of each of the 
fractions were prepared in DMSO and Tween 20 and stored at -20C. 5% DMSO and 
1%TWEEN 20 was used because DCM and Hexane extracts were not soluble in water. 
However, the effect of the DMSO and TWEEN 20 were tested on the cells (data not shown). A 
panel of human cell lines (HepG2, HT29, MCF7, H157 and KMST6) was treated for 24hours 
with a range of concentrations (0.06 to 2mg/ml) of the organic solvent extracts. The induction 
of apoptosis was measured using the APOPercentage
TM
 apoptosis assay as previously 
described. Figure 5.1 shows the dose responses of H157 cells treated with four solvent extracts. 
Figure 5.2 shows the quantification of apoptosis in all cell lines treated with 2mg/ml of four 
organic solvent extracts 
 
The results obtained from the APOPercentage
TM
 apoptosis assay were also used to 
determine the IC50 values (Table 5.2). The responses of the different cell lines varied based on 
the solvent extract that was used. In general, the hexane and DCM extracts were more active 
compared to the methanol and 50% methanol extracts. The MCF7 cell line was more resistant 
to the effects of the solvent extracts. The IC50 values for the hexane, methanol and 50% 
methanol extracts were more than 2mg/ml when tested on MCF7 cells. The H157 cell line was 
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the most sensitive cell line. The IC50 values for the hexane, DCM, methanol and 50% methanol 
extracts on H157 cells were 38mcg/ml, 7mcg/ml, 302 mcg/ml and 1289 mcg/ml, respectively. 
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Figure 5.1: Quantification of apoptosis induced by organic solvent extracts of T.violacea leaves. H157 cells were treated for 
24hours with increasing concentrations (0.06 to 2mg/ml) of the different organic solvent extracts of T.violacea leaves. Apoptosis was quantified by the 
flow cytometry using the APOPercentage
TM
 assay. The graph indicates the percentage of apoptosis cells observed with different treatments. Each bar is 
the mean ±SEM of three values. Letter a represent significance difference between untreated and the extracts (p < 0.05); b represent significant 
difference between Hexane and DCM extracts (p < 0.05), c represent significant difference between hexane and 50% Methanol extracts (p < 0.05), d 
represent significant difference between hexane and Methanol extracts (p < 0.05), ); e represent significant difference between DCM and 50% Methanol 
extracts (p < 0.05), ); f represent significant difference between DCM and Methanol extracts (p < 0.05). 
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Table 5.2: IC50 values for organic solvent extracts of T. violacea leaves. 
 
The cells were treated for 24hours with increasing concentrations of different organic extracts of the T .violacea leaves. 
Apoptosis was quantified using the APOPercentage
TM
 assay. GraphPad prism software was used to determine the IC50 
values for the organic solvents extracts on the four human cell lines.  
ND means not determined 
IC50 2.0mg/ml was considered to be inactive 
Selectivity index >1 is indicating high selectivity  
 
 
 
 
 Hexane 
(mg/ml) 
DCM 
(mg/m) 
50% Methanol / Water 
(mg/ml) 
Methanol 
(mg/ml) 
Extract Selectivity 
index 
Extract Selectivity 
index 
Extract Selectivity 
index 
Extract Selectivity 
Index 
H157 0.04 47.75  
 
Cell  
Line 
41 1.09 1.18 0.30 3.27 
HT29 0.07 27.29 0.01 41 > 2 ND >2 ND 
HepG2 0.72 2.65 0.15 2.73 >2 ND 1.12 0.88 
MCF7 >2 ND >2 ND >2 ND >2 ND 
KMST6 1.19 1 0.41 1 1.29 1 0.98 1 
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Figure 5.2: Quantification of apoptosis of different organic solvent extracts T.violacea leaves treated on different cell 
lines. Several cancer cell lines (HepG2, HT29, MCF7 and H157) and the non-cancerous human cell line (KMST6) were treated with 2mg/ml of 
organic solvent fractions of T. violacea leaves for 24hours. Apoptosis was quantified by the flowcytometry using APOPercentage
TM
 assay. Each graph 
indicates the percentage of apoptosis cells observed with different treatments. A: Hexane extract; B: DCM; C; Methanol extract; D: 50 % methanol.  
Each bar is mean±SEM of three values. Letter a represent significance difference between untreated and extracts (P<0.05); b represent significant 
difference between the most sensitive cell line and other cell lines (P<0.05), c represent significance difference between the most resistant cell line and 
other cell lines (P<0.05) 
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5.4 Assessing the activation of caspase-3 in response to treatment with a DCM extract 
of T.violacea leaves  
The APOPercentage
TM
 apoptosis assay showed that the activity of the DCM extract was 
significantly higher in comparison to the hexane, methanol and 50% methanol extract. To 
further investigate the pro-apoptotic activity of the DCM extract, the activation of caspase-3 
was assessed using a PE-conjugated anti-active caspase-3 monoclonal antibody and flow 
cytometry as described in section 2.4.4. The results are displayed in Figure 5.3 and show 
that DCM extracts induced caspase-3 activation in all 5 cell lines tested in this study. 
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Figure 5.3 The activation of caspase-3 in response to treatment with the DCM extract 
of T.violacea leaves. Four human cell lines (HepG2, HT29, MCF7 and H157) and the non-cancerous 
human cell line (KMST6) were treated for 24hours with 2mg/ml of DCM extract of T. violacea leaves and 
10µM . doxorubicin (positive control). The cells were fixed and stained with an anti-active caspase-3-PE 
antibody. Cell fluorescence was measured by flow cytometry. Each bar is means±SEM of three values. Letter a 
represent significance difference between untreated and extracts (P<0.05); b represent significant difference 
between the most sensitive cell line and other cell lines (P<0.05), c represent significance difference between 
the most resistant cell line and other cell lines (P<0.05) 
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5.5 Evaluating the production of ROS in cells treated with the DCM extract 
The ROS assay was used to evaluate the production of ROS in a panel of cell lines treated 
with the DCM extract. The DCFH-DA probe was used to measure the production of ROS as 
described in section 2.4.6. The results showed that the 2mg/ml of the DCM extract induced 
significant ROS production in HT29, KMST6, HepG2, and H157 cells. MCF7 cells were the 
most resistant cell line (Figure 5.4). 
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Figure 5.4: The effects of the DCM extract of T. violacea on ROS production. Four human 
cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell line (KMST6) were 
treated for 24hours with 2mg/ml of DCM fraction of T. violacea leaves and 1% of H2O2 (positive control). 
ROS production was measured by flow cytometry using the DCFH-DA probe. Each bar is mean ±SEM of 
three values. Letter a represent significance difference between untreated and extracts (P<0.05); b represent 
significant difference between the most sensitive cell line and other cell lines (P<0.05), c represent significance 
difference between the most resistant cell line and other cell lines (P<0.05) 
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5.6. Discussion  
The aim of this chapter was to perform bioactivity-guided fractionation of T. violacea leaf 
extract. The fractions containing the bioactive compounds were identified using bioassays 
that specifically measure the activation of apoptosis. The induction of apoptosis was 
evaluated using the APOPercentage
TM
 assay, the caspase-3 assay and the ROS production 
assay. The extracts were tested on four different human cancer cell lines (HepG2, HT29, 
MCF7 and H157) and a non-cancerous human cell line (KMST6).  
 
As shown in Table 5.1, 50% methanol / water and methanol extracts showed the 
highest yield 20 and 25 % respectively, while the DCM and hexane fractions yielded 15% 
and 7%, respectively. A report by Herode, et al (2003) showed that percentage of extraction 
yield could be affected by particle size of the sample, the temperature extraction and the 
ratio of solvent to sample (Herode, et al., 2003). The average extraction yield in 50% 
methanol and methanol were 20% and 25%, respectively, indicating that the procedure were 
efficient in dissolving cellular components, soluble fibres and possibly some high molecular 
weight polysaccharides. Hexane and DCM had the lowest yield but still showed higher 
bioactivity. This could support the report by Pineolo et al. (2004) that the chemical 
characteristics of the solvent, the method used during the extraction process as well as 
different structural and compositional aspects of the natural products may show a distinct 
behaviour. Higher efficiency in the extraction of solutes is not automatically directly related 
to the biological activity of the plant species. Differences in the solubility of the active 
compound(s) present in the plant can account for the variations in the biological activities. 
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In general, compounds extracted with methanol and 50% methanol solvents were not 
as active as the compounds extracted with hexane and DCM solvents. This suggests that the 
nature of the compounds with pro-apoptotic activity tends to be non-polar. H157 cells were 
susceptible to the effects of the hexane and DCM extracts, while MCF7 and KMST6 cells 
were more resistant to the effects of the hexane and DCM extracts. This is an interesting 
finding because MCF7 cells were highly susceptible to effects of the water extract of T. 
violacea leaves (Chapter 4).This may suggest that the compound(s) that were present in the 
water extract of T. violacea leaves and were able to induce apoptosis in MF7 cells have 
variable polarity and hence extractability, in other words, the compounds in the water 
extract are polar and those in the hexane and DCM are non-polar such that the MCF7 cells 
are more sensitive to the polar compounds in comparison with the non-polar compounds in 
T.violacea leaves 
 
Based on the IC50 values obtained for T. violacea water extract, the hexane extract 
and the DCM extract, it can be said the less polar fractions exhibited greater potency. As an 
example, a comparison of the IC50 values for T. violacea extract (0.28mg/ml) and hexane 
(0.04mg/ml) on H157 cells show that there is a significant increase in the bioactivity. The 
IC50 value for the DCM extract decreased to 0.01mg/ml. This increase in bioactivity was 
also observed for HT29, HepG2 and KMST6 cells. It can be concluded that the hexane and 
DCM extracts contain most of the bioactive compounds with pro-apoptotic activity. As a 
result, it was decided to use the DCM extract for further study. 
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The caspase-3 assay (figure 5.3) showed that DCM extracts of T. violacea induced 
significant levels of caspase-3 activation particularly in the four cancer cell lines with the 
highest bioactivity exerted on the H157 cell lines. This result confirms that DCM extracts of 
T. violacea have significant pro-apoptotic effects. Caspases belongs to a family of cysteine 
proteases that are involved in the induction of cell death by apoptosis. Caspase-3 has been 
implicated as a key regulator of apoptosis (Alan & Reiner, 1999). Apoptosis is sometimes 
accompanied by the activation of caspases (Nicholson & Thornberry, 1997).  
   
 ROS play a vital role in the induction of apoptosis in many cells (Barbora & Ales, 
2011). During apoptosis process, ROS generation and DNA damage usually occur and the 
increase of ROS level and DNA damage could act independently or they may be affected by 
one another (Barbora & Ales, 2011). Studies have shown that an increase in cellular 
concentration of oxidant species to a level that overcomes the endogenous antioxidant 
system leads to oxidative stress and this result in protein, lipid as well as DNA damage thus 
triggering apoptosis mechanism (Barbora & Ales, 2011). Figure 5.4 shows the production of 
ROS in several cell lines. The result indicates 68.5%, 67.5%, 66%, 51% and 35% ROS 
production for HT29, KMST6, HepG2, H157 and MCF7 cells, respectively. The bioactivity 
of DCM extract of T. violacea was highest on HT29 cell line and lowest on the MCF7 cell 
lines.  
 This study showed that the DCM and hexane extracts of T. violacea leaves contain 
compounds with pro-apoptotic activity in all the cell lines tested in this study. However, 
DCM extracts appeared to be more bioactive than hexane extracts. Furthermore, it was 
shown that the bioactivity of the DCM and hexane extracts were higher compared to the 
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water extracts of T. violacea. The bioactivity of methanol and 50% methanol were also 
higher than water extract. However, the bioactivity of the extract varied depending on the 
cell line that was used, demonstrating the selectivity of the compounds to induce apoptosis 
in certain cell. 
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CHAPTER SIX: CHEMICAL CHARACTERIZATION OF DCM FRACTIONS OF 
T.VIOLACEA LEAVES 
Table of Contents/Outline 
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6.0 Background:   
There has been a rapid advancement in the study of plants (phytochemicals) and herbal 
products for the past few decades. There has also been a vast increase in the sales of herbal 
products such as Allium sativum, Hypericum perforatum, Spirulina, Echinacea angustifolia, 
Ginkgo biloba and Silybum marianum (Chauhan, et al., 2011). The chemistry of natural 
products involves three areas, which includes methods of isolation, structural elucidation 
and synthetic approaches. Structural elucidation involves determination of chemical 
structure of an uncharacterized substance such as natural products which is normally 
determined through chromatographic and mass spectroscopic techniques. Nuclear Magnetic 
Resonance (NMR spectroscopy is the gold standard for the characterization. In previous 
chapters, it was concluded that the DCM extract of T. violacea leaves contains some pro-
apoptotic compound(s). Therefore the objective of this study was to isolate these 
compound(s) by bio-activity guided fractionation using column chromatography and to 
characterize the compounds by NMR and GC-MS. The processes involved in isolation of 
these compounds are illustrated in figure 6.1.  
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Figure 6.1: Flowchart of the bio assay-guided isolation procedures 
KEY S: 
A-E – 90% HEX/ DCM; F-I - 25% DCM/HEX; J - 75% DCM/HEX; K -75% DCM/HEX;L -75% DCM/HEX; 
M -90% DCM/HEX; N=100%EA; P=90%EA/MEOH; Q=50%EA/MEOH; R =50%EA/MEOH TO 100%  
MEOH  
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DCM extract were fractionated into several sub-fractions using Versaflash
®
 column 
chromatography (described in section 2.4.3). The DCM extract was fractionated into 10 
fractions (A-E, F-I, J, K, L, M, N, P Q and R). One compound precipitated from fractions A-
E as a white amorphous crystalline compound which was coded TVD-001. It was not 
readily soluble in water but soluble in chloroform. Characterization of TVD-001 was done 
by a combination of spectroscopic techniques viz: IR, NMR spectroscopy and Mass 
spectrometry.  
 
6.1  Structural elucidation of TVD-001 
The IR spectroscopy was done as described in section 2.3.9 the IR spectrum of TVD-001 is 
shown in Figure.6.1. The absorption band observed at 1704 cm
-1
 (stretching) confirmed the 
presence of a carbonyl group (C=O) which may be part of ketone, aldehyde or ester 
functional groups. The other notable absorption frequencies between 1100 and 900 cm
-1
 
(stretching) revealed the presence of C-C bond. The signals at 2923 and 1704 correspond to 
the presence of alkanes. The spectrum also has an OH at 393cm
-1
. 
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Figure 6.2 IR spectrum of TVD-001 
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6.1.1 Nuclear Magnetic Resonance  
NMR spectra were generated at Stellenbosch University, Central Analytical facility (CAF).  
The 
1
H and 
13
C NMR spectra for the compounds are given in Figures 6.3 and 6.5. The 
assignment of protons and carbons peaks for the compound as described in section 2.4.6.1 
was done using COSY plot (figure 6.4). The summary of the 
1
H and 
13
C NMR chemical 
shifts for TVD-001 is shown in Table 6.1. The proton NMR spectrum of the compound 
showed a set of four signals. The most downfield signal was a triplet centred at δ2.38, a 
position characteristic of protons deshielded due to close proximity to a carbonyl group. The 
splitting pattern suggests the presence of a methylene group on the opposite side to the 
carbonyl group. The multiplets at δ1.55 and at δ1.25 are suggestive of repeating methylene 
chains. The most upfield signal appearing as a triplet at δ0.88 is due to terminal methyl 
protons split by the presence neighbouring methylene protons.  
In the 
13
C NMR spectrum (figure 6.4), the presence of a carbonyl group was 
confirmed by the appearance of a signal at 211.8 ppm. The other signals of interest included 
carbon peaks due to the pairs: C-15 and C-17 at 42.8ppm, as well as C-1 and C-31 at 
14.1ppm. 
13
C NMR showed 16 signal peaks between δ14 and δ212. The downfield signal at 
δ211.7 is typical of ketonic carbon, and the signal at δ76.8 is germinal to it. Methylene 
carbons were seen between δ22 and δ42 as can be expected (Dudley & Ian, 2007). Many of 
these appear to be arranged in an alkane chain format as can be seen from their closeness in 
chemical shifts. A methyl is evident from the signal at δ14.1. 
Based on the NMR data, it was apparent that TVD-001 was a long chain alkane with 
a terminal methyl and a ketone. There was no evidence of the presence of methines 
confirming the presence of the ketone and absence of aldehyde. 
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Figure 6.3  
1
H NMR spectrum of TVD-001 
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 Figure. 6.4 COSY plot for 
1
H NMR chemical shifts assignment. 
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Figure. 6.5   
13
C NMR spectrum of TVD-001. 
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6.1.2 Mass spectrometry 
 The structure was confirmed by mass spectral analysis (Figures.6.6), which showed the 
molecular ion peak at m/z 450. Other peaks were at m/z 255, 239 (base peak), 194, 127, 96, 
85,71,57 and  43 and 29 ( Figure 6.6). The peaks at m/z 255 and 239 are due to the repeated 
double transfer from different position of the alkyl chain as a result of McLafferty 
rearrangements (Rontani, et al., 1990). The transition from m/z 255 to 239 was due to loss 
of CH4, and from 239 to 194 there was loss of CH3CHO; from 127 to 96 there is the loss of 
31 CH3O, and 85 to 71, to 57 to 43 to 29 is consistent with the repeated loss of methylenes. 
The fragmentation pattern confirms the presence of methyl, ketone and a long chain alkane. 
Further the fracture from a molecule with m/z of 450 to a base peak of almost half is 
suggestive of a dimeric arrangement. 
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Figure 6.6 From the foregoing, the literature and a search of the Wiley library of the GC-MS, it was concluded that 
TVD-001 was 16-hentriacontanone. The structure is shown in Figure  6.2 and the NMR results matched to the atomic positions in Table 6.1.  
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O  
Figure 6.7 Structure of palmitone (16-hentriacontanone) (C31H62O) 
 
 
Table 6.1: Summary of the 
1
H and 
13
C NMR chemical shift for 16-hentriacontanone 
  
 
1
H NMR (ppm) 
 
Position 
 
Multiplicity 
 
13
C NMR(ppm) 
 
Position 
 
2.3 
 
H-15 
 
Triplet 
 
42.8 
 
C-15 
 
1.5 
 
H-14 
 
Multiplet 
 
23.9 
 
C-14 
 
1.2 
 
H-2 – H-13 
 
broad multiplet 
 
22.7 
 
C-2 
 
0.88 
 
H-1 
 
Triplet 
 
14.1 
 
C-1 
 
16-hentriacontanone (more commonly known as palmitone) is a common hydrophobic 
dialkyl ketone with reported hypnotic and anticonvulsant activity (González-Trujano, et al., 
2001). It has previously been isolated from fruits of Cassia fistula (Thirumal, et al., 2012), 
the fern genus Adiantum caudatum, (Pan, et al., 2011), Santalum album (Pradeep, et al., 
2011). This is the first report of its present in this species and genus as far as we could 
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ascertain. It was present in abundance in the DCM fraction of T. violacea leaves as it 
precipitated from several sub-fractions. 
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6.2. Discussion 
 Drug solubility plays a vital role in drug disposition and poor solubility has been known as 
one of the causes of various drug development failures (Lokamatha, et al., 2010). This is 
one of the problems that were encountered in this study. Although the DCM extract was 
soluble and highly active on cancer cells, the sub-fractions of the DCM extract was not 
soluble and could therefore not be tested. It is possible that the various compounds present 
in the sub-fraction of the DCM extract are required to maintain the solubility of the DCM 
extract. However, one compound (16-hentriacontanone) was present in high concentration 
in sub-fraction A-E. The structure of the compound 16-hentriacontanone was elucidated 
using NMR spectroscopy and Mass Spectrometry.  
The assignment of protons and carbons peaks for the compound was done using 
COSY and was also assisted by comparison with the literature (González-Trujano, et al., 
2001). The proton NMR spectrum of the compound (Figure 6.3) showed a set of four 
signals. The most downfield signal appeared as a triplet centred at δ2.38, a position 
characteristic of protons located at a carbon adjacent to a carbonyl group, while the splitting 
pattern suggests the presence of a methylene group on the opposite side to the carbonyl 
group. This therefore confirms the presence of methylene protons at H-15 and H-17. The 
next signal observed as a multiplet at δ1.55 represents the methylene protons located at H-
14 and H-18. The methylene protons H-2 to H-13 and H-19 to H-30 all appeared as a 
multiplet at δ1.25. Finally, the most upfield signal appearing as a triplet at δ0.88 is due to 
the terminal methyl protons H-1 and H-31, and the triplet is caused by the splitting effect of 
methylene protons H-2 and H-30  
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(http://www2.chemistry.msu.edu/faculty/reusch/VirtTxtJml/Spectrpy/nmr/nmr1.htm)
.  
The structure was finally confirmed by mass spectral analysis which showed the molecular 
ion peak at m/z 450 with a molecular formula of C31H62O (González-Trujano, et al., 2001). 
Furthermore, the prominence of the base peak at m/z 255 is characteristic of a 
fragment ion which incorporates the resonance-stabilized and positively charged carbonyl 
group. However, it is important to mention that palmitone is a hydrophobic aliphatic ketone 
(Cano-Europaa, et al., 2010). In conclusion, all the spectral data which has been gathered 
confirm the structure of 16-hentriacontanone. It is not known if this compound has any anti-
cancer or pro-apoptotic. However, it is one of the compounds identified in the DCM extract 
of T.violacea leaves. 
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CHAPTER SEVEN: BIO-GUIDED FRACTIONATION OF METHANOL 
EXTRACTS OF T.VIOLACEA LEAVES 
Table of Content/ Outline 
7.1 Background: 
7.2 Percentage yield 
7.3 Apoptotic activity of methanol sub-fractions  
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7.1 Background: 
It was shown in previous chapters that the pro-apoptotic bioactivity of the DCM extracts of 
T. violacea leaves was significantly higher than the activities observed for the hexane, 
methanol and 50% methanol extracts. In an attempt to isolate the bioactive compound(s), the 
DCM extract was subjected to column chromatography, which produced 10 sub-fractions. 
However, these sub-fractions were insoluble in water and DMSO and as result testing could 
not be done in the bioassays. Since methanol is more polar than DCM, the expectation was 
that the compounds extracted with methanol might be more water-soluble and suitable for 
biological testing. Therefore, the objective of this section was to further fractionate the 
methanol leaf extract using column chromatography and evaluate activity using the 
APOPercentage
TM
 assay.  
 
7.2 Percentage yield 
Methanol fraction was obtained from the sequential extraction made on the leaves (see 
Figure 7. 1). The fractions were further purified using Versaflash as described in section 
2.4.6. The solvents were chosen (see Figure 7.1) based on solvent polarity as follows and in 
this order: 100% Hexane (MF1), 50% Hex/DCM (MF2), 100% DCM (MF3), 
70%DCM/Methanol (MF4), 50% DCM/Methanol (MF5), 20% DCM/Methanol (MF6) and 
finally with 100% Methanol (MF7). The fractions were spotted on TLC to monitor the 
purification processes. The percentage yield was determined as previously described 
(section 2.4.5). 
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Table 7.1 Percentage (%) recovery for individual methanol sub-fractions from a methanol extract of T. 
violacea leaves. 
 
 
 
 
 
 
 
 
 
 
The methanol extract obtained from the leaves of T. violacea was further separated using different solvent 
combinations. The percentage yield of organic solvent of T. violacea leaves are calculated as %Yield = (weight 
of dried extract / weight of dried sample) x 100. 
 
 
 
 
 
 
 
 
 
 
Solvent 
fractions 
% 
Recovery 
MFI 0.20 
MF2 0.61 
MF3 25.33 
MF4 21.67 
MF5 26.3 
MF6 18.8 
MF7 2.20 
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7.3 Apoptotic activity of methanol sub-fractions  
A dose-response study was performed to establish if sub-fractions (MF3 to MF7) of a 
methanol extract of T. violacea leaves had any pro-apoptotic activity. The IC50 values for 
these sub-fractions were also determined. MF1 and MF2 were pooled together with MF3 
because TLC showed that similar compounds are present in these sub-fractions. The cell 
panel was treated for 24hours with the sub-fractions and apoptosis was measured using the 
APOPercentage
TM
 assay. The IC50 values were determined as previously described (table 
7.2). Figure 7.1 shows the result obtained for cells treated for 24hours with 2mg/ml of the 
sub-fractions. Table 7.2 shows that HT29 cells were the only cells that were susceptible to 
the effects of sub-fraction. The IC50 values for the sub-fractions were higher than 2mg/ml 
for MCF7, H157 and KMST6 cells. It is only MF3 and MF4, which showed significant 
activity on HT29 cells
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Figure 7.1: Quantification of apoptosis of different sub-fractions of methanol extract of T.violacea leaves in different cell lines. 
A panel of cell lines were treated for 24hours with 2mg/ml of methanol sub-fractions (MF3 to MF7). Apoptosis was quantified by the flow cytometry using 
APOPercentage
TM
 assay. The graph indicates the percentage of apoptosis cells observed with different treatments. A: MF3; B: MF4; C; MF5; D: MF6; E: MF7 
fractions.  Each bar is mean ±SEM of three values. Letter a represent significance difference between untreated and extracts (p < 0.05); b represent significant 
difference between the most sensitive cell line and other cell lines (p < 0.05) and c represents most resistant cell line and other cell lines (p < 0.05) 
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Cell 
 Line 
MF3 
(mg/ml) 
MF4 
(mg/ml) 
MF5 
(mg/ml) 
MF6 
(mg/ml) 
MF7 
(mg/ml) 
HT29 0.6 1.6 >2 >2 >2 
MCF7 >2 >2 >2 >2 >2 
H157 >2 >2 >2 >2 >2 
KMST6 >2 >2 >2 >2 >2 
 
Table 7.2 IC50 values for methanol sub-fractions on different human cell lines. Several 
cancer cells (HT29, MCF7 and H157) and the non-cancerous human cell line (KMST6) were treated for 
24hours with various concentrations of the sub-fractions (MF3 to MF7) of the T.violacea leaf extract. 
Apoptosis was quantified by APOPercentage
TM 
dye and analyzed using the flow cytometry. The experiments 
were done in triplicate. The IC50 values were calculated using GraphPad prism software. 
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7.4 Discussion  
In this study, the goal was to test sub-fractions (MF3 to MF7) of the methanol extract of 
T.violacea leaves for pro-apoptotic activity in order to identify the sub-fraction that contains 
apoptotic compound(s). This was done using the APOPercentage
TM
 apoptosis assay. Table 
7.1 shows the percentage yield for each of the fractions. MF1 and MF2 produced very low 
yields. Based on the TLC results the composition of MF1, MF2 and MF3 were very similar. 
Consequently, MF1, MF2 and MF3 were combined. Yields of 25.33, 21.67, 26.3, 18.8 and 
2.61% were observed for MF3, MF4, MF5, MF6 and MF7, respectively (table 7.1). 
 
The APOPercentage data shows that HT29 cells are the only cells that are 
susceptible to the sub-fraction of methanol extract of T. violacea. Furthermore, only MF3 
and MF4 were able to induce significant levels of apoptosis in HT29 cells (Figure 7.1). A 
comparison of IC50 values obtained for the methanol extract (Chapter 6) and the sub-
fractions of the methanol extract (MF3 to MF7) on HT29 cells shows that the bioactivity 
was lost during sub-fractionation. The IC50 value for the methanol extract on this cell lines 
was 0.27mg/ml, while the IC50 values for the two bioactive sub-fractions, MF3 and MF4 
were 0.6mg/ml and 1.6mg/l, respectively. 
 
It can be concluded that the sub-fractionation of the methanol extract resulted in 
reduced bioactivity. The bioactive compounds were possibly lost during column 
chromatography. Alternatively, these compounds work in a synergistic fashion in the 
methanol extract and the separation of the bioactive compounds by column chromatography 
has a negative impact on the bioactivity.
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CHAPTER EIGHT: CHEMICAL FINGERPRINTING OF T. VIOLACEA FRACTIONS 
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8.1 Background: 
Phytochemical studies usually involve a combination of the use of different analytical 
instruments, including nuclear magnetic resonance (NMR), X-ray crystallography, 
mass spectrometry (MS), ultraviolet (UV) and infrared (IR). For the gross analysis 
(fingerprinting) of complex mixtures, liquid chromatographic separation followed by 
spectroscopic measurement is suitable. Liquid chromatography coupled to mass 
spectrometry (LC-MS) in particular has recently emerged as the preferred method of 
choice as it is more comprehensive and independent of physico-chemical factors, e.g. 
chromophoric properties (Brandt, et al., 2004). Methanol extract was sub-fractionated 
into MF1 to MF7 but MF2 to MF7 was used for fingerprinting because MF1 and MF2 
were pooled together based on the TLC results, both MF1 and MF2 have similar 
composition. In this phytochemical study, screening and identification of compounds in 
the T. violacea extract was carried out using LC-MS with a view of generating 
metabolomic fingerprints. The present study compared the total ion chromatograms 
(TIC), UV spectra and the LC-MS-MS fragmentation of the four most prominent 
abundant compounds each of the methanol fractions. 
 
8.2 Metabolic fingerprinting of MF2- MF7  
The LC-MS metabolomic fingerprints showed in general a great diversity of compounds 
eluting between 0.45 min and 14 min. MF2 was the most complex extract with a wide 
spread of compounds. The early eluting compounds are polar compounds while the late 
eluting compounds are non-polar. MF3 and MF4 are similar in that they both contain a lot of 
polar compounds while MF7 is the simplest fraction with fewer compounds. Tables 8.1 and 
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8.2 show the elution times and molecular mass of the different extracts as well as 
overlapping constituents. It shows that the fractionation was largely successful in separating 
out the constituents. MF-2 remained the most complex extracts with a wide number of 
compounds with masses ranging from 270 to 610. MF5 and MF-6 were the least complex 
and also showed the most overlap of constituents. Figure 8.1 A to C shows the 
chromatograms of the extracts from which Table 8.1 has been compiled. 
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Figure 8.1 A Chromatograms of the methanol fractions (MF2- MF3) of T.violacea leaves 
 
 
 
 
 148 
 
Figure 8.1 B Chromatograms of the methanol fractions (MF4—MF5) of T.violacea leaves 
 
 
 
 
 
 149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 C Chromatograms of the methanol fractions (MF6—MF7) of T.violacea leaves
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Based on the foregoing, attempts were made to elucidate the chemical structures of the four 
most abundant peaks of each of the fractions (MF2 to MF7) using MS/MS and UV. While 
this information will not yield a definite answer, it does allow for evidence based 
speculation on the possible structures within the fractions. Therefore MF2 to MF7 
abundance peaks were further analysed to give what was contained in table 8.2. The peaks 
which were selected in order of their abundance are shown with their retention times, 
molecular masses and UV max in Table 8.2.  
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Table 8.2 The retention times, molecular mass and UVmax of selected peaks of the 
extracts. 
Fractions Retention time(tR)  M+H amu UV max 
MF2-1 4.32 265.1 230.2, 275.2, 342.2, 405.2 
MF2-2 5.46 344.2 237.2,  286.2, 316.2 
MF2-3 7.25 323.1 274.2, 364.2 
MF2-4 5.86                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  271.1 241.2, 276.6
MF3-2 3.80 476.3 309.2 
MF3-3 5.49 344.2 239.2, 288.2, 317.2 
MF3-4 13.88 282.3 does not absorb UV 
MF4-1 5.65 319.1 239.2, 286.2, 352.2, 412.2 
MF4-2 9.19 318 246.2 
MF4-3 9.37 332 247 
MF4-4 13.92 282.3 does not absorb UV 
MF5-1 3.23 217.1 230.2, 270.2 
MF5-2 3.35 231.1 230.2, 271.2 
MF5-3 3.69 757.2 266.2, 348.2 
MF5-4 4.26 287 265.2, 347 
MF6-1 3.23 347.1 230.2, 270.2 
MF6-2 3.67 757.2 270.2, 348 
MF6-3 3.78 275 230.2, 270.2,348.2 
MF6-4 5.67 309.1 242.2, 273.2 
MF6-5 11.74 494.4 265.2, 347 
MF7-1 3.28 347 274.2, 361.2 
MF7-2 6.38 447.2 245.2 
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Figure 8.2A showing MS/MS fragmentation of MF2-1 
 
Figure 8.2B showing methyl hexadeca-4,7,10-trienoate which matches with MF2-1. 
MF2-1 eluted at tR 4.32 minute and had a molecular ion at m/z 265 [M+H] which corresponded to C17H28O2. 
Fragment ions were at m/z 247.1 [M-H2O], 206.1 [M-C3H5], 167.1 [M-C6H7], 133.1 [M-C8H11], 105 [C8H9] 
and 91.1 (C7H7). The latter fragments at m/z 105 and 91.1 and the repeated loss of 14 (CH2) or 28 (CH2–CH2) 
is suggestive of a long chain alkane attachment. The UVmax were at 230.2, 275.2, 342.2 and 405.2. The loss 
of a fragment with 59 amu suggests the existence of a terminal alkyl-methoxyl group (CH3-CH2-O-CH2). 
MF2-1 is probably a long chain fatty acid or ester. From the literature and as shown for compound in Figure 
6.2, hexadecatrienoate compounds also show prominent fragments at 91 and 105 in addition to the loss of CH2 
fragments (http://lipidlibrary.aocs.org/ms/masspec.html). 
 
 
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 
380 390 400 
% 
0 
100 
m/z 
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 
% 
0 
100 DK_MRC_110930_2 221 (4.368) Cm (221:222-226) 2: TOF MS ES+ 4.33e4 265.1 
206.1 
205.1 
179.1 
133.1 
105.1 
91.1 
79.1 77.0 67.1 61.0 47.1 55.0 84.1 93.1 115.1 119.1 
167.1 
140.1 
161.1 
151.1 168.1 
197.1 
194.1 
180.1 
219.1 
207.1 
218.1 
217.1 
247.1 
220.1 
235.1 248.1 
251.0 
266.1 
267.1 
287.1 344.2 328.9 297.1 303.1 321.7 317.1 337.1 378.2 347.1 372.2 356.0 391.1 398.1 
DK_MRC_110930_2 221 (4.359) Cm (221:223-217:218) 1: TOF MS ES+ 
2.85e5 265.1 
234.0 219.1 213.2 200.1 248.1 262.9 
266.1 
393.2 
344.2 
318.2 285.1 280.1 311.1 305.1 289.1 322.1 328.2 356.1 386.3 377.0 365.1 400.2 
 
m/z 
O
O
 
 
 
 
 153 
 
    Figure 8.3A showing MS/MS fragmentation of MF2-2 
 
O CH3
H3C
O
 
 Figure 8.3B showing methyl hexadeca-9, 12-dienoate which matches with MF2-2 
MF2-2 eluted at tR 5.46 minute and a molecular ion of m/z 344.2 [M+H]. The base peak is at m/z 177.1 after 
the loss of a fragment of m/z 167. This is typical of a fatty acid fragment undergoing McLafferty ion 
rearrangement. The UV max was 237.2, 286.2 and 316.2. There are also fragments of the loss of 28 amu which 
is typical of removal of CH2-CH2. From the literature, MF2-2 can be predicted as methyl hexadeca-9, 12-
dienoate (http://lipidlibrary.aocs.org/ms/masspec.html) (figure 8.3B).   
 
MF 2 10xd
m/z
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780
%
0
100
m/z
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780
%
0
100
DK_MRC_110930_2 277 (5.465) Cm (276:278-273) 2: TOF MS ES+ 
5.55e4177.1
145.0
117.0
89.0
69.155.1 106.1
119.1
151.1
169.1
344.2
178.1
178.1
299.1293.1194.1206.1 267.1247.1241.1 342.1307.2
345.2
687.3
398.1346.2 366.1 480.1426.2 462.2451.2 567.3494.2 542.2537.2 574.2 602.3 671.9637.3621.3 665.3 740.2709.3 745.2 760.8 783.4
DK_MRC_110930_2 277 (5.456) Cm (277:279-274) 1: TOF MS ES+ 
1.83e5344.2
261.2
227.1216.1202.1 294.1
271.1
299.1 343.2
345.2
687.3
346.2 680.4366.1
459.6382.1 414.2 454.0429.2 599.4572.3518.1474.3 490.3
528.3
542.3 657.3616.4 630.3
688.3
709.3
762.5732.5 776.5
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Figure 8.4A showing MS/MS fragmentation of MF2-3 
 
 
 
 
Figure 8.4B showing methyl 8, 11-eicosadienoate which matches with MF2-3 
 MF2-3 eluted at tR 7.25 minute. It has a molecular ion of m/z 323 [M+H] which correspond to C21H38O2. Major 
fragments were seen at 291 [M-(CH3OH)], 263.1 [M-C2H4O2], 206 [M-C2H402–C4H9]. MF2-3 is probably long 
chain fatty acid / ester from the loss of 60 (CH2=C(OH)OH) and 57 (C2H5CO or C4H9). From the literature MF2-3 is 
likely to be methyl 8, 11-eicosadienoate (methyl icosa-8,11-dienoate) (http://lipidlibrary.aocs.org/ms/masspec.html).   
 
 
 
 
OO
MF 2 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410
%
0
100
DK_MRC_110930_2 368 (7.251) Cm (367:369-362:363) 2: TOF MS ES+ 
4.56e4263.1
206.1
205.1
151.1
131.1103.191.184.081.169.166.954.540.7 121.1
110.1 140.1
180.1
177.1152.1 167.1
204.1182.2
207.1
235.1216.1 221.1
241.1245.1 254.1
323.1
291.1
264.1
265.1
281.1
292.1 301.2
307.1
324.1
345.1
329.2 337.1
367.2363.2
399.2388.1379.2 407.2411.1
DK_MRC_110930_2 368 (7.242) Cm (367:369-363:364) 1: TOF MS ES+ 
1.88e5323.1
301.2285.1242.1228.1225.1201.2 207.1 275.2264.2256.2
307.1 323.1
324.1
325.1
345.1 361.1 381.1373.1 392.2 397.2 407.2
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MF 2 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410
%
0
100
DK_MRC_110930_2 297 (5.853) Cm (296:297-299) 2: TOF MS ES+ 
9.32e3137.1
133.1
107.1
91.1
79.1
77.067.145.0 65.058.7
81.1
103.1
122.1
109.1
131.1
191.1
173.1
138.1
149.1
147.1 168.1165.1 189.1174.1
271.1
192.2 219.1
195.1 208.1 267.1235.1220.1 248.1 251.1
308.2
293.1
290.2272.1
307.1 325.1309.2 369.2329.1 355.1344.2 384.1380.1 405.0391.1 409.2
DK_MRC_110930_2 297 (5.845) Cm (296:297-301:302) 1: TOF MS ES+ 
1.28e5271.1
211.1207.1200.2 229.2
223.2 259.1251.1246.2 270.1
272.1
273.1
308.2288.2
274.1
293.1
329.1312.0 341.1 358.2345.0 373.1 405.1391.9379.2 411.1  
Figure 8.5A showing MS/MS fragmentation of MF2-4 
 
OOH
OH
OH
O  
 
Figure 8.5B showing structure of apigenin which matches with MF2-4 
MF2-4 eluted at tR 5.85 minutes and has a molecular ion of m/ z 271.1 [M+H] which corresponds to C15H10O5 
The major fragments are at m/z 271.1 [M+H], 191.1 [M+H-CO] and, 137.1 (base peak), 91.1 [C7H7], 107 
[C7H7O]. The peaks at 91.1 and 107 is indicative of a tropylium and hence the presence of a phenolic ring. 
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This fragmentation is suggestive of flavonoids and the UV max of 241.2 and 276.2 is typical 
of these compounds too. Based on the above and comparisons with the literature MF-2.4 
was suggestive of apigenin or closely related isomers. Flavonoids have been previously 
isolated from T. violacea (Alfonso, et al., 1996)  
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Figure 8.6A showing MS/MS fragmentation of MF3-1 
OO
 
Figure 8.6B showing methyl octacosa-13,17,21,25-tetraenoate which matches for MF3-1 
MF3-1 eluted at tR 3.61 minutes and had a molecular ion of m/z 431 [M+H] which corresponded to C29H50O2. It had poor chromophoric properties. The 
base peak was at m/z 415. There is repeated loss of fragments of m/z 44 which may be due to CO2 and also C3H8  or aldehydic fragments (CH2CH(OH)). 
This implies that MF3-1 is probably a long chain fatty acid ester. From the literature the structure  can be predicted as octacosa-13, 17, 21, 25-
tetraenoate (http://lipidlibrary.aocs.org/ms/masspec.html). 
MF 3 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430
%
0
100
DK_MRC_110930_3 182 (3.608) Cm (182-178) 2: TOF MS ES+ 
1.83e3415.3
133.1
89.1
87.0
45.047.0 55.1 75.863.3 87.0
90.1 131.1
103.0110.9 123.1
177.1
134.1
149.1 175.1152.1
371.2
327.2
309.2221.1191.1
183.1
196.1
208.0
283.2239.2226.1 249.0 279.1256.0 294.8 322.9 367.2350.9334.8 355.2
372.2
384.8 397.9 404.9
416.3
432.3417.3
421.9 433.8
DK_MRC_110930_3 182 (3.599) Cm (182-179) 1: TOF MS ES+ 
1.06e5432.3
415.3
312.2223.1207.1203.1 211.1 271.1234.1 243.1 252.1 266.9 298.1280.0 285.1 411.2397.3358.2316.1 328.0 344.1332.1 376.0372.1 390.0
416.3
433.3
434.3
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Figure 8.7A MS/MS fragmentation for MF3-2 
MF3-2 eluted at tR 3.80 minutes with a molecular ion of m/z 476 [M+H] and molecular formula of C31H54O3. It appears to be a homologue of MF3-1. 
Figure 8.7A shows a similar fragmentation pattern with common fragments at m/z 89.1, 133.1, 177.1 and 415.3 (base peak). It differs only in possessing 
an additional ethoxyl substituent.  
 
 
 
 
 
 
 
 
 
MF 3 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480
%
0
100
DK_MRC_110930_3 192 (3.802) Cm (191:192-197) 2: TOF MS ES+ 
4.85e3459.3
133.1
89.1
87.0
45.0 79.1
67.155.1
131.190.1
117.198.0
177.1
134.1
167.1149.0
415.3265.2195.1188.1 221.1210.1201.1 249.1236.1 253.0
371.2327.2
309.2298.9284.2267.2
353.2333.2
398.3393.2 416.3 441.3 456.3
460.3
476.3
461.3 477.3
DK_MRC_110930_3 192 (3.794) Cm (192-197) 1: TOF MS ES+ 
8.88e4476.3
459.3
386.2372.2210.1201.0 314.0285.1273.1265.2233.1221.1 247.0 298.9 369.2328.2 359.5350.7 434.3430.3415.3397.0
457.2440.2 460.3
477.3
478.3
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Figure 8.8A showing MS/MS fragmentation of MF3-3 
MF3-3 which elutes a at tR 5.49 minutes with a molecular ion of m/z 344.2 [M+H] and a UVmax 239.2, 288.8 and 317.2. It appears to be a homologue 
of MF2-2. It shows a similar fragmentation pattern with common fragments at m/z 89, 117, 145 and 177 (base peak). There were also fragments loss of 
28 which is typical of removal of 28 (C2H4) which is a typical of a fatty acid fragment undergoing McLaffety ion rearrangement  
 
MF 3 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390
%
0
100
DK_MRC_110930_3 279 (5.499) Cm (279-283) 2: TOF MS ES+ 
1.22e4177.1
145.0
117.0
89.0
78.064.056.143.951.9 71.2 84.0
91.1
97.0 103.0
119.1
134.0
141.1
149.1
152.1 162.0 173.0
344.2
178.1
197.1179.1 190.0
342.1
207.1 241.1232.0214.1 220.1 259.1246.1 325.2304.1294.1287.1284.0270.1
319.2
366.1
345.2
349.2 366.0
367.1
382.1 391.2
DK_MRC_110930_3 279 (5.491) Cm (278:279-289) 1: TOF MS ES+ 
7.90e4344.2
314.1303.2261.2251.2247.2241.0219.1209.2200.5 229.1 293.1279.1
265.1 325.2 342.1
345.2
366.1
346.2
359.2 367.1 382.1 391.3
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Figure 8.9A showing MS/MS fragmentation of MF3-4 
MF3-4 eluted at tR 13.88 minutes with a molecular ion of m/z 282.2 [M+H]. It has poor UV activity. The major fragments occurred at m/z 247.3 and 
265.5 (both due to loss of OH). The fragments at m/z 304 is probably a sodium adduct. The elution time indicates that this compound is non-polar in its 
nature but the poor fragmentation makes it difficult for further elucidation. 
 
 
 
 
 
MF 3 10xd
m/z
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40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590
%
0
100
DK_MRC_110930_3 704 (13.868) Cm (704-710) 2: TOF MS ES+ 
9.30e3282.3
247.3
135.1
121.195.181.169.1
55.141.0
114.1 149.1 163.2 184.1 191.2 240.3226.2212.2
265.3
248.3 266.3
304.3
283.3
284.3
305.3
351.3341.2318.2 451.4393.3375.3 447.4
401.3 415.3 461.3 485.4 539.3517.4507.3 591.5569.4555.4
DK_MRC_110930_3 705 (13.877) Cm (704:706-696:698) 1: TOF MS ES+ 
5.48e5282.3
265.3247.2212.2205.2 226.2 281.3
563.6283.3
304.3
284.3
305.3 351.3339.2320.3 494.4427.3384.2376.3 416.3406.3 450.9 475.4457.4 501.4 545.4540.5511.4
564.6
565.6 585.5
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MF 4 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360
%
0
100
DK_MRC_110930_4 287 (5.659) Cm (286:288) 2: TOF MS ES+ 
4.02e4263.1
206.1
205.1
180.1177.1
167.1152.1140.1133.1120.1113.1107.189.181.179.1 91.1 155.1
204.1
190.1
193.1
207.1
235.1
216.1 221.1
236.1 245.1 251.1
309.1
291.1264.1
265.1
281.1279.1
292.1
299.1
310.1
331.1
311.1 320.1 353.1347.1 355.1 363.0
DK_MRC_110930_4 287 (5.650) Cm (286:288-292:293) 1: TOF MS ES+ 
1.75e5309.1
291.1221.2203.2201.0 205.2 239.2223.2 257.2249.1
263.1 273.2 279.1 298.2 305.2
310.1
311.1
331.1325.1 347.1344.2 365.2359.1  
 
Figure 8.10A showing MS/MS fragmentation of MF4-1 
O O
CH3
H3C
 
Figure 8.10B showing methyl arachidonate which matches for MF4-1 
MF4-1 eluted at tR 5.65 minute with a molecular ion of m/z 319.1 [M+H] giving a molecular formula of C21H34O2. The UVmax were 239.2, 286.2, 
352.2 and 412.2. The prominent fragments were at m/z 206.1(loss of 57), 263.1(loss of 28) and 291.1 (loss of 18). The losses of 57(C4H9 , 28(C2H4) and 
18(H2O) is typical of a long chain fatty ester with ethyl ketone or propionate ester functions. From this information and the literature MF4-1 could be 
Methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate (methyl arachidonate) or a conjugate isomer.  
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Figure 8.11A showing MS/MS fragmentation of MF4-2 
O
O
 
 
Figure 8.11B showing methyl 5, 8, 11, 14-eicosatetraenoate.which matches with MF4-2 
M4-2 elutes at tR 9.19 minutes and has a molecular ion of m/z 318 [M+H]. The UVmax was 246.2. The compound did not fragment easily and only had 
fragments at 282.3 (loss of 18) and 300.3 (loss of 18). From the literature MF4-2 was predicted to be methyl 5, 8, 1, 14-eicosatetraenoate 
(http://lipidlibrary.aocs.org/ms/masspec.html)(figure 8.11B) 
 
MF 4 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330
%
0
100
DK_MRC_110930_4 467 (9.197) Cm (467:468-461:462) 2: TOF MS ES+ 
1.29e4318.3
300.3282.3
119.1
113.189.167.145.0 55.851.9 60.0 77.069.0
86.1 107.1105.197.1
264.3252.3133.1131.1 227.1219.1177.1164.9153.1151.1135.1 159.1 213.1197.1185.1 195.1 211.1 244.3238.3 254.3
270.3 275.2
283.3 290.2
301.3
317.2
310.1
319.3
320.3
328.2
DK_MRC_110930_4 467 (9.188) Cm (467:468-463) 1: TOF MS ES+ 
1.17e5318.3
268.2251.2244.3219.2217.1205.2200.2 229.1 235.2 261.2 290.2278.3 300.3 308.2310.2
319.3
320.3
328.3
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MF 4 10xd
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380
%
0
100
m/z
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380
%
0
100
DK_MRC_110930_4 476 (9.374) Cm (475:476-479:480) 2: TOF MS ES+ 
2.00e4332.3
314.3
296.3
74.170.155.143.7 47.3 59.4
268.3213.1118.196.192.186.1 106.1 169.1146.1139.0135.1128.0 159.1 187.1180.1 205.1203.0 251.1241.3233.2221.1 254.3
278.3 293.2
297.3
309.2
332.2
315.3
331.2
333.3
334.3
354.3351.2 363.2 371.2 382.2
DK_MRC_110930_4 477 (9.383) Cm (475:477-481:484) 1: TOF MS ES+ 
2.05e5332.3
310.2
288.3268.2251.2219.2211.1209.1202.0 240.1233.2 261.2 279.2
292.2
332.2
314.3
333.3
334.3
354.3348.2 359.3 370.3 384.2  
Figure 8.12A showing MS/MS fragmentation of MF4-3 
MF4-3 eluted at tR 9.37 minutes with a molecular ion of m/z 332 [M+H] which gave the molecular formula as C22H35O2.. It has a UVmax at 247 and MS 
fragment at m/z 296.3 and 314.3. It appears to be a homologue of MF4-1 with an additional CH2 It may be 7, 10, 13,16-docosatetraenoate or an 
analogue of the docosatetraenoates. 
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MF 4 10xd
m/z
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%
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DK_MRC_110930_4 707 (13.921) Cm (706:707-701:703) 2: TOF MS ES+ 
1.98e4282.3
247.2
135.1
121.195.193.169.167.141.3
55.151.5 57.9
83.181.172.1
97.1
111.1107.1
115.1
128.1
149.1
139.1 142.2
163.2156.1 177.2170.2 240.3191.2184.0 198.2 226.2209.2 212.2 221.1 233.2
265.3
248.3
264.3
266.3
277.2
283.3
284.3
296.3
DK_MRC_110930_4 707 (13.912) Cm (706:709-700:702) 1: TOF MS ES+ 
6.45e5282.3
265.3247.2226.2212.2209.2203.1 223.2 240.2228.1 249.3255.2 267.3 280.3
283.3
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Figure 8.13A showing MS/MS fragmentation of MF4-4 
MF4-4 elutes at tR 13.92 minutes. It has molecular ion of m/z 282.3 [M+H]. The UV properties are poor. The MS fragment patterns were at m/z 93.1, 
107.1, 121.1, 135.1, 149.1, 163.2, 177.2, 191.2 (all due to (CH2) losses), 240.2 (loss of OH), 247.1(loss of H20), 265.3 (loss of OH) and 282.3 (base 
peak). It would appear that this is a long chain fatty acid or alcohol.  
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Figure 8.14A showing MS/MS fragmentation of MF5-1 
H3C
O
O
CH3
O
O
CH3
 
Figure 8. 14B showing methyl 9-(methylperoxy) nonanoate which matches with MF5-1. 
MF5-1 eluted at tR 3.23minutes with molecular ion of m/z 217.1 [M+H] and a molecular formula of C11H20O4. The UVmax were at 230.2 and 
270.2. MS fragmentation was generally poor with a single major peak (also base peak) at m/z 144.1 due to loss of 73 (C3H5O2) from molecular 
ion. This implied that this compound is an ethyl ether of a long chain alkane (Williams and Fleming, 1995). This compound appears to cleave 
near the middle where the ester resides. From the this information and from the literature MF51 can be predicted as ethyl 3-methylbutyl 
succinate or closely related isomer (figure 8.14B) 
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Figure 8.15A showing MS/MS fragmentation of MF5-2 
 
COOH3C
HO  
 
Figure 8. 15B showing methyl 2-hydroxydodecanoate which matches with MF5-2 
MF5-2 eluted tR at 3.35minutes with molecular ion of m/z 231.1 [M+H] and a molecular formula of C13H26O3. The UVmax were 230.2 and 271.2. The 
MS fragments were at 143.1 (loss of 15 (CH3)), 158.1 (loss of 73 (C3H5O2), 188 (loss of 43 (C3H7) and 214 (loss of 17 (OH). From the foregoing and 
literature MF5-2 was predicted to be methyl 2-hydroxy-dodecanoate (http://lipidlibrary.aocs.org/ms/masspec.html) (figure 8.15B). 
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Figure 8.16A showing MS/MS fragmentation of MF5-3 
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Figure 8.16B showing MS/MS fragmentation and chromatograms of MF5-3 and MF5-4. 
MF5-3 and MF5-4 have super imposable UV spectra (table 8.2). MF5-3 eluted at tR 3.69 minutes and had a molecular ion of 757.2 [M+H]. The 
fragmentation pattern was poor and only two fragments were produced in the MS-MS experiment i.e. 611.2 [M-146] and 287.1 (M-146 – 324).  
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Figure 8.17 showing MS/MS fragmentation of MF5-4 
MF5-4 on the other hand eluted at tR 4.26 minute and had fragment ions at m/z 595 [M+H], 447 [M-146], 287.1 (M–146 –162) (base peak). The loss of 
similar moieties in both compounds m/z 146 and m/z 162 (or m/z 324 which is double) suggests that these compounds are homologues in a closely 
related series. The fragment of m/z 162 may result from the loss of allicin and the fragment of m/z 146 is due to the fragmentation of the allicin into a 
thiol or hydroxyl sugar. 
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Figure 8.18A showing MS/MS fragmentation MF6-1. 
COOH3C
 
Figure 8. 18B showing methyl docosa-7,10,13,16-tetraenoate which matches with MF6-1 
MF6-1 eluted at tR 3.23minutes with molecular ion of m/z 347 [M+H] and molecular formula of C23H38O2. UVmax are 230.2 and 270.2. The prominent 
fragments were at 347.1, 329.1 (loss of 18), 311.1 (loss of 18), 293.1 (loss of 18), 217.1 (loss of 76), 144.1 (loss of 73). This fragmentation patterns 
suggests the presence of ethyl ester groups in a long chain alkane. From the literature MF6-1 was predicted as methyl docosa-7, 10, 13, 16-tetraenoate 
(figure 8.18B). 
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Figure 8.19 showing MS/MS fragmentation MF6-2 
MF6-2 eluted at tR 3.67 minutes and had molecular ion of m/z 757.2 [M+H], the fragmentation pattern is poor, only two fragments were produced in the 
MS-MS experiment at 611.2 [M-146] and 287.1 [M-146–324] which is similar to both MF5-3 and MF5-4.but their tR were different figure (8.19A). The 
loss of similar moieties indicates that these compounds are homologues and probably possess thiol functional groups. 
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Figure 8.20A showing MS/MS fragmentation  MF6-3 
MF6-3 eluted at tR 3.78 minutes with a molecular ions of m/z 275 [M+H]. The UVmax were 230.2, 270.2 and 348.2. The main fragments were 258 (loss 
of 27), 115 (loss of 14). From this information and from the literature MF6-3 was 2,3-dihydroxypropyl laurate or 2,15-dihydroxypentadecanoic acid.  
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Figure 8.21A showing MS/MS fragmentation MF6-4 
O
CH3
O
H3C
 
 
Figure 8. 21B showing Ethyl (9E,12E)-9,12-octadecadienoate which possibly matches with MF6-4 
MF6-4 eluted at tR 5.67minutes and had a molecular ion of m/z 309 (M+H) and molecular formula of C20H36O2. The fragment were 291, 264, 283.1, and 
205.1 with loss of 18(H20), 45(CHCH=OH+) and 28(C2H4). The UVmax are 242.2 and 273.2. From the literature MF6-4 could be any of the isomers in 
Fig 21B 
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Figure 8.22A showing MS/MS fragmentation MF6-5 
O
-O
N
 
Figure 8. 22B showing 3-pyridylcarbinyl 5,9, 19-heptacosatrienoate which matches with MF6-5.  
MF6-5 eluted at tR 11.14 minutes. It had molecular ions of m/z 496 [M+H]. UVmax were 274.2 and 361.1. The fragments were 478(loss of 18), 421.3 
(loss of 75), 184.1(loss of 237 (molecular cleavage)), and 125 (loss of 59).From the literature MF6-5 was predicted as 3-pyridylcarbinyl 5, 9, 19-
heptacosatrienoate  (http://lipidlibrary.aocs.org/ms/masspec.html) (figure 8.22B). 
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Figure 8.23A showing MS/MS fragmentation MF7-1 
O
-O   
Figure 8. 23B showing 7, 10, 13, 16, -docosatetraenoate which matches with MF7-1.  
MF7-1 elutes at 3.28 minutes with a molecular ion of m/z 347.1 [M+H]. The UV max was 274.2 and 361.2. The main fragments patterns were 329 (loss 
of 18), 311 (loss of 18), 293 (loss of 18), 283 (loss of 28), 265 (loss of 18). This compound is similar to MF6-1 
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Figure 8.24A showing MS/MS fragmentation MF7-2 
MF7-2 eluted at tR 6.38 minutes and a had a molecular ion of m/z 447 [M+H]. Fragmentation was extremely poor. 
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8.4 Discussion 
Most of the compounds isolated from methanol fractions of T. violacea leaves are long 
chain fatty acid (esters and alkanes). Long chain fatty acids are carboxylic acids consisting 
of carboxylic head group as well as a long hydrocarbon chain (Lynda & Robert, 2010). 
Some saturated fatty acid such as palmitic, palmitate, stearic or stearate acids have no 
double bonds along their hydrocarbon chains while the unsaturated fatty acids contains 
minimum of one double bond. Consumption of dietary fatty acids in various concentrations 
is report to result in changes in cell membrane structure and function  (Linda, et al., 2006) . 
Studies have shown that fatty acids play a vital role in biological systems, they reduce most 
of the risk factors associated with several diseases such as cancer, diabetes and 
cardiovascular diseases (Richard, et al., 2006), they are the component of both 
phospholipids and glycolipids. They are linked to the regulation of inflammatory processes 
such as cancer (Shawn, et al., 2001). Fatty acids have different effects on the production of 
cytokines, chemotaxis and modulation of blood coagulation pathways.  
Studies have shown that dietary n-3 Polyunsaturated fatty acids (PUFA) can inhibit 
both initiation and promotion  stages of  carcinogenesis by suppression of arachidonic acid 
derived eicosanoid biosynthesis which lead to changes in immune response to cancer cells 
as well as modulation of inflammation, cell proliferation, metastasis and angiogenesis. 
PUFAs also affect carcinogenesis by influencing the transcription factor activity, gene 
expression and signal transduction which later result in changes in cell growth and 
differentiation as well as metabolism, it could also be through either decrease or increase in 
production of ROS and free radical (Susanna, et al., 2004). In drug development, PUFAs 
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have been used to either kill or inhibit growth of cancer cells in culture as well as using 
animal model for effectiveness of chemotherapeutic drugs (Elaine, et al., 2001).  
 
In conclusion from the chemical investigation of T.violacea, it was demonstrated that 
that this plant species contains several long chain fatty acids, allicin-like compounds and 
flavonoids. These compounds have been shown to have anti-proliferative, and in some 
cases, pro-apoptotic properties which may explain the biological activity demonstrated in 
this study, and also explain the rationale behind traditional use of this herb. 
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CHAPTER NINE:GENERAL DISCUSSION AND CONCLUSION 
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9.1  MDG does not induce morphological changes in human cell cultures. 
Two studies previously demonstrated that extracts of T.violacea induce apoptosis in human 
cancer cell cultures (Lyantagaye, 2005; Bungu, et al., 2006). The study from Lyantagaye 
identified MDG as one of three bioactive compounds in the extract (Lyantagaye, 2005). In 
the present study the pro-apoptotic activity of MDG was evaluated on MCF7 and CHO 
cells (section 2.2.1). It was observed that, the positive control (doxorubicin) was able to 
induce morphological changes (cell shrinkage and cell detachment) in cell cultures that 
were indicative of apoptosis, while the MDG failed to induce noticeable morphological 
changes in two cell cultures (CHO and MCF7) (figure 3.2). Previous studies showed that 
the induction of apoptosis is usually associated with changes in cell morphology 
(Kroemer, et al., 2005). Hacker’s report in 2000 also supported that morphological 
features of apoptosis would provide a reliable basis for the detection of apoptosis, which 
could be used in combination with other apoptosis assays for the study of apoptosis (Ross 
& Brain, 1977; Häcker, 2000; Kroemer, et al., 2005).  
 
9.2 MDG does not induce apoptosis in cultured cells. 
Since morphological studies on its own cannot be used to confirm the induction of 
apoptosis, the APOPercentage
TM
 assay, which is an assay that specifically quantify of 
apoptosis in cell cultures was used. The results showed that no apoptosis was detected when 
MCF7 and CHO were treated with different concentrations (0.6, 0.125, 0.25, 0.5, 1 and 
2mM) of MDG for 24hours (figure3.3). This study appeared to contradict the previous 
findings by Lyantagaye in 2005 that MDG induced apoptosis in these cell lines.  
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9.3 Cell proliferation assay show that the effects of MDG are transient.  
The xCelligence system (Roche) provides the biological status of the cell in real time. The 
xCelligence data showed that both the MCF and CHO cells were transiently affected by the 
addition of MDG to the culture (figure 3.4). The cell index decreased for a period of 
30minutes following the exposure to MDG. After 30minutes, the cell index increased which 
is an indication that the cells recovered from the effects of MDG. A decrease in the cell 
index indicates cell shrinkage or cell detachment, while an increase in the cell index 
suggests that the cells are proliferating. These results explained the apparent contradiction 
between the Lyantagaye study (2005) and this study in that it demonstrated that the effects 
of MDG are transient. In the Lyantagaye (2005) study CHO and MCF7 cells were treated 
for only 1hour before apoptosis was quantified. However, as was demonstrated in the 
current study, the cells recovered after 1hour and 24hours later, the cells were still viable. 
This demonstrated that MDG do not induce apoptosis in MCF7 and CHO cells. It also 
illustrates the limitation of end-point analysis assays, which only gives an indication of what 
is happening at the time-point when assay is stopped.  
 
9.4 The leaf extract and not the tuber extract of T.violacea induce morphological 
changes in cultured cells  
 In the Lyantagaye (2005) study the whole plant was used for the extraction of possible 
bioactive compounds, while the study by Bungu et al. (2006) studied the effects of the leafs 
and the tubers were independently studied. Both these studies showed that organic extracts 
(hexane, chloroform, ethyl acetate, n-butanol and methanol) of T.violacea induce apoptosis 
in cancer cells.  
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In the current study the leafs and tubers were separated before the extractions were 
performed. It is likely that the chemical composition of the tuber and leaf extract will differ; 
hence the objective was to investigate if there is a difference in the bioactivity of the two 
plant parts. Water extracts of T.violacea leaves induced discernible morphological changes 
(such as cellular shrinking, chromatin condensation and cell detachments) (Kroemer, et al., 
2007) in MCF7 cells. All these morphological changes are features that are associated with 
apoptotic cell death. However there were little or no discernible morphological changes in 
the cells treated with the tuber extract. This suggested that the leaf extract of T.violacea 
either contains more of the cytotoxic compounds or that these compounds are completely 
absent in the tuber extract. This is in contradiction to the study by Bungu et al. (2006), 
which found that the tuber extract was more active than the leaf extract. The Bungu study 
(Bungu, et al., 2006) found that a crude water extract and a methanol extract of the leafs 
were more active than an extract of the tubers. This was demonstrated in four human cancer 
cell lines (MCF7, WHCO3, HT29 and Hela). The cells were treated for up to 48hrs with 
250ug/ml of the extracts and cell death was quantified using a cell viability assay and the 
annexin V assay. It is known that seasonal changes and geographical location can affect the 
bioactivity of medicinal plants (Sanjay, et al., 2010). It is not known where and when the 
plant material for the Bungu study was sourced, but it is possible that the location where the 
plant material was collected may account for the apparent contradiction between the current 
study and the study by Bungu et al. (2006). In the Bungu study MCF7, WHCO3, HT29 and 
Hela cells were used, while the current study used MCF7, HT29, H157, HepG2 and KMST6 
cells. Both studies therefore used MCF7 and HT29 cells. However the current study also 
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included a noncancerous control cell line (KMST6), which made it possible to determination 
the selectivity index of the extracts. 
 
9.5 The leaf and not the tuber contains compounds that can selectively induce apoptosis 
in cancer cell lines 
The MTT assay was used to determine the IC50 values (the concentration of plant extract 
that is required for 50% cellular growth inhibition) for water extracts of T.violacea leaves 
and tubers on a panel of 5 human cell lines (table 4.1). Based on the MTT assay the tuber 
extract of T.violacea contained no cytotoxic compounds, while the leaf extract was 
cytotoxic to all the cell lines tested in this study. The IC50 values for the tuber extract were 
more than 2.5mg/ml on all the cell lines tested and the tuber extract was therefore 
considered to be inactive. The IC50 values for MCF7, H157, HT29, HepG2 and KMST6 
cells were 1.2±0.5, 1.5±0.8, 2.6±1.5, 2.8±0.5, 3.0±0.9 mg/ml, respectively. The selectivity 
index (calculated based on the non-cancerous KMST6 cell line) showed that the MCF7 cell 
line was the most sensitive cell line.  
The MTT assay measures cell viability as a function of the cells active enzymes 
(mitochondrial succinate dehydrogenase) and does not discriminate between necrotic and 
apoptotic cell death. Since the objective of this study was to investigate the pro-apoptotic 
activity of the plant extract, a second assay, the APOPercentage
TM
 assay was used to assess 
cell death in cells treated with the plant extracts. The principle of the APOPercentage
TM
 
assay is based on the externalisation of phosphatidylserine, which is a feature observed only 
in apoptotic cells. Apoptotic cells take up the fluorescent APOPercentage
TM
 dye and the 
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cells can be quantified by flow cytometry. The water extracts of T.violacea leaves showed a 
dose-dependent increase in the number cells staining positive for apoptosis (figure 4.2a).  
This was observed in all the cell lines tested in this study. The tuber extract failed to induce 
significant levels of apoptosis in these cells. The results of the APOPercentage
TM
 assay was 
used to determine the IC50 values (the concentration of the plant extract that is required kill 
50% of the cells by apoptosis) for water extracts of T.violacea leaves and tubers on 5 
different human cell lines (table 4.2). The IC50 values for MCF7, H157, HT29, HepG2 and 
KMST6 cells were 0.19±0.4, 0.28±0.1, 1.21±0.6, 2.09±1.4, 4.4±1.4 mg/ml, respectively. 
The Selectivity Index (calculated based on the non-cancerous KMST6 cell line) showed that 
the MCF7 cell line was the most sensitive cell line. The results for the APOPercentage
TM
 
assay are in agreement with the results obtained for the MTT assay. Both assays 
demonstrated that the MCF7 cell line is the most sensitive cell line and that the non-
cancerous cell line, KMST6 was the most resistant cell line. However, the IC50 values 
obtained for the APOPercentage
TM
 assay was much lower than that obtained for the MTT 
assay. For example, using the MTT assay the IC50 value for the MCF7 cell line was 
calculated to be 1.2±0.5 mg/ml, while the IC50 value for the same cell line was 
0.19±0.4mg/ml when the APOPercentage
TM
 assay was used. This may be due to the fact 
that the APOPercentage
TM
 assay is a more sensitive assay and that it detects the 
externalisation of phosphatidylserine, which may occur well before the mitochondrial 
enzyme activity diminishes. 
These results demonstrated that the water extract of the T.violacea tubers do not contain any 
cytotoxic or pro-apoptotic compounds. As a result the tuber extract was excluded from 
further investigation and the rest of the study focussed on the leaf extract of T.violacea. 
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Medicinal plants such as T.violacea are under threat of extinction due to overexploitation 
and destructive harvesting methods (Jeremy, 2008). The fact this study demonstrated that 
the potential anti-cancer bioactivity of the plant is in the leaves of the plant and not the 
tubers benefits the preservation of T.violacea, since the harvesting of the leaves of this plant 
is less destructive than harvesting the whole plant. 
 
9.6 Apoptosis induced by the water extract is associated with the activation of caspase-
3 cleavage and ROS production 
The cleavage and activation of caspase-3 are universal markers for the induction of 
apoptosis (Frankline, et al., 2008) and play a vital role in the initiation and execution of 
programmed cell death (Fischer & Schulze-Osthoff, 2005). However, the activation of these 
enzymes is often inhibited in cancer cells. These enzymes are therefore targets for the 
development of anti-cancer drugs. The activation of cellular caspases via small cell 
permeable drugs could offer a more efficient way to target cancer cells.  
 
The activation of caspase-3 was assessed in four human cancer cell lines (HepG2, HT29, 
MCF7 and H157) and a non-cancerous human cell line (KMST6) following treatments with 
the water extract of T.violacea leaves and 10µM doxorubicin (positive control). The results 
showed that the water extract of T.violacea activated caspase-3 cleavage in the five cell lines 
tested in this study (figure 4.4). However, the cell lines differed significantly in the 
percentage cells that were positive for cleaved caspase-3. At 68%, the HepG2 cell line 
exhibited the highest percentage active caspase-3 positive cells, while 28% of MCF7 cells, 
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23% of H157 cells and 22% of HT29 cells were positive for active caspase-3. This is in 
agreement with the study by Lyantagaye, which demonstrated that a water extract of 
T.violacea induced the activation of caspase-3 in Chinese Hamster Ovary cells (Lyantagaye, 
2005). This study also found that the water extract of T.violacea failed to induce caspase-3 
cleavage in KMST6 cells, demonstrating the selective killing of cancer cells by the extract. 
 
ROS activate signal molecules that are involved in inflammation and carcinogenesis such as 
nuclear transcription factor NF-κB, inducible nitric oxide synthetase (iNOS) as well as 
cyclooxygenase-2 (COX-2) (Ohshima, et al., 2005). Increased levels of ROS can cause 
oxidative damage of intracellular macromolecules (lipids, DNA, RNA and protein) (Elisa, et 
al., 2000). This in turn can activate the induction of apoptosis. Chemotherapeutic agents and 
radiation have been shown to induce ROS in cancer cells, leading to the destruction of the 
cancer cells through the induction of apoptosis (Stacey & Wei-Xing, 2006). To assess 
whether the water extract of T.violacea induce ROS production in cancer cells a panel four 
human cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-cancerous human cell 
line (KMST6) were treated for 24hours with 2mg/ml of the extract. Hydrogen peroxide was 
used as a positive control and the production of ROS was evaluated using the CM-
H2DCFDA probe. This probe is a general oxidative stress indicator, which diffuses into cells 
and is oxidised into a fluorescent adduct which is trapped inside cells in the presence of 
ROS (Kim, et al., 2009). These fluorescent cells can be quantified by flow cytometry. The 
results demonstrated that the water extract of T.violacea induce significant ROS production 
three of the cancer cell lines (H157, MCF7 and HepG2) (figure 4.5). ROS production in 
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H157 cells was the highest with 83% of the cells being positive for ROS production, while 
50% of HepG2 cells and 30% of MCF7 cells were positive for ROS production.  
 
These results show that the water extract of T.violacea induces apoptosis in human cancer 
cells and that the mechanism most likely involves the activation of caspase-3 and the 
generation of ROS. However, the varied responses in human cancer cell lines were 
observed. The non-cancerous KMST6 cell line was very resistant to the effects of the plant 
extract, with very low levels of apoptosis induced in this cell line. These results support 
claims that extracts of this plant can be used to treat cancer. The selective killing of cancer 
cells by T.violacea extracts can be exploited for the development of an alternative anti-
cancer treatment that has lower levels of bystander cytotoxic effects (i.e. the killing of 
normal cells). 
 
9.7 The hexane and DCM extracts of T.violacea contains the major pro-apoptotic 
compounds 
It was shown that the leaf extract and not the tuber extract of T.violacea contain pro-
apoptotic compounds. Since the objective of this study was to isolate the bioactive 
compounds, the next phase was to apply bioactivity guided fractionation to isolate the 
bioactive (or pro-apoptotic) compound(s). Sequential extraction of T.violacea leaves was 
performed using organic solvents (hexane, DCM, methanol and 50% methanol). This differs 
from the Lyantagaye study in that a crude water extract of T.violacea was prepared of the 
whole plant, which was then fractionated using organic solvents (Lyantagaye, 2005).  One 
of the limitations of the Lyantagaye study is that the extraction process will only extract 
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water-soluble compounds. Consequently, non-polar compounds cannot be extracted with 
this strategy. Sequential extraction using organic solvents should also increase the yield of 
compounds extracted from the plant material. The organic solvent extracts were tested on a 
panel of four human cancer cell lines (HepG2, HT29, MCF7 and H157) and a non-
cancerous human cell line (KMST6) using the APOPercentage
TM
 assay. An increase in the 
bioactivity was observed for all four solvent extracts when compared to the water extract of 
T.violacea leaves, suggesting that the solvent extracts contained increased levels of the 
bioactive phytochemicals. Based on the IC50 values obtained for the four extracts, the 
bioactivity of the methanol and 50% methanol extracts were very low (table 5.2). The 
hexane and DCM extracts on the other hand displayed significant bioactivity towards most 
of the cell lines. The H157 cell line was the most sensitive cell line with SI values of 47.75 
and 41 for hexane and DCM extracts, respectively. The MCF7 cell line was highly resistant 
to the effects of all four solvent extracts, with IC50 values above 2mg/ml, interestingly this 
cell line was highly susceptible to the effects of the water extract of T.violacea leaves. In 
fact the IC50 and SI values suggested that the MCF7 was more susceptible to the effects of 
the water extract than any other cell line. It is possible that the compounds that were 
responsible for the bioactivity in this cell line were lost during the solvent extraction process 
or that more than one compound was responsible for the bioactivity of the water extract and 
that these compounds were separated by solvent extraction resulting in the loss of 
bioactivity. This also suggests that it is not the same compound(s) that is responsible for the 
bioactivity in the different cell lines. The wide-ranging responses of the different cancer cell 
lines can be ascribed to the different mutations in these cell lines. It is known that cancer 
cells have acquired genetic mutations, which make these cells more resistant to apoptosis 
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(Michael, et al., 2005). It is to be expected that different cancer cell types will have different 
mutations and will therefore respond differently to pro-apoptotic agents. 
 
The objective was to isolate and identify the bioactive compound(s). Based on the IC50 
values, the DCM extract was selected for further study. Two additional assays (caspase-3 
cleavage and ROS production) were used to confirm the pro-apoptotic activity of the DCM 
extract. The caspase-3 cleavage assay showed that the DCM extract induced caspase-3 
cleavage in all cell lines tested in this study (figure 5.3). Figure 5.4 shows the production of 
ROS in several cell lines. ROS production in H157 cells was the highest, while ROS 
production in KMST6 and HT29 were the lowest compared to H157 and HepG2 cells, ROS 
production in MCF7 cells were much lower. However, MCF7 were more susceptible to the 
leaf extract, since higher levels of apoptosis were observed for MCF7. 
 
9.8 Palmitone (16-hentriacontanone) is a major component of the DCM extract of 
T.violacea  
Palmitone precipitated in several DCM fractions of T.violacea. This is the first report of its 
occurrence in this species. The compound was elucidated using NMR spectroscopy and 
mass spectrometry as well as comparison with the literature (González-Trujano, et al., 
2001). Though it was isolated from DCM, it proved impossible to re-dissolve in that solvent 
for the purposes of testing it in biological media. An abortive attempt to use cyclodextrin to 
solubilise palmitone was unsatisfactory, and it is recommended that proper formulation such 
as encapsulation of the compound in lipid vehicle should be done prior to conducting further 
biological assays. 
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 9.9 Further fractionation of the methanol extract results in reduced activity 
Due to the solubility problems experienced with the DCM extract, the focus of the study 
was redirected towards the methanol extract.  The methanol extract selectively induced 
apoptosis in H157, HepG2 and KMST6 while HT29 and MCF7 cells were resistant. Five 
fractions were obtained by Versaflash chromatography of the methanol extract. In general, 
sub-fractionation resulted in the loss of bioactivity on most of the cell lines tested in this 
study. This can be ascribed to loss of compounds or the separation of synergistic 
compounds. Synergy is well-recognized in natural products chemistry (Jeremy, 2008). 
Interestingly, fractionation of the methanol extract resulted in increase of activity on HT29 
cells. While HT29 cells were resistant (IC50 value > 2mg/ml) to the effects of the methanol 
extract, these cells were susceptible to the effects of the methanol sub-fractionations (MF3 
and MF4). This may be due to an increase in the concentration of the active compound (s).  
 
9.10 Long chain fatty acid derivatives, flavonoids and allicin derivatives are present in 
T. violacea 
Fingerprinting showed the presence of long chain fatty acid derivatives, flavonoids and 
allicin derivatives in the methanol extract. These were not isolated but they were 
characterized with reasonable confidence from LC-MS. It was noted however that some of 
the more unusual compounds seen i.e. the alkaloidal and silylated derivatives were probably 
synthetic contaminants which might have entered the extracts during the various extraction 
and drying stages. This finding reinforces the need to conduct further phytochemistry 
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investigations on this plant species. However the fingerprints do point to a mix of 
compounds which have all been previously reported to have anti-proliferative and / or anti-
apoptotic activity. 
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9.11 Conclusions and Recommendations and future work 
Lyantagaye (2005) reported that MDG was one of the compounds present in the water 
extract of T.violacea that was responsible for the pro-apoptotic activity of the plant extract. 
In this study it was proposed that this compound could be further investigated as an anti-
cancer agent. The study by Lyantagaye (2005) did not investigate the mechanism by which 
MDG induce apoptosis. Hence the main focus of this study was to further investigate MDG 
as a novel anticancer agent with pro-apoptotic activity that can be used to treat cancer. The 
question that this study that wanted to addressed was how MDG induces apoptosis in 
cultured human cancer cells, however from this study it was found out that MDG does not 
induce apoptosis therefore, more compounds were isolated and identified from T.violacea 
leaves using alternative extraction methods based on organic solvent extraction. 
From the results obtained it can be concluded that 
a) MDG does not induce apoptosis in the cell lines tested in this study. 
b) The T.violacea leaf extract contains pro-apoptotic compounds that selectively induced 
apoptosis in cancer cells. 
c) The bioactivity of organic extracts especially DCM and hexane extracts was higher 
compared to the water extract of T.violacea leaves.  
d)  Palmitone is the major compound present in the DCM extract of T.violacea leaves.  
e) Sub-fractions generated from the DCM extract of T.violacea are insoluble in water.  
f) Sub-fractionation of the methanol extract of T.violacea results in loss of bioactivity.  
g) Methanol sub-fractions of T.violacea are rich in flavonoid borne out by existence of many 
compounds, which were UV active at 280 nm.  
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h) The compounds that are responsible for the pro-apoptotic activity of T.violacea leaf extract 
most likely work in a synergistic fashion are still to be identified.  
 
Further work needs to be done on this plant species. The study showed that extracts of T. 
violacea have useful biological activity which appears to be supported by the chemical 
constituents fingerprinted. The phytochemistry requires further work. In addition isolation, 
formulation and testing of some of the compounds herein reported will be important. 
Assembling synthetic analogues of some of the compounds e.g. palmitone is also a viable 
approach to the development of drugs from this important traditional herb. 
Cancer remains a leading cause of morbidity and mortality globally and research into new 
therapies continues to be necessary and relevant. This study has provided important new 
evidence which should be followed up. 
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APPENDICES 
Appendix 1: Summary of the major compound peaks found and their molecular masses 
Molecular ion (M+) Retention time (tR) MF2 MF3 MF4  MF5 MF6 MF7
266 0.45 X X
274.1 0.5 XX
305.1 0.71 X
274 1.11 X
310 2.13 X x
283.2 2.89 X
327 3.16 X
281 3.19 XX
217 3.23 XX XXX
281 3.25 X
347.1 3.26 X
231.1 3.33 X
388.3 3.37 XX
388.3 3.4 X
432.3 3.6 XX
432.3 3.62 XXX X
757.2 3.69 XX XXX
278.1 3.78 X
476.3 3.79 XXX XX X
520.3 3.94 X
520.3 3.97 XX X
287.1 4.25 X XXXX
265.1 4.36 XXXX
314.1 5.31 XX
344.2 5.46 XXX
344.2 5.49 X
309.1 5.65 X
271.1 5.84 XXX
442.3 6.41 X
298.2 6.87 XX
500.4 7.08 X
323.1 7.24 XXX
375.2 9.28 XXXX
318.3 9.19 X
332.3 9.37 X
277.2 9.61 X
417.1 10.06 X
301.1 11.61 X X
301.2 11.49 X
282.3 13.81 XX XXXX
607.3 13.81 X
262.3 13.88 XXXX
640.6 15.61 X
522.6 15.93 X
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Appendix2: Examples of previously isolated compounds from garlic 
 
 
Compounds Structures Formula  and molecular weight s 
diallyl disulfide (DADS  
 
C6H10S2 
146.022385 Da  
Allyl Sulfide 
 
C6H10S 
114.05  
allyl methyl trisulfide 
 
C4H8S3 
151.978806 Da 
gamma-glutamyl cysteine 
 
C3H7NO2S 
121.1582 
 
 
 
gamma-glutamyl cysteine 
 
C3H7NO2S 
121.1582 
 
 
Ajoene 
(1E)-1-(Allyldisulfanyl)-3-
(allylsulfinyl)-1-propene  
 
C9H14OS3 
234.020676 
2, 4, 5, 7-tetrathiaoctane 
 
C4H10S4  
186.3822 
S-[(1Z)-1-Propen-1-yl] 1-
butanesulfinothioate 
 
C7H14OS2 
S-prop-1-en-1-yl propane-1-
sulfinothioate 
 
C6H12OS2 
164.032959 Da 
2,4,6-Trithiaheptane 
 
C4H10S3 
153.994461 Da 
 
 
 
 
